(S)-2-(2-methylazetidin-1-yl)pyrimidine derivatives and pharmaceutical compositions containing the same
Novel (S)-2-(2-methylazetidin-1-yl)pyrimidine derivatives are developed as selective ketohexokinase inhibitors, addressing safety concerns and enhancing treatment efficacy for metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis.
Patent Information
- Application Number
- JP2024538456
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-24
- Filing Date
- 2022-12-23
- Publication Date
- 2024-12-04
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current ketohexokinase (KHK) inhibitors face challenges in selectivity towards other kinases, raising safety concerns for the treatment of metabolic diseases like non-alcoholic steatohepatitis, and there is a need for more effective therapeutic agents.
Development of novel (S)-2-(2-methylazetidin-1-yl)pyrimidine derivatives and their pharmaceutically acceptable salts, which act as selective ketohexokinase (KHK) inhibitors, formulated into pharmaceutical compositions for preventing or treating metabolic diseases.
The compounds effectively inhibit KHK, providing therapeutic benefits for diabetes, obesity, non-alcoholic steatohepatitis, and steatohepatitis, with reduced side effects due to improved selectivity.
Smart Images

Figure 2024544794000001 
Figure 2024544794000002 
Figure 2024544794000003
Abstract
Description
[Technical field]
[0001] The present invention claims the benefit of priority based on Korean Patent Application No. 10-2021-0187602 filed on December 24, 2021, and Korean Patent Application No. 10-2021-0187603 filed on December 24, 2021, and all contents disclosed in the documents of said Korean patent applications are incorporated as part of this specification.
[0002] The present invention relates to a novel (S)-2-(2-methylazetidin-1-yl)pyrimidine derivative compound having inhibitory activity against ketohexokinase (KHK), a pharma- ceutically acceptable salt thereof, or an isomer thereof, and a pharmaceutical composition containing the same as an active ingredient. [Background technology]
[0003] The causes of non-alcoholic steatohepatitis, a metabolic disease, are known to be mainly the formation of fatty liver, increased inflammation, cell death, etc. As a chronic disease, non-alcoholic steatohepatitis can gradually progress to liver fibrosis, cirrhosis, and liver cancer.
[0004] Meanwhile, ketohexokinase (KHK) is an enzyme involved in fructose metabolism, and is a type of kinase responsible for the phosphorylation of fructose in fructose metabolism. Unlike glucose metabolism, fructose metabolism is not subject to energy-dependent inhibition, so it induces rapid fat accumulation in the liver and affects the formation of fatty liver. Therefore, inhibiting ketohexokinase (KHK) is expected to have an effect of suppressing the formation of fatty liver, which is one of the causes of the onset of non-alcoholic steatohepatitis.
[0005] In animal experimental models, it has been observed that when ketohexokinase (KHK) activity is suppressed, general indicators of metabolic disease are improved, and since the phenotype of ketohexokinase (KHK) knockout mice shows no difference from that of normal mice, it is predicted that side effects from ketohexokinase (KHK) inhibition will not be significant.
[0006] However, since ketohexokinase (KHK) is responsible for phosphorylation using ATP, it is true that when ketohexokinase (KHK) is inhibited, other types of kinases may be inhibited, which raises many concerns about the safety of chronic disease treatment drugs. Therefore, it is important that ketohexokinase (KHK) inhibitors have selectivity over other kinases.
[0007] Currently, research on ketohexokinase (KHK) inhibitors is being actively conducted, but there is still a need for the development of therapeutic agents that can be effectively used to prevent or treat metabolic diseases such as diabetes, diabetic complications, obesity, non-alcoholic steatohepatitis, and steatohepatitis. [Prior art documents] [Patent documents]
[0008] [Patent Document 1] U.S. Patent No. 9,809,579 Summary of the Invention [Problem to be solved by the invention]
[0009] The present invention has been made to solve the above problems of the prior art, and has an object to provide a novel compound having inhibitory activity against ketohexokinase (KHK), or a pharma- ceutically acceptable salt or isomer thereof.
[0010] Another object of the present invention is to provide a pharmaceutical composition for a ketohexokinase inhibitor, which contains the compound as an active ingredient.
[0011] Another object of the present invention is to provide a pharmaceutical composition for preventing or treating metabolic diseases, which contains the compound as an active ingredient.
[0012] It is a further object of the present invention to provide a method for treating metabolic disorders, including non-alcoholic steatohepatitis, in a mammal, comprising the step of administering said compound. [Means for solving the problem]
[0013] In order to solve the above problems, the present invention provides a compound represented by the following Chemical Formula 1, or a pharma- ceutically acceptable salt or isomer thereof:
[0014] [Chemical formula 1] [ka]
[0015] In the above Chemical Formula 1, A is a C3-C8 heterocycloalkyl group that is unsubstituted or substituted with a C1-C3 alkyl group or a carbonyl group; or [ka] X and Y are each independently N or CR a and R ais hydrogen or a halogen group; Z is a direct bond, a C1-C3 alkylene group, -O-, or -C(O)-; R1 and R2 are each independently hydrogen, a halogen group, or a C1-C3 alkyl group which is unsubstituted or substituted with 1 to 5 halogen groups; or R1 and R2 are linked together to form a C3-C6 aliphatic ring group which is unsubstituted or substituted with 1 to 3 halogen groups, or a C3-C6 heterocycloalkyl group which is unsubstituted or substituted with 1 to 3 halogen groups; and R3 is -(CR4R5). n -B-R6, in which R4 and R5 are each independently hydrogen or a C1-C3 alkyl group, n is an integer from 0 to 3, B is a direct bond, -C(O)-, or -S(O)2-, and R6 is a hydroxyl group or a C3-C7 heterocycloalkyl group containing N which is unsubstituted or substituted with a C1-C3 alkyl group, a carbonyl group, or a C1-C3 alkylcarbonyl group.
[0016] The present invention also provides a pharmaceutical composition for inhibiting ketohexokinase (KHK), which contains the compound or a pharma- ceutically acceptable salt or isomer thereof as an active ingredient.
[0017] The present invention also provides a pharmaceutical composition for preventing or treating a metabolic disease, which comprises the compound or a pharma- ceutically acceptable salt or isomer thereof as an active ingredient.
[0018] The present invention also provides a method for producing a pharmaceutical composition for the prevention or treatment of diabetes, diabetic complications, obesity, non-alcoholic steatohepatitis, and steatohepatitis, comprising the step of mixing the compound, a pharma- ceutically acceptable salt, or isomer thereof, as an active ingredient, with a pharma- ceutically acceptable carrier.
[0019] The invention also provides a method of treating metabolic disorders, including non-alcoholic steatohepatitis, in a mammal comprising the step of administering said compound, a pharma- ceutically acceptable salt, or an isomer thereof.
[0020] (1) The present invention provides a compound of formula 1, a pharma- ceutically acceptable salt thereof, or an isomer thereof.
[0021] (2) The present invention provides the compound according to (1) above, wherein in Chemical Formula 1, when A is a heterocycloalkyl group, A is a substituent represented by the following Chemical Formula 1a or Chemical Formula 1b, or a pharma- ceutically acceptable salt or isomer thereof:
[0022] [Chemical formula 1a] [ka] (In the above Chemical Formula 1a, X and Y are, independently of each other, CH or N; R a and R b are each independently a C1 to C3 alkylene group, R c is a C1-C3 alkyl group or a carbonyl group, m is 0 or 1; [Formula 1b] [ka] In the above Chemical Formula 1b, R d is a direct bond or CH2.
[0023] (3) The present invention relates to a method for producing [ka] If In the above Chemical Formula 1, X and Y are each independently N or CR a and R ais hydrogen or a halogen group, Z is a C1-C3 alkylene group or -O-, R1 and R2 are linked together to form a C3-C6 aliphatic ring group that is unsubstituted or substituted with 1 to 3 halogen groups, and R3 is -(CR4R5) n The compound according to (1), or a pharma- ceutically acceptable salt or isomer thereof, is provided, wherein the compound is -B-R6, R4 and R5 are hydrogen, n is an integer of 0 to 3, B is -C(O)-, and R6 is a hydroxyl group or a C4 to C6 heterocycloalkyl group containing N which is unsubstituted or substituted with a C1 to C3 alkyl group.
[0024] (4) The present invention relates to a method for producing [ka] If In the above Chemical Formula 1, X is N and Y is CR a where R a is hydrogen, Z is a C1-C3 alkylene group or -O-, R1 is a C1-C3 alkyl group substituted with 1 to 3 halogen groups, R2 is hydrogen or a C1-C3 alkyl group, and R3 is -(CR4R5) n The present invention provides a compound according to (1) or (3), or a pharma- ceutically acceptable salt or isomer thereof, wherein the compound is -B-R6, R4 and R5 are hydrogen, n is an integer of 0 to 3, B is -C(O)-, and R6 is a C4 to C6 heterocycloalkyl group containing N that is unsubstituted or substituted with a C1 to C3 alkyl group.
[0025] (5) The present invention provides a compound according to any one of (1) to (4) above, or a pharma- ceutically acceptable salt or isomer thereof, wherein in Chemical Formula 1, the halogen group is F or Cl.
[0026] (6) The present invention provides the compound according to any one of (1) to (5), or a pharma- ceutically acceptable salt or isomer thereof, wherein the compound of Chemical Formula 1 is one or more selected from the group consisting of: (S)-2-((1-(2-(2-methylazetidin-2-yl)-6-(trifluoromethyl)pyrimidin-4-yl)azetidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; (S)-2-((1-(5-chloro-2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)azetidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; (S)-2-((1-(7,7-difluoro-2-(2-(methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)azetidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; (S)-2-((1-(8,8-difluoro-2-(2-methylazetidin-1-yl)-5,6,7,8-tetrahydroquinazolin-4-yl)azetidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; 2-(((2S,3R)-1-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-methylazetidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; 2-(((S)-1-(2-((S)-2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)pyrrolidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; 2-(((S)-1-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyrrolidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; 2-(((R)-1-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyrrolidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; 2-((R)-1-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyrrolidin-3-yl)-1-(piperazin-1-yl)ethan-1-one; (S)-2-((1-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperidin-4-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; (S)-2-(4-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)piperazin-1-yl)-1-(piperazin-1-yl)ethan-1-one; (S)-2-(4-(5-chloro-2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)piperazin-1-yl)-1-(piperazin-1-yl)ethan-1-one; (S)-2-(4-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)-1-(2-oxo-2-(piperazin-1-yl)ethyl)piperazin-2-one; (S)-2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-1-(piperazin-1-yl)ethan-1-one; (S)-2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-1-morpholinoethan-1-one; (S)-1-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(piperazin-1-yl)propane-1,3-dione; (S)-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-1-(2-oxo-2-(piperazin-1-yl)ethyl)piperazin-2-one; (S)-2(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]-pyrimidin-4-yl)piperidin-1-yl)-1-(piperazin-1-yl)ethan-1-one; 2-((1R,5S,6R)-3-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-azabicyclo[3.1.0]hexan-6-yl)-1-(piperazin-1-yl)ethan-1-one; 2-((1R,5S,6R)-3-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-azabicyclo[3.1.0]hexan-6-yl)-1-(4-methylpiperazin-1-yl)ethan-1-one; 4-(2-((1R,5S,6R)-3-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-azabicyclo[3.1.0]hexan-6-yl)acetyl)piperazin-2-one; 2-((1R,5S,6S)-3-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-azabicyclo[3.1.0]hexan-6-yl)-1-(piperazin-1-yl)ethan-1-one; 1-(4-acetylpiperazin-1-yl)-2-((1R,5S,6S)-3-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopentane[d]pyrimidin-4-yl)-3-azabicyclo[3.1.1]heptan-6-yl)ethan-1-one; 2-((1R,5S,6S)-3-(8,8-difluoro-2-((S)-2-methylazetidin-1-yl)-5,6,7,8-tetrahydroquinazolin-4-yl)-3-azabicyclo[3.1.1]heptan-6-yl)-1-(piperazin-1-yl)ethan-1-one; 2-((1R,5S,6S)-3-(8,8-difluoro-2-((S)-2-methylazetidin-1-yl)-5,8-dihydro-6H-pyrazole[3,4-d]pyrimidin-4-yl)-3-azabicyclo[3.1.1]heptan-6-yl)-1-(piperazin-1-yl)ethan-1-one; 7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-4-((1R,5S,6S)-6-((piperazin-1-ylsulfonyl)methyl)-3-azabicyclo[3.1.0]hexan-3-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine; (S)-2-((1-(5-methyl-2-(2-methylazetidin-1-yl)-6-(trifluoro)pyrimidin-4-yl)azetidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; (S)-2-((1-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)piperidin-4-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; (S)-2-((1-(5-methyl-2-(2-methylazetidin-1-yl)-6-(trifluoro)pyrimidin-4-yl)piperidin-4-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; (S)-2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]-pyrimidin-4-yl)phenyl)acetic acid; (S)-2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]-pyrimidin-4-yl)phenyl)-1-(piperazin-1-yl)ethan-1-one; (S)-2-(5-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)pyridin-2-yl)-1-(piperazin-1-yl)ethan-1-one; (S)-2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)-1-(piperazin-1-yl)ethan-1-one; (S)-2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-fluorophenoxy)-1-(piperazin-1-yl)ethan-1-one; (S)-2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2,6-difluorophenoxy)-1-(piperazin-1-yl)ethan-1-one; (S)-2-(2-chloro-4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)-1-(piperazin-1-yl)ethan-1-one; (S)-2-(2-chloro-4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)-1-(1,4-diazepan-1-yl)ethan-1-one; (S)-2-((5-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyridin-2-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; (S)-2-((3-chloro-5-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyridin-2-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; (S)-2-((5-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)pyridin-2-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; (S)-2-((5-(5-methyl-2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)pyridin-2-yl)oxy)-1-(piperazin-1-yl)ethan-1-one.
[0027] (7) The present invention provides the compound according to any one of (1) to (6) above, or a pharma- ceutically acceptable salt or isomer thereof, which is a ketohexokinase (KHK) inhibitor.
[0028] (8) The present invention provides a compound according to any one of (1) to (6) above, or a pharma- ceutically acceptable salt or isomer thereof, for use in the prophylaxis or treatment of a metabolic disease.
[0029] (9) The present invention provides a pharmaceutical composition for a ketohexokinase (KHK) inhibitor, comprising, as an active ingredient, the compound according to any one of (1) to (6) or a pharma- ceutical acceptable salt or isomer thereof.
[0030] (10) The present invention provides a pharmaceutical composition for preventing or treating a metabolic disease, comprising, as an active ingredient, the compound according to any one of (1) to (6) or a pharma- ceutical acceptable salt or isomer thereof.
[0031] (11) The present invention provides a pharmaceutical composition for preventing or treating a metabolic disease according to (10) above, wherein the metabolic disease is diabetes, diabetic complications, obesity, non-alcoholic steatohepatitis, or steatohepatitis.
[0032] (12) The present invention provides the pharmaceutical composition for preventing or treating a metabolic disease according to (10) or (11) above, wherein the metabolic disease is non-alcoholic steatohepatitis.
[0033] (13) The present invention provides a method for producing a pharmaceutical composition for preventing or treating diabetes, diabetic complications, obesity, non-alcoholic steatohepatitis, and steatohepatitis, comprising a step of mixing, as an active ingredient, a compound according to any one of (1) to (6) above, a pharma- ceutical acceptable salt thereof, or an isomer thereof with a pharma- ceutical acceptable carrier.
[0034] (14) The present invention provides a method for treating metabolic diseases, including non-alcoholic steatohepatitis, in a mammal, comprising the step of administering a compound according to any one of (1) to (6) above, or a pharma- ceutically acceptable salt or isomer thereof. Effect of the Invention
[0035] The (S)-2-(2-methylazetidin-1-yl)pyrimidine derivative compound of the present invention represented by Chemical Formula 1 acts as a ketohexokinase (KHK) inhibitor and can be effectively used for the prevention or treatment of metabolic diseases such as diabetes, diabetic complications, obesity, non-alcoholic steatohepatitis, and steatohepatitis. BEST MODE FOR CARRYING OUT THEINVENTION
[0036] The present invention will now be described in more detail for the sake of understanding.
[0037] The terms and words used in the description of the present invention and the claims should not be interpreted in a limited manner to their ordinary or dictionary meanings, but should be interpreted in a manner that is consistent with the technical idea of the present invention, based on the principle that the inventors can appropriately define the concepts of terms in order to best describe their invention.
[0038] Terminology justice In this specification, the term "substituted" means that hydrogen of a functional group, an atomic group, or a compound is replaced with a specific substituent, and when hydrogen of a functional group, an atomic group, or a compound is replaced with a specific substituent, there may be one or more multiple substituents depending on the number of hydrogens present in the functional group, atomic group, or compound. When there are multiple substituents, each of the substituents may be the same or different.
[0039] As used herein, the term "alkyl group" means a monovalent aliphatic saturated hydrocarbon group, and can be meant to include any of straight-chain alkyl groups such as methyl, ethyl, propyl, and butyl; branched alkyl groups such as isopropyl, sec-butyl, tert-butyl, and neo-pentyl; and cyclic saturated hydrocarbons or cyclic unsaturated hydrocarbon groups containing one or more unsaturated bonds.
[0040] As used herein, the term "alkylene group" may mean a divalent aliphatic saturated hydrocarbon group, such as methylene, ethylene, propylene, butylene, and the like.
[0041] As used herein, the term "heterocycloalkyl group" refers to a partially or fully saturated hydrocarbon group that contains an N, S, or O heteroatom as a ring atom and forms a single or fused ring, and can be meant to include a monocyclic ring formed by one ring, and a polycyclic structure formed by combining two or more rings.
[0042] As used herein, the term "direct bond" may refer to a single covalent bond itself, with no other atoms or molecular groups involved.
[0043] In this specification, the terms "comprise", "have" and their derivatives are not intended to exclude the presence of any additional components, steps or procedures, whether they are specifically disclosed or not. To avoid any uncertainty, all compositions claimed using the term "comprise" may include any additional additives, adjuvants, or compounds, whether polymeric or otherwise, unless stated to the contrary. In contrast, the term "consisting essentially of" excludes from the scope of any consecutive description any other components, steps or procedures, except those that are not essential for operability. The term "consisting of" excludes any components, steps or procedures not specifically stated or listed.
[0044] In the present specification, the term "pharmaceutically acceptable salts" includes acid addition salts formed with acids that form non-toxic acid addition salts containing pharmaceutically acceptable anions, for example, inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, hydroiodic acid, etc.; organic acids such as tartaric acid, formic acid, citric acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, gluconic acid, benzoic acid, lactic acid, fumaric acid, maleic acid, salicylic acid, etc.; sulfonic acids such as methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, etc. The term "pharmaceutically acceptable salts" also includes carboxylates, which include, for example, alkali metal or alkaline earth metal salts formed with lithium, sodium, potassium, calcium, magnesium, etc.; amino acid salts such as lysine, arginine, guanidine, etc.; and organic salts such as dicyclohexylamine, N-methyl-D-glucamine, tris(hydroxymethyl)methylamine, diethanolamine, choline, triethylamine, etc. Thus, in this specification, the term "a pharma- ceutically acceptable salt thereof" refers to a form in which the compound of Chemical Formula 1 is converted into a pharma- ceutically acceptable salt as described above.
[0045] As used herein, the term "isomer" refers to molecules that have the same molecular formula but differ from one another in atomic arrangement or conformation, and may have asymmetric carbon centers and asymmetric axes or planes, and thus includes E or Z isomers, R or S isomers, racemates, mixtures of diastereoisomers, and individual diastereoisomers. Thus, as used herein, "an isomer" may refer to a compound of Formula 1 that includes any of the above isomers and mixtures.
[0046] The present invention provides an (S)-2-(2-methylazetidin-1-yl)pyrimidine derivative compound represented by the following chemical formula 1, a pharma- ceutically acceptable salt thereof, or an isomer thereof, which acts as a ketohexokinase (KHK) inhibitor and is effective in preventing or treating metabolic diseases such as diabetes, diabetic complications, obesity, nonalcoholic steatohepatitis, and steatohepatitis.
[0047] [Chemical formula 1] [ka]
[0048] In the formula 1, R1 and R2 may each independently be any one selected from the group consisting of hydrogen, halogen, and C1-C3 alkyl groups, or may be linked together to form a C3-C6 aliphatic ring group or a C3-C6 heterocycloalkyl group. In particular, R1 and R2 may each independently be hydrogen or a C1-C3 alkyl group, or may be linked together to form a C3-C6 aliphatic ring group. In this case, the alkyl group, aliphatic ring group, or heterocycloalkyl group may be substituted with 1 to 5, particularly 1 to 3, halogen groups, and the halogen groups may be F or Cl.
[0049] In addition, in the formula 1, R3 is -(CR4R5). n -B-R6.
[0050] In this case, the n may be an integer of 0 to 3, particularly an integer of 0 to 2, for example, an integer of 0 to 1.
[0051] Furthermore, R4 and R5 may each independently be hydrogen or a C1 to C3 alkyl group, and in particular, R4 and R5 may each independently be hydrogen or a C1 to C2 alkyl group.
[0052] Moreover, the B may be a direct bond or any one of -C(O)- and -S(O)2-.
[0053] Furthermore, the R6 may be hydrogen, a hydroxyl group, or a C3-C7 heterocycloalkyl group, particularly, the R6 may be a hydroxyl group or a C3-C7 heterocycloalkyl group. In this case, the C3-C7 heterocycloalkyl group may contain N, O, or S, particularly, N. Furthermore, the C3-C7 heterocycloalkyl group may be substituted with a C1-C3 alkyl group, a carbonyl group, or a C1-C3 alkylcarbonyl group. For example, the R6 may be a C3-C7 heterocycloalkyl group containing N, particularly, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, imidazolinyl, piperazinyl, etc.
[0054] In addition, in the above Chemical Formula 1, Z may be a direct bond, a C1 to C3 alkylene group, -O-, or -C(O)-.
[0055] In addition, in the above Chemical Formula 1, A may be a C3-C8 heterocycloalkyl group. In this case, the C3-C8 heterocycloalkyl group may contain N, O, or S, particularly N. In addition, the C3-C8 heterocycloalkyl group may be substituted with a C1-C3 alkyl group or a carbonyl group.
[0056] In particular, A may be a substituent represented by the following formula 1a or 1b:
[0057] [Chemical formula 1a] [ka]
[0058] In the formula 1a, X and Y are each independently CH or N; R a and R b are each independently a C1 to C3 alkylene group, R c is a C1-C3 alkyl group or a carbonyl group, m is 0 or 1, [Formula 1b] [ka] In the above formula 1b, R d may be a direct bond or CH2.
[0059] Meanwhile, in the above Chemical Formula 1, A is [ka] It may be.
[0060] X and Y are each independently N or CR a and R a is hydrogen or a halogen group, Z is a C1-C3 alkylene group or -O-, R1 and R2 are linked together to form a C3-C6 aliphatic ring group that is unsubstituted or substituted with 1 to 3 halogen groups, and R3 is -(CR4R5) n -B-R6, R4 and R5 are hydrogen, n is an integer from 0 to 3, B is -C(O)-, and R6 is a hydroxy group or a C4 to C6 heterocycloalkyl group containing N which is unsubstituted or substituted with a C1 to C3 alkyl group, and the halogen group may be F or Cl.
[0061] In yet another embodiment, the compound of formula 1 according to the present invention is [ka] In the formula 1, X is N and Y is CR a where R a is hydrogen, Z is a C1-C3 alkylene group or -O-, R1 is a C1-C3 alkyl group substituted with 1 to 3 halogen groups, R2 is hydrogen or a C1-C3 alkyl group, and R3 is -(CR4R5) n -B-R6, where R4 and R5 are hydrogen, n is an integer from 0 to 3, B is -C(O)-, and R6 may be a C4 to C6 heterocycloalkyl group containing N that is unsubstituted or substituted with a C1 to C3 alkyl group.
[0062] In yet another example, the compound of Formula 1 according to the present invention may be one or more selected from the following group: (S)-2-((1-(2-(2-methylazetidin-2-yl)-6-(trifluoromethyl)pyrimidin-4-yl)azetidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; (S)-2-((1-(5-chloro-2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)azetidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; (S)-2-((1-(7,7-difluoro-2-(2-(methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)azetidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; (S)-2-((1-(8,8-difluoro-2-(2-methylazetidin-1-yl)-5,6,7,8-tetrahydroquinazolin-4-yl)azetidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; 2-(((2S,3R)-1-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-methylazetidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; 2-(((S)-1-(2-((S)-2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)pyrrolidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; 2-(((S)-1-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyrrolidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; 2-(((R)-1-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyrrolidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; 2-((R)-1-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyrrolidin-3-yl)-1-(piperazin-1-yl)ethan-1-one; (S)-2-((1-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperidin-4-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; (S)-2-(4-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)piperazin-1-yl)-1-(piperazin-1-yl)ethan-1-one; (S)-2-(4-(5-chloro-2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)piperazin-1-yl)-1-(piperazin-1-yl)ethan-1-one; (S)-2-(4-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)-1-(2-oxo-2-(piperazin-1-yl)ethyl)piperazin-2-one; (S)-2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-1-(piperazin-1-yl)ethan-1-one; (S)-2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-1-morpholinoethan-1-one; (S)-1-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(piperazin-1-yl)propane-1,3-dione; (S)-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-1-(2-oxo-2-(piperazin-1-yl)ethyl)piperazin-2-one; (S)-2(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]-pyrimidin-4-yl)piperidin-1-yl)-1-(piperazin-1-yl)ethan-1-one; 2-((1R,5S,6R)-3-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-azabicyclo[3.1.0]hexan-6-yl)-1-(piperazin-1-yl)ethan-1-one; 2-((1R,5S,6R)-3-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-azabicyclo[3.1.0]hexan-6-yl)-1-(4-methylpiperazin-1-yl)ethan-1-one; 4-(2-((1R,5S,6R)-3-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-azabicyclo[3.1.0]hexan-6-yl)acetyl)piperazin-2-one; 2-((1R,5S,6S)-3-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-azabicyclo[3.1.0]hexan-6-yl)-1-(piperazin-1-yl)ethan-1-one; 1-(4-acetylpiperazin-1-yl)-2-((1R,5S,6S)-3-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopentane[d]pyrimidin-4-yl)-3-azabicyclo[3.1.1]heptan-6-yl)ethan-1-one; 2-((1R,5S,6S)-3-(8,8-difluoro-2-((S)-2-methylazetidin-1-yl)-5,6,7,8-tetrahydroquinazolin-4-yl)-3-azabicyclo[3.1.1]heptan-6-yl)-1-(piperazin-1-yl)ethan-1-one; 2-((1R,5S,6S)-3-(8,8-difluoro-2-((S)-2-methylazetidin-1-yl)-5,8-dihydro-6H-pyrazole[3,4-d]pyrimidin-4-yl)-3-azabicyclo[3.1.1]heptan-6-yl)-1-(piperazin-1-yl)ethan-1-one; 7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-4-((1R,5S,6S)-6-((piperazin-1-ylsulfonyl)methyl)-3-azabicyclo[3.1.0]hexan-3-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine; (S)-2-((1-(5-methyl-2-(2-methylazetidin-1-yl)-6-(trifluoro)pyrimidin-4-yl)azetidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; (S)-2-((1-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)piperidin-4-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; (S)-2-((1-(5-methyl-2-(2-methylazetidin-1-yl)-6-(trifluoro)pyrimidin-4-yl)piperidin-4-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; (S)-2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]-pyrimidin-4-yl)phenyl)acetic acid; (S)-2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]-pyrimidin-4-yl)phenyl)-1-(piperazin-1-yl)ethan-1-one; (S)-2-(5-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)pyridin-2-yl)-1-(piperazin-1-yl)ethan-1-one; (S)-2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)-1-(piperazin-1-yl)ethan-1-one; (S)-2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-fluorophenoxy)-1-(piperazin-1-yl)ethan-1-one; (S)-2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2,6-difluorophenoxy)-1-(piperazin-1-yl)ethan-1-one; (S)-2-(2-chloro-4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)-1-(piperazin-1-yl)ethan-1-one; (S)-2-(2-chloro-4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)-1-(1,4-diazepan-1-yl)ethan-1-one; (S)-2-((5-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyridin-2-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; (S)-2-((3-chloro-5-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyridin-2-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; (S)-2-((5-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)pyridin-2-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; (S)-2-((5-(5-methyl-2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)pyridin-2-yl)oxy)-1-(piperazin-1-yl)ethan-1-one.
[0063] The compound of the present invention, a pharma- ceutically acceptable salt thereof, or an isomer thereof, has an effect as a ketohexokinase (KHK) inhibitor, and thus, the compound of the present invention, a pharma-ceutically acceptable salt thereof, or an isomer thereof, can be used as a ketohexokinase (KHK) inhibitor, and as another example, can be suitably used for the prevention or treatment of metabolic diseases associated with ketohexokinase (KHK).
[0064] The present invention also provides a pharmaceutical composition for a ketohexokinase (KHK) inhibitor, comprising as an active ingredient the compound of Chemical Formula 1, or a pharma- ceutical acceptable salt or isomer thereof. In addition, various forms of prodrugs that are converted in vivo to the compound of Chemical Formula 1 according to the purpose are also included within the scope of the present invention.
[0065] The pharmaceutical composition according to the present invention can be used for the prevention or treatment of metabolic diseases involving ketohexokinase (KHK). The metabolic diseases involving ketohexokinase (KHK) may be induced by overexpression or overactivation of the ketohexokinase. Specifically, metabolic diseases that can be prevented or treated by the pharmaceutical composition according to the present invention include, but are not limited to, diabetes, diabetic complications, obesity, non-alcoholic steatohepatitis, and steatohepatitis, and are preferably used for the prevention or treatment of non-alcoholic steatohepatitis.
[0066] The present invention also provides a method for preparing a pharmaceutical composition for preventing or treating diabetes, diabetic complications, obesity, non-alcoholic steatohepatitis, and steatohepatitis, comprising the step of mixing a compound of Chemical Formula 1, a pharma- ceutically acceptable salt, or an isomer thereof, as an active ingredient, with a pharma- ceutically acceptable carrier.
[0067] The "pharmaceutical composition" may include the compound of the present invention and other chemical components such as diluents, carriers, etc. Thus, the pharmaceutical composition may include a pharma- ceutically acceptable carrier, diluent, or excipient, or a combination thereof, as appropriate. The pharmaceutical composition facilitates administration of the compound into an organism. There are various techniques for administering the compound, including, but not limited to, oral, injection, aerosol, parenteral, and topical administration.
[0068] The term "carrier" refers to a compound that facilitates the introduction of a compound into cells or tissues. For example, dimethyl sulfoxide (DMSO) is a common carrier that facilitates the introduction of many organic compounds into cells or tissues of living organisms.
[0069] The term "diluent" is defined as a compound that is diluted with water to dissolve the compound as well as stabilize the biologically active form of the compound of interest. Salts dissolved in buffers are used as diluents in the art. A commonly used buffer is phosphate buffered saline, which mimics the salt form of human body fluids. The buffer salts can control the pH of the solution at low concentrations, so the buffer diluent hardly alters the biological activity of the compound.
[0070] The term "pharmaceutical acceptable" means a property that does not impair the biological activity and physical properties of a compound.
[0071] The compound of the present invention can be formulated into various pharmaceutical dosage forms according to the purpose.When preparing the pharmaceutical composition of the present invention, the active ingredient, specifically the compound of formula 1, its pharma- ceutically acceptable salt, or isomer is mixed with various pharma- ceutically acceptable carriers that can be selected according to the dosage form to be prepared.For example, the pharmaceutical composition of the present invention can be formulated into an injection preparation, an oral preparation, etc. according to the purpose.
[0072] The compounds of the present invention may be formulated by known methods using known pharmaceutical carriers and excipients, and may be placed in unit dose form or multi-dose containers. The formulation may be in the form of a solution, suspension or emulsion in an oil or aqueous medium, and may contain conventional dispersing, suspending or stabilizing agents. It may also be in the form of a dry powder, for example, to be dissolved in sterile, pyrogen-free water before use. The compounds of the present invention may also be formulated in the form of suppositories using conventional suppository bases, such as cocoa butter or other glycerides. Solid dosage forms for oral administration can be capsules, tablets, pills, powders, and granules, with capsules and tablets being particularly useful. Tablets and pills are preferably prepared in the form of enteric coating. Solid dosage forms may be prepared by mixing the compounds of the present invention with one or more inert diluents, such as sucrose, lactose, starch, and the like, and carriers, such as lubricants, disintegrants, binders, and the like, such as magnesium stearate. If necessary, the compound according to the present invention or a pharmaceutical composition containing it can be administered in combination with other drugs, for example, other antidiabetic drugs.
[0073] The present invention also provides a method for preventing or treating a metabolic disease involving ketohexokinase (KHK) in a mammal by administering a compound of formula 1, a pharma- ceutically acceptable salt, or an isomer thereof as an active ingredient. Representative examples of diseases treatable by a ketohexokinase (KHK) inhibitor include, but are not limited to, the metabolic diseases such as diabetes, diabetic complications, obesity, non-alcoholic steatohepatitis, and steatohepatitis mentioned above, and preferably non-alcoholic steatohepatitis. In this specification, "treatment" means that the progression of a disease is stopped, delayed, or alleviated when used in a subject who shows onset, and "prevention" means that the symptoms of onset are stopped, delayed, or alleviated when used in a subject who does not show onset but is at high risk.
[0074] Meanwhile, the compound of Formula 1 according to one embodiment of the present invention can be prepared according to Reaction Schemes 1 to 12, which are specifically illustrated in the following Examples.
[0075] In the following, a method for preparing the compound of Chemical Formula 1 will be described based on an exemplary reaction scheme for understanding the present invention. However, a person having ordinary skill in the art to which the present invention pertains can prepare the compound of Chemical Formula 1 by various methods based on the structure of Chemical Formula 1, and all such methods should be interpreted as being included in the scope of the present invention. That is, the compound of Chemical Formula 1 can be prepared by any combination of various synthetic methods described in this specification or disclosed in the prior art, and these should be understood to be within the scope of the present invention, and the method for preparing the compound of Chemical Formula 1 is not limited to the following description.
[0076] When producing the compound of the present invention, the reaction order can be changed as appropriate. That is, any step can be carried out first, or any substituent change step can be inserted, and any other reagent than the exemplified reagents can be used as necessary. The compound obtained in each step can be separated or purified by a conventional method such as recrystallization, distillation, or silica gel column. In addition, the compound obtained in each step can be carried out to the next step without separating or purifying it.
[0077] In the following reaction schemes, all substituents are as previously defined unless otherwise specified. The reagents and starting materials are readily commercially available. Otherwise, they can be prepared by the synthetic methods described in the Preparations and Examples below, including the synthetic methods of compounds similar to known structures. Unless the method is specifically described, the compounds used as starting materials are known compounds or compounds that can be synthesized from known compounds by known synthetic methods or methods analogous thereto. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0078] DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The present invention will now be described in detail with reference to the accompanying drawings, in which: FIG. 1 is a block diagram of a semiconductor device according to an embodiment of the present invention;
[0079] Manufacturing Example 1 The following steps A to C were carried out in order to produce (4,5-dichloro-2-(methylthio)-6-(trifluoromethyl)pyrimidine represented by the following chemical formula a.
[0080] [Chemical formula a] [ka] (1) Step A: Preparation of 2-(methylthio)-6-(trifluoromethyl)pyrimidinyl-4-ol Ethyl 4,4,4-trifluoro-3-oxobutanoate (4.0 g, 21.7 mmol), S-methylisothiourea hemisulfate (6.0 g, 43.4 mmol) and sodium carbonate (9.2 g, 86.9 mmol) were dissolved in 50 ml of water and stirred at room temperature for 12 hours. After the reaction was completed, 1N hydrochloric acid solution was slowly added to the reaction solution at 0°C. The resulting solid was filtered, washed with water and dried to obtain 2-(methylthio)-6-(trifluoromethyl)pyrimidinyl-4-ol (2.5 g, 11.9 mmol, yield 55%). The obtained 2-(methylthio)-6-(trifluoromethyl)pyrimidinyl-4-ol was 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (400 MHz, DMSO-d6) δ 2.51 (s, 3H).
[0081] (2) Step B: Preparation of 5-chloro-2-(methylthio)-6-(trifluoromethyl)pyrimidinyl-4-ol 2-(methylthio)-6-(trifluoromethyl)pyrimidinyl-4-ol (9.3 g, 44.2 mmol) obtained in step A, N-chlorosuccinimide (8.9 g, 66.4 mmol), and acetic acid (5.1 ml, 88.0 mmol) were dissolved in 300 ml of acetonitrile and stirred at 80° C. for 12 hours. After the reaction was completed, concentrated 5-chloro-2-(methylthio)-6-(trifluoromethyl)pyrimidinyl-4-ol was obtained by distillation under reduced pressure, and was used in the next reaction without further purification. The obtained 5-chloro-2-(methylthio)-6-(trifluoromethyl)pyrimidinyl-4-ol was also 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, DMSO-d6) δ 2.51 (s, 3H).
[0082] (3) Step C: Preparation of 4,5-dichloro-2-(methylthio)-6-(trifluoromethyl)pyrimidine 5-Chloro-2-(methylthio)-6-(trifluoromethyl)pyrimidinyl-4-ol obtained in step B, phosphoryl trichloride (20.6 ml, 221 mmol), and benzyltriethylammonium chloride (10.1 g, 44.2 mmol) were dissolved in 200 ml of dichloroethane and stirred at 80° C. for 3 hours. After the reaction was completed, the reaction solution was concentrated by distillation under reduced pressure, and a saturated sodium bicarbonate solution was added to the concentrate and extracted with ethyl acetate. The organic layer was washed with an aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography (ethyl acetate / hexane = 1 / 10 weight ratio) to obtain 4,5-dichloro-2-(methylthio)-6-(trifluoromethyl)pyrimidine (8.63 g, 32.8 mmol, yield 74%). The resulting 4,5-dichloro-2-(methylthio)-6-(trifluoromethyl)pyrimidine was 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, DMSO-d6) δ 2.54 (s, 3H).
[0083] Manufacturing Example 2 The following steps A to K were carried out in order to produce 4-chloro-7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidine represented by the following chemical formula b.
[0084] [Chemical formula b] [ka] (1) Step A: Preparation of 5-(tert-butyl) 1-ethyl 2,2-difluoropentanedioate Ethyl 2-bromo-2,2-difluoroacetate (20 g, 99 mmol), tert-butyl acrylate (11.1 ml, 76 mmol), copper (9.6 g, 152 mmol), N1,N1,N2,N2-tetramethylethane-1,2-diamine (5.7 ml, 37.9 mmol), and acetic acid (4.8 ml, 83 mmol) were dissolved in 100 ml of tetrahydrofuran and stirred at 50° C. for 4 hours. After the reaction was completed, a saturated aqueous solution of ammonium chloride was added to the reaction solution, and the solution was extracted with ethyl acetate. The organic layer was washed with an aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain 5-(tert-butyl) 1-ethyl 2,2-difluoropentanedioate. The obtained 5-(tert-butyl) 1-ethyl 2,2-difluoropentanedioate was 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (400 MHz, CDCl3) δ 4.31 (q, J=7.0 Hz, 2H), 2.32-2.47 (m, 4H), 1.43 (s, 9H), 1.34 (t, J=7.3 Hz, 3H).
[0085] (2) Step B: Preparation of 5-ethoxy-4,4-difluoro-5-oxopentanoic acid The 5-(tert-butyl) 1-ethyl 2,2-difluoropentanedioate obtained in step A was dissolved in trifluoroacetic acid (30 ml) and dichloromethane (70 ml) and stirred at room temperature for 8 hours. After the reaction was completed, the mixture was concentrated under reduced pressure. A saturated aqueous solution of sodium bicarbonate was added to the concentrated solution, and the solution was extracted with ethyl acetate. The organic layer was washed with an aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain 5-ethoxy-4,4-difluoro-5-oxopentanoic acid (15 g, 76 mmol, yield 100%). The obtained 5-ethoxy-4,4-difluoro-5-oxopentanoic acid was 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, CDCl3) δ 4.36 (q, J=7.2 Hz, 2H), 2.66 (t, J=7.6 Hz, 2H), 2.42-2.51 (m, 2H), 1.39 (t, J=7.2 Hz, 3H).
[0086] (3) Step C: Preparation of ethyl 2,2-difluoro-5-hydroxypentanoate 5-Ethoxy-4,4-difluoro-5-oxopentanoic acid (12.0 g, 61 mmol) obtained in step B and borane dimethyl sulfide tetrahydrofuran solution (2 M, 36.6 ml, 73 mmol) were dissolved in 300 ml of tetrahydrofuran and stirred at 50° C. for 12 hours. After the reaction was completed, water (10 ml) was added to the reaction solution and stirred at 60° C. for 1 hour. After the reaction was completed, water was added to the reaction solution and extracted with ethyl acetate. The organic layer was washed with an aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain ethyl 2,2-difluoro-5-hydroxypentanoate (6.5 g, 35.7 mmol, yield 59%). The obtained ethyl 2,2-difluoro-5-hydroxypentanoate was 1 The synthesis was confirmed by 1 H NMR analysis. 1H NMR (500MHz, CDCl3) δ 4.35 (q, J=7.1 Hz, 2H), 3.74 (t, J=6.3 Hz, 2H), 2.16-2.26 (m, 2H), 1.72-1.81 (m, 2H), 1.38 (t, J=7.2 Hz, 3H).
[0087] (4) Step D: Preparation of ethyl 2,2-difluoro-5-((methanesulfonyl)oxy)pentanoate Ethyl 2,2-difluoro-5-hydroxypentanoate (9.4 g, 51.6 mmol), methanesulfonyl chloride (4.42 ml, 56.8 mmol), diisopropylethylamine (18.0 ml, 103 mmol), and 4-dimethylaminopyridine (315 mg, 2.58 mmol) obtained in step C were dissolved in dichloromethane (200 ml) and stirred at room temperature for 3 hours. After the reaction was completed, 1N hydrochloric acid solution was added to the reaction solution and extracted with ethyl acetate. The organic layer was washed with an aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography (ethyl acetate / hexane = 1 / 3 weight ratio) to obtain ethyl 2,2-difluoro-5-((methanesulfonyl)oxy)pentanoate (13.3 g, 51.1 mmol, yield 99%). The resulting ethyl 2,2-difluoro-5-((methanesulfonyl)oxy)pentanoate was 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, CDCl3) δ 4.37 (q, J=7.1 Hz, 2H), 4.31 (t, J=6.3 Hz, 2H), 3.06 (s, 3H), 2.20-2.29 (m, 2H), 1.99-2.05 (m, 2H), 1.38-1.40 (m, 3H).
[0088] (5) Step E: Preparation of ethyl 5-cyano-2,2-difluoropentanoate The ethyl 2,2-difluoro-5-((methanesulfonyl)oxy)pentanoate (13.3 g, 51.1 mmol) prepared in step D and potassium cyanate (10.0 g, 153.3 mmol) were dissolved in a mixed solution of 150 ml of tetrahydrofuran and 150 ml of dimethylformamide, and then stirred at 70° C. for 18 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure. A saturated aqueous solution of ammonium chloride was added to the concentrated solution, and the solution was extracted with ethyl acetate. The organic layer was washed with an aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography (ethyl acetate / hexane=1 / 1 weight ratio) to obtain ethyl 5-cyano-2,2-difluoropentanoate (7.1 g, 37.1 mmol, yield 73%). The obtained ethyl 5-cyano-2,2-difluoropentanoate was 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (400MHz, CDCl3) δ 4.27-4.35 (m, 2H), 2.45 (t, J=7.1 Hz, 2H), 2.15-2.29 (m, 2H), 1.91 (t, 7.1 Hz, 2H), 1.31-1.37 (m, 3H).
[0089] (6) Step F: Preparation of diethyl 2,2-difluorohexanedioate Ethyl 5-cyano-2,2-difluoropentanoate (7.1 g, 37.7 mmol) prepared in step E and acetyl chloride (30 ml) were dissolved in 60 ml of ethanol and refluxed for 48 hours. After the reaction was completed, the mixture was concentrated under reduced pressure. A saturated aqueous solution of sodium bicarbonate was added to the concentrate, and the concentrate was extracted with ethyl acetate. The organic layer was washed with an aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain diethyl 2,2-difluorohexanedioate (6.5 g, 27.3 mmol, yield 74%). The obtained diethyl 2,2-difluorohexanedioate was 1 The synthesis was confirmed by 1 H NMR analysis. 1H NMR (500MHz, CDCl3) δ 4.35 (q. J=7.1 Hz, 2H), 4.16 (q, J=7.1 Hz, 2H), 2.40 (t, J=7.3 Hz, 2H), 2.07-2.20 (m, 2H), 1.86 (m, 2H), 1.38 (t, J=7.2 Hz, 3H), 1.28 (t, J=7.2 Hz, 3H).
[0090] (7) Step G: Preparation of ethyl 3,3-difluoro-2-oxocyclopentane-1-carboxylate The diethyl 2,2-difluorohexanedioate (51.57 g, 216 mmol) prepared in step F was dissolved in tetrahydrofuran (1000 ml), and potassium tert-butoxide (26.7 g, 238 mmol) was slowly added and stirred at room temperature for 4 hours. 240 ml of 1N hydrochloric acid solution was slowly added to the solution after the reaction was completed at 0° C., and the mixture was stirred for about 10 minutes. The reactant was diluted with ethyl acetate, and the organic layer was washed with an aqueous sodium chloride solution. The aqueous solution was extracted with ethyl acetate, and the collected organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure and thoroughly dried under reduced pressure to obtain ethyl 3,3-difluoro-2-oxocyclopentane-1-carboxylate (41.6 g, 216 mmol, yield 99%), which was used in the subsequent reaction without further purification.
[0091] (8) Step H: Preparation of 7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-ol Ethyl 3,3-difluoro-2-oxocyclopentane-1-carboxylate (540 mg, 2.41 mmol), methylisothiourea hemisulfate (672 mg, 4.82 mmol), and sodium carbonate (767 mg, 7.24 mmol) prepared in step G were dissolved in 50 ml of water and stirred at room temperature for 12 hours. After the reaction was completed, excess water was added to the reaction solution, which was then extracted with ethyl acetate. The organic layer was washed with an aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography (ethyl acetate / hexane = 1 / 1 weight ratio) to obtain 7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-ol (250 mg, 1.15 mmol, yield 48%). The resulting 7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-ol was 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, DMSO-D6) δ 1.92-1.97 (m, 2H), 1.81 (s, 3H), 1.71-1.79 (m, 2H).
[0092] (9) Step I: Preparation of 4-chloro-7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidine 7,7-Difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-ol (5.2 g, 23.83 mmol), phosphoryl trichloride (22.21 ml, 238 mmol), and benzyltriethylammonium chloride (5.43 g, 23.93 mmol) prepared in step H were dissolved in 150 ml of dichloroethane and stirred at 80° C. for 3 hours. After the reaction was completed, the reaction solution was distilled under reduced pressure. A saturated sodium bicarbonate solution was added to the concentrated solution, and the solution was extracted with ethyl acetate. The organic layer was washed with an aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography (ethyl acetate / hexane = 1 / 10 weight ratio) to obtain 4-chloro-7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidine (5.00 g, 23.83 mmol, yield 89%). The obtained 4-chloro-7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidine was 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, CDCl3) δ 2.99-3.03 (m, 2H), 2.62-2.71 (m, 5H).
[0093] Production Example 3 The following reaction was carried out to prepare 4-chloro-8,8-difluoro-2-(methylthio)-5,6,7,8-tetrahydroquinazoline represented by the following chemical formula c.
[0094] 8,8-Difluoro-2-(methylthio)-5,6,7,8-tetrahydroquinazolin-4-ol (1.5g, 6.45mmol) and benzyltriethylammonium chloride (1.4g, 6.45mmol) were dissolved in 50ml of dichloroethane, and the temperature was lowered to 0°C. Phosphoryl trichloride (4.95g, 32.29mmol) was added, and the temperature was raised to 90°C and stirred for 1 hour. The reaction solution was concentrated under reduced pressure after the reaction was completed. After adding an excess of water and ethyl acetate, the organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography (ethyl acetate / hexane = 1 / 1 weight ratio) to obtain 4-chloro-8,8-difluoro-2-(methylthio)-5,6,7,8-tetrahydroquinazoline (0.95g, 3.82mmol, yield 59%) of the following chemical formula c. The resulting 4-chloro-8,8-difluoro-2-(methylthio)-5,6,7,8-tetrahydroquinazoline was 1 The synthesis was confirmed by 1 H NMR analysis.
[0095] [Chemical formula c] [ka] 1 H NMR (500MHz, CDCl3) δ 2.86-2.68 (m, 2H), 2.69-2.51 (m, 3H), 2.50-2.23 (m, 2H), 2.04 (tt, J=9.4, 3.2 Hz, 2H).
[0096] Production Example 4 The following reaction was carried out to prepare 4-chloro-8,8-difluoro-2-(methylthio)-5,8-dihydro-6H-pyrano[3,4-d]pyrimidine of the following chemical formula d.
[0097] 8,8-Difluoro-2-(methylthio)-5,8-dihydro-6H-pyrano[3,4-d]pyrimidin-4-ol (3.13g, 13.36mmol) and benzyltriethylammonium chloride (3.03g, 13.36mmol) were dissolved in 50ml of dichloroethane, and the temperature was lowered to 0°C. Phosphoryl trichloride (10.24g, 66.78mmol) was added, and the temperature was raised to 90°C and stirred for 1 hour. The reaction solution was concentrated under reduced pressure after the reaction was completed. After adding an excess of water and ethyl acetate, the organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure and then purified by column chromatography (ethyl acetate / hexane = 1 / 1 weight ratio) to obtain 4-chloro-8,8-difluoro-2-(methylthio)-5,8-dihydro-6H-pyrano[3,4-d]pyrimidine (2.60 g, 10.29 mmol, yield 77%) of the following chemical formula d. The obtained 4-chloro-8,8-difluoro-2-(methylthio)-5,8-dihydro-6H-pyrano[3,4-d]pyrimidine was 1 The synthesis was confirmed by 1 H NMR analysis.
[0098] [Chemical formula d] [ka] 1 H NMR (500MHz, CDCl3) δ 4.37 (t, J=6.0 Hz, 2H), 3.01-2.87 (m, 2H), 2.60 (s, 3H).
[0099] Production Example 5 The following reaction was carried out to prepare 4-chloro-2-(methylthio)-6-(trifluoromethyl)pyrimidine of the following chemical formula e.
[0100] 2-(Methylthio)-6-(trifluoromethyl)pyrimidinyl-4-ol (44 g, 209 mmol), phosphoryl trichloride (66 ml, 837 mmol), and benzyltriethylammonium chloride (23.8 g, 104.7 mmol) were stirred at 80° C. for 3 hours. The reaction solution after the completion of the reaction was concentrated by distillation under reduced pressure. Saturated sodium bicarbonate solution was added to the concentrated solution, and it was extracted with ethyl acetate. The organic layer was washed with an aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography (ethyl acetate / hexane=1 / 10 weight ratio) to obtain 4-chloro-2-(methylthio)-6-(trifluoromethyl)pyrimidine (38.9 g, 170 mmol, yield 81%) of the following chemical formula e. The obtained 4-chloro-2-(methylthio)-6-(trifluoromethyl)pyrimidine was: 1 The synthesis was confirmed by 1 H NMR analysis.
[0101] [Chemical formula e] [ka] 1 H NMR (500MHz, CDCl3) δ 7.27 (s, 1H), 2.60 (s, 3H).
[0102] Production Example 6 The following steps A and B were carried out in order to prepare 4-chloro-5-methyl-2-(methylthio)-6-(trifluoromethyl)pyrimidine of the following chemical formula f.
[0103] [chemical formula f] [ka]
[0104] (1) Step A: Preparation of 5-methyl-2-(methylthio)-6-(trifluoromethyl)pyrimidin-4-ol Ethyl 4,4,4-trifluoro-2-methyl-3-oxobutanoate (5.0 g, 25.2 mmol), methylisothiourea hemisulfate (7.0 g, 50.3 mmol), and sodium carbonate (5.3 g, 50 mmol) were dissolved in 40 ml of water and stirred at room temperature for 12 hours. After the reaction was completed, an excess amount of water was added to the reaction solution, which was then extracted with ethyl acetate. The organic layer was washed with an aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography (ethyl acetate / hexane = 1 / 1 weight ratio) to obtain 5-methyl-2-(methylthio)-6-(trifluoromethyl)pyrimidin-4-ol (4.0 g, 17.8 mmol, yield 71%). The obtained 5-methyl-2-(methylthio)-6-(trifluoromethyl)pyrimidin-4-ol was, 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, DMSO-d6) δ 13.29 (s, 1H), 2.49 (s, 3H), 2.03 (s, 3H).
[0105] (2) Step B: Preparation of 4-chloro-5-methyl-2-(methylthio)-6-(trifluoromethyl)pyrimidine In Preparation Example 5, instead of 2-(methylthio)-6-(trifluoromethyl)pyrimidinyl-4-ol, 5-methyl-2-(methylthio)-6-(trifluoromethyl)pyrimidin-4-ol (18 g, 80 mmol) prepared in Step A was used to obtain the title compound, 4-chloro-5-methyl-2-(methylthio)-6-(trifluoromethyl)pyrimidine (16.46 g, 67.8 mmol, 84% yield). The obtained 4-chloro-5-methyl-2-(methylthio)-6-(trifluoromethyl)pyrimidine was 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, CDCl3) δ 2.57 (s, 3H), 2.42 (q, J=1.5 Hz, 3H).
[0106] Production Example 7 The following reaction was carried out to prepare tert-butyl 4-(2-bromoacetyl)piperazine-1-carboxylate of the following chemical formula g.
[0107] tert-Butyl piperazine-1-carboxylate (6.00g, 32.21mmol) and diisopropylethylamine (8.32g, 64.37mmol) were dissolved in 200ml of dichloromethane and cooled to -78℃. Bromoacetyl bromide (7.15g, 35.43mmol) was slowly added and stirred for 1 hour while gradually raising the temperature to room temperature. After the reaction was completed, the reaction solution was concentrated under reduced pressure. 1N aqueous hydrochloric acid was added and extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography (ethyl acetate / hexane = 1 / 1 weight ratio) to obtain tert-butyl 4-(2-bromoacetyl)piperazine-1-carboxylate (6.62g, 21.5mmol, yield 66%) of the following chemical formula g. The resulting tert-butyl 4-(2-bromoacetyl)piperazine-1-carboxylate was 1 The synthesis was confirmed by 1 H NMR analysis.
[0108] [Chemical formula g] [ka] 1 H NMR (400MHz, CDCl3) δ 3.87 (s, 2H), 3.77-3.55 (m, 2H), 3.51 (dd, J=16.2, 5.8 Hz, 4H), 3.47-3.32 (m, 2H), 1.49 (d, J=18.3 Hz, 9H).
[0109] Production Example 8 The following steps A and B were carried out in order to prepare tert-butyl 4-(2-(azetidin-3-yl)acetyl)piperazine-1-carboxylate of the following chemical formula h.
[0110] [Chemical formula h] [ka]
[0111] (1) Step A: Preparation of benzyl 4-(2-((1-tert-butoxycarbonyl)azetidin-3-yl)acetyl)piperazine-1-carboxylate Benzyl 3-hydroxyazetidine-1-carboxylate (15g, 72.34mmol) was dissolved in 200ml of dimethylformamide and cooled to 0℃. Sodium hydride (60%, 3.18g, 79.57mmol) was added and stirred for 30 minutes. tert-Butyl 4-(2-bromoacetyl)piperazine-1-carboxylate (26.67g, 86.81mmol) was slowly added and stirred for 18 hours at room temperature while gradually increasing the temperature. After the reaction was completed, the reaction solution was concentrated under reduced pressure. It was extracted with water and ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography (ethyl acetate / hexane = 1 / 1 weight ratio) to obtain benzyl 4-(2-((1-tert-butoxycarbonyl)azetidin-3-yl)acetyl)piperazine-1-carboxylate (27.61 g, 63.68 mmol, yield 88%). The obtained benzyl 4-(2-((1-tert-butoxycarbonyl)azetidin-3-yl)acetyl)piperazine-1-carboxylate was 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (400MHz, MeOD) δ 7.32 (d, J=16.2 Hz, 5H), 5.07 (s, 2H), 4.38 (d, J=4.6 Hz, 1H), 4.20 (d, J=27.2 Jz. 4H), 3.93 (s, 2H), 3.63-3.49 (m, 2H), 3.43 (s, 6H), 1.64-1.35 (m, 9H).
[0112] (2) Step B: Preparation of tert-butyl 4-(2-(azetidin-3-yl)acetyl)piperazine-1-carboxylate Benzyl 4-(2-((1-tert-butoxycarbonyl)azetidin-3-yl)acetyl)piperazine-1-carboxylate (51.01 g, 117.66 mmol) prepared in step A was dissolved in 300 ml of methanol, and then palladium / charcoal (10 wt%, 3 g) was added and stirred at room temperature for 18 hours. After the reaction was completed, the mixture was filtered through celite and washed with methanol. The filtrate was concentrated under reduced pressure to obtain tert-butyl 4-(2-(azetidin-3-yl)acetyl)piperazine-1-carboxylate (38.81 g, 129.63 mmol, yield 110%). The obtained tert-butyl 4-(2-(azetidin-3-yl)acetyl)piperazine-1-carboxylate was 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (400MHz, MeOD) δ 4.48-4.32 (m, 1H), 4.19 (s, 2H), 32.77-3.66 (m, 2H), 3.63 (t, J=7.3 Hz, 2H), 3.55 (s, 2H), 3.50-3.38 (m, 6H), 1.64-1.38 (m, 9H).
[0113] Production Example 9 Steps A and B of Preparation Example 8 were carried out in order, except that benzyl 4-hydroxypiperidine-1-carboxylate (750 mg, 3.19 mmol) was used instead of benzyl 3-hydroxyazetidine-1-carboxylate in Step A of Preparation Example 8, to prepare tert-butyl 4-(2-(piperidin-2-4-yl)acetyl)piperazine-1-carboxylate (800 mg, 2.44 mmol, 76% yield) of the following formula i. The prepared tert-butyl 4-(2-(piperidin-2-4-yl)acetyl)piperazine-1-carboxylate was 1 The synthesis was confirmed by 1 H NMR analysis.
[0114] [Chemical formula i] [ka] 1 H NMR (400MHz, CDCl3) δ 7.37-7.28 (m, 5H), 5.14 (s, 2H), 4.61 (s, 2H), 3.82 (m, 2H), 3.59-3.44 (m, 9H), 3.25 (m, 2H), 1.88 (m, 2H), 1.59 (m, 2H), 1.49 (s, 9H).
[0115] Manufacturing Example 10 The following steps A to E were carried out in order to produce tert-butyl 4-((((1R,5S,6R)-3-azabicyclo[3.1.0]hexan-5-yl)methyl)sulfonyl)piperazine-1-carboxylate represented by the following chemical formula j.
[0116] [chemical formula j] [ka]
[0117] (1) Step A: Preparation of benzyl (1R,5S,6R)-6-(((methylsulfonyl)oxy)methyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate Benzyl (1R,5S,6R)-6-(hydroxymethyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (862 mg, 3.49 mmol) was dissolved in 20 ml of dichloromethane, cooled with ice water, and then triethylamine (0.73 ml, 5.23 mmol) was added. Methanesulfonyl chloride (0.35 ml, 4.53 mmol) was slowly added and stirred for 1 hour. After the reaction was completed, water was added to the reaction solution and extracted with dichloromethane. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to obtain benzyl (1R,5S,6R)-6-(((methylsulfonyl)oxy)methyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (1.174 g, 99% yield). It was used in the subsequent reaction without further purification. The produced benzyl (1R,5S,6R)-6-(((methylsulfonyl)oxy)methyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate was 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, CDCl3) δ 7.32-7.40 (m, 5H), 5.13 (d, J=2.1 Hz, 2H), 4.10-4.20 (m, 2H), 3.73 (m, 2H), 3.46-3.50 (m, 2H), 3.04 (s, 3H), 1.66 (s, 2H), 1.12-1.16 (m, 1H).
[0118] (2) Step B: Preparation of benzyl (1R,5S,6R)-6-((acetylthio)methyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate Benzyl (1R,5S,6R)-6-(((methylsulfonyl)oxy)methyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (135 mg, 0.145 mmol) prepared in step A and potassium thioacetate (62 mg, 0.539 mmol) were dissolved in acetonitrile and stirred at 60° C. for 2 hours. After the reaction was completed, the mixture was extracted with ethyl acetate, washed with water and saturated sodium chloride solution, and the organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography (ethyl acetate / hexane) to obtain benzyl (1R,5S,6R)-6-((acetylthio)methyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (93 mg, 73% yield). The resulting benzyl (1R,5S,6R)-6-((acetylthio)methyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate was 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (400MHz, CDCl3) δ 7.27-7.36 (m, 5H), 5.08 (d, J=2.3 Hz, 2H), 3.63 (dd, J=17.8, 11.0 Hz, 2H), 3.38 (t, J=9.1 Hz, 2H), 2.80-2.87 (m, 2H), 2.32 (s, 3H), 1.46 (s, 2H), 0.81-0.86 (m, 1H).
[0119] (3) Step C: Preparation of benzyl (1R,5S,6R)-6-((chlorosulfonyl)methyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate Benzyl (1R,5S,6R)-6-((acetylthio)methyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (93 mg, 0.305 mmol) prepared in step B was dissolved in 10 ml of acetonitrile and cooled to 0°C. N-chlorosuccinimide (163 mg, 1.218 mmol) and 1N hydrochloric acid solution (0.365 ml, 0.365 mmol) were added and stirred at room temperature for 18 hours. After the reaction was completed, the mixture was concentrated under reduced pressure, dissolved in ethyl acetate, washed with saturated sodium chloride solution, and the organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to obtain benzyl (1R,5S,6R)-6-((chlorosulfonyl)methyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (151 mg), which was used in the next reaction without purification.
[0120] (4) Step D: Preparation of benzyl (1R,5S,6R)-6-(((4-(tert-butoxycarbonyl)piperazin-1-yl)sulfonyl)methyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate Benzyl (1R,5S,6R)-6-((chlorosulfonyl)methyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (100 mg, 0.303 mmol) prepared in step C was dissolved in 10 ml of dichloromethane and cooled to 0°C. tert-Butyl piperazine-1-carboxylate (68 mg, 0.364 mmol) and diisopropylethylamine (0.11 ml, 0.606 mmol) were added and stirred at room temperature for 3 hours. After the reaction was completed, it was extracted with dichloromethane, and the organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure and then purified by column chromatography (ethyl acetate / hexane = 1 / 1 weight ratio) to obtain benzyl (1R,5S,6R)-6-(((4-(tert-butoxycarbonyl)piperazin-1-yl)sulfonyl)methyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (145 mg, yield 86%). 1 The synthesis was confirmed by 1 H NMR analysis. 1H NMR (400MHz, CDCl3) δ 7.27-7.37 (m, 5H), 5.09 (m, 2H), 3.70 (dd, J=15.6, 11.0 Hz, 2H), 3.42-3.50 (m, 6H), 3.24 (t, J=5.0 Hz, 4H), 2.88 (m, 2H), 1.58-1.62 (m, 2H), 1.48 (d, J=14.6 Hz, 9H), 0.92-0.97 (m, 1H).
[0121] (5) Step E: Preparation of tert-butyl 4-((((1R,5S,6R)-3-azabicyclo[3.1.0]hexan-6-yl)methyl)sulfonyl)piperazine-1-carboxylate Benzyl (1R,5S,6R)-6-(((4-(tert-butoxycarbonyl)piperazin-1-yl)sulfonyl)methyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (125 mg, 0.261 mmol) prepared in step D was dissolved in 10 ml of methanol, and then 10 wt% palladium / charcoal (27 mg, 0.026 mmol) was added and stirred with hydrogen gas. After the reaction was completed, the mixture was filtered through Celite and concentrated under reduced pressure to obtain tert-butyl 4-((((1R,5S,6R)-3-azabicyclo[3.1.0]hexane-6-yl)methyl)sulfonyl)piperazine-1-carboxylate (89 mg, 99% yield), 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (400MHz, CDCl3) δ 3.50 (t, J=5.0 Hz, 4H), 3.25 (t, J=4.8 Hz, 4H), 3.00-3.05 (m, 2H), 2.90 (d, J=7.3 Hz, 4H), 1.59 (br, 2H), 1.46 (s, 9H), 0.90-0.95 (m, 1H).
[0122] Example 1: Preparation of (S)-2-((1-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)azetidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one As shown in the following reaction scheme 1, steps A to D were carried out in order to prepare the title compound of formula 1-1.
[0123] [Reaction Scheme 1] [ka]
[0124] (1) Step A: Preparation of 1-(2-chloro-6-(trifluoromethyl)pyrimidin-4-yl)azetidin-3-ol 2,4-Dichloro-6-(trifluoromethyl)pyrimidine (500 mg, 2.30 mmol), azetidin-3-ol hydrochloride (252 mg, 2.30 mmol), and diisopropylethylamine (1.2 ml, 6.91 mmol) were dissolved in 50 ml of dichloromethane and stirred at room temperature for 2 hours. After the reaction was completed, 1N aqueous hydrochloric acid was added to the reaction solution and extracted with dichloromethane. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography to obtain 1-(2-chloro-6-(trifluoromethyl)pyrimidin-4-yl)azetidin-3-ol (550 mg, 2.17 mmol, yield 94%) (mass [M+H] = 254.6). 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, CDCl3) δ 6.40 (d, J=12.5 Hz, 1H), 4.90 (d, J=4.9 Hz, 1H), 4.63-4.27 (m, 2H), 4.08 (s, 2H), 2.43 (d, J=5.2 Hz, 1H).
[0125] (2) Step B: Preparation of (S)-1-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)azetidin-3-ol 1-(2-chloro-6-(trifluoromethyl)pyrimidin-4-yl)azetidin-3-ol (200 mg, 0.78 mmol) prepared in step A, (2S)-2-methylazetidine [(1R,4S)-7,7-methyl-2-oxo-norbornan-1-yl] methanesulfonate (285 mg, 0.94 mmol), and triethylamine (236 mg, 2.36 mmol) were dissolved in 10 ml of acetonitrile and stirred at 80 ° C for 1 hour. After the reaction was completed, the mixture was cooled to room temperature, concentrated under reduced pressure, dissolved in ethyl acetate, and washed with saturated sodium chloride solution. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (ethyl acetate / hexane=1 / 1 weight ratio) to obtain (S)-1-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)azetidin-3-ol (219 mg, 0.75 mmol, yield 96%). 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, CDCl3) δ 5.84 (d, J=2.4 Hz, 1H), 4.85-4.70 (m, 1H), 4.51-4.37 (m, 1H), 4.37-4.21 (m, 2H), 4.03 (td, J=8.9, 5.0 Hz, 1H), 3.99-3.81 (m, 3H), 2.47-2.30 (m, 1H), 2.23 (d, J=6.1 Hz, 1H), 2.02-1.85 (m, 1H), 1.48 (t, J=5.6 Hz, 3H).
[0126] (3) Step C: Preparation of tert-butyl (S)-4-(2-((1-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)azetidin-3-yl)oxy)acetyl)piperazine-1-carboxylate (S)-1-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)azetidin-3-ol (50 mg, 0.17 mmol) prepared in step B was dissolved in 10 ml of dimethylformamide and cooled to 0° C. Sodium hydride (60%, 8 mg, 0.20 mmol) was added and stirred for 30 minutes. tert-Butyl 4-(2-bromoacetyl)piperazine-1-carboxylate (64 mg, 0.21 mmol) prepared in Preparation Example 7 was added and stirred at room temperature for 16 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure. The solution was dissolved in ethyl acetate and washed with saturated sodium chloride solution. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (ethyl acetate / hexane=1 / 1 weight ratio) to obtain tert-butyl (S)-4-(2-((1-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)azetidin-3-yl)oxy)acetyl)piperazine-1-carboxylate (29 mg, 0.05 mmol, yield 21%). 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, CDCl3) δ 5.84 (d, J=3.1 Hz, 1H), 4.51 (dd, J=10.4, 4.3 Hz, 1H), 4.48-4.36 (m, 1H), 4.32-4.21 (m, 2H), 4.18 (s, 2H), 4.09-3.95 (m, 2H), 3.66-3.57 (m, 2H), 3.55-3.31 (m, 8H), 2.46-2.30 (m, 1H), 2.01-1.85 (m, 1H), 1.49-1.40 (m, 12H).
[0127] (4) Step D: Preparation of (S)-2-((1-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)azetidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one tert-Butyl (S)-4-(2-((1-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)azetidin-3-yl)oxy)acetyl)piperazine-1-carboxylate (29 mg, 0.056 mmol) prepared in step C and 1 ml of trifluoroacetic acid were dissolved in 5 ml of dichloromethane and stirred for 18 hours. After the reaction was completed, the reaction solution was dried under reduced pressure, and ethyl acetate and a saturated aqueous ammonium chloride solution were added, followed by extraction with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (dichloromethane / 7N ammonia methanol=10 / 1 weight ratio) to obtain (S)-2-((1-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)azetidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one (23 mg, 0.056 mmol, yield 100%). 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, MeOH-d4) δ 5.79 (d, J=2.7 Hz, 1H), 4.59-4.35 (m, 2H), 4.33-4.18 (m, 4H), 4.07-3.83 (m, 4H), 3.64-3.37 (m, 4H), 2.89-2.74 (m, 4H), 2.49-2.32 (m, 1H), 1.96 (d, J=6.4 Hz, 1H), 1.55-1.39 (m, 3H).
[0128] Example 2: Preparation of (S)-2-((1-(5-chloro-2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)azetidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one As shown in the following reaction scheme 2, steps A to D were carried out in order to prepare the title compound of formula 1-2.
[0129] [Reaction Scheme 2] [ka]
[0130] (1) Step A: Preparation of tert-butyl 4-(2-((1-(5-chloro-2-(methylthio)-6-(trifluoromethyl)pyrimidin-4-yl)azetidin-3-yl)oxy)acetyl)piperazine-1-carboxylate 4,5-Dichloro-2-(methylthio)-6-(trifluoromethyl)pyrimidine (1.0g, 3.80mmol), tert-butyl 4-(2-(azetidin-3-yloxy)acetyl)piperazine-1-carboxylate (1.7g, 5.70mmol), and diisopropylethylamine (2.0ml, 11.4mmol) were dissolved in 100ml of dichloromethane and stirred at room temperature for 2 hours. After the reaction was completed, an excess amount of water was added to the reaction solution and extracted with dichloromethane. The organic layer was washed with a saturated aqueous sodium chloride solution, and then the organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure and then purified by column chromatography (ethyl acetate / hexane=1 / 1 weight ratio) to obtain tert-butyl 4-(2-((1-(5-chloro-2-(methylthio)-6-(trifluoromethyl)pyrimidin-4-yl)azetidin-3-yl)oxy)acetyl)piperazine-1-carboxylate (1.2 g, 2.28 mmol, yield 60%). 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, CDCl3) δ 4.62 (br, s, 2H), 4.67 (m, 1H), 4.36 (br, s, 2H), 4.18 (s, 2H), 3.58 (br, s, 2H), 3.44 (br, s, 6H), 2.47 (s, 3H), 1.46 (s, 9H).
[0131] (2) Step B: Preparation of tert-butyl 4-(2-((1-(5-chloro-2-(methylsulfonyl)-6-(trifluoromethyl)pyrimidin-4-yl)azetidin-3-yl)oxy)acetyl)piperazine-1-carboxylate tert-Butyl 4-(2-((1-(5-chloro-2-(methylthio)-6-(trifluoromethyl)pyrimidin-4-yl)azetidin-3-yl)oxy)acetyl)piperazine-1-carboxylate (1.2 g, 2.28 mmol) prepared in step A and 3-chloroperbenzoic acid (70%, 1.41 g, 5.70 mmol) were dissolved in 100 ml of dichloromethane and stirred at room temperature for 10 hours. After the reaction was completed, a saturated sodium thiosulfate solution and a saturated sodium bicarbonate solution were added to the reaction solution in this order, and the solution was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (methanol / dichloromethane=1 / 9 weight ratio) to obtain tert-butyl 4-(2-((1-(5-chloro-2-(methylsulfonyl)-6-(trifluoromethyl)pyrimidin-4-yl)azetidin-3-yl)oxy)acetyl)piperazine-1-carboxylate (1.2 g, 2.28 mmol, yield 94%). 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, CDCl3) δ 5.11-4.90 (1H), 4.48-4.53 (m, 2H), 4.21 (s, 2H), 3.58 (s, 2H), 3.39-3.44 (m, 6H), 3.29 (d, J=6.9 Hz, 3H), 1.46 (s, 9H).
[0132] (3) Step C: Preparation of tert-butyl (S)-4-(2-((1-(5-chloro-2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)azetidin-3-yl)oxy)acetyl)piperazine-1-carboxylate tert-Butyl 4-(2-((1-(5-chloro-2-(methylsulfonyl)-6-(trifluoromethyl)pyrimidin-4-yl)azetidin-3-yl)oxy)acetyl)piperazine-1-carboxylate (200 mg, 0.36 mmol) prepared in step B, (2S)-2-methylazetidine [(1R,4S)-7,7-dimethyl-2-oxo-norbornan-1-yl] methanesulfonate (253 mg, 0.54 mmol), and potassium carbonate (149 mg, 1.08 mmol) were dissolved in 20 ml of acetonitrile and stirred at 80° C. for 2 hours. After the reaction was completed, an excess of water was added to the reaction solution and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (ethyl acetate / hexane=1 / 1 weight ratio) to obtain tert-butyl (S)-4-(2-((1-(5-chloro-2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)azetidin-3-yl)oxy)acetyl)piperazine-1-carboxylate (140 mg, 0.26 mmol, yield 72%). 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, CDCl3) δ 4.59 (m, 2H), 4.45 (m, 2H), 4.26 (m, 2H), 4.19 (s, 2H), 4.01 (m, 1H), 3.03 (m, 1H), 3.61 (s, 2H), 3.48 (br s, 6H), 2.40 (m, 1H), 1.95 (m, 1H), 1.60 (s, 9H), 1.59 (d, 3H).
[0133] (4) Step D: Preparation of (S)-4-(2-((1-(5-chloro-2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)azetidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one tert-Butyl (S)-4-(2-((1-(5-chloro-2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)azetidin-3-yl)oxy)acetyl)piperazine-1-carboxylate (140 mg, 0.26 mmol) prepared in step C and 1 ml of trifluoroacetic acid were dissolved in 3 ml of dichloromethane and stirred at room temperature for 10 hours. After the reaction was completed, a saturated sodium bicarbonate solution was added to the reaction solution, which was then extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (7N ammonia methanol solution / dichloromethane=1 / 9 weight ratio) to obtain (S)-4-(2-((1-(5-chloro-2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)azetidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one (100 mg, 0.22 mmol, yield 87%). 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, CDCl3) δ 4.50 (d, J=6.4 Hz, 2H), 4.36-4.44 (m, 2H), 4.23 (d, J=10.1 Hz, 2H), 4.16 (s, 2H), 3.86-4.00 (m, 2H), 3.64 (s, 2H), 3.51 (s, 2H), 2.91 (s, 4H), 2.32-2.41 (m, 1H), 1.88-1.96 (m, 1H), 1.46 (t, J=6.4 Hz, 3H).
[0134] Example 3: Preparation of (S)-2-((1-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)azetidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one As shown in the following reaction scheme 3, steps A to E were carried out in order to prepare the title compound of formula 1-3.
[0135] [Reaction Scheme 3] [ka]
[0136] (1) Step A: Preparation of 4-chloro-7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine 4-Chloro-7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidine (3.00g, 12.73mmol) and 3-chloroperbenzoic acid (5.51g, 31.82mmol) were dissolved in 200ml of dichloromethane and stirred at room temperature for 16 hours. After the reaction was completed, saturated sodium thiosulfate solution and saturated sodium bicarbonate solution were added to the reaction solution in order, and the solution was extracted with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography (ethyl acetate / hexane = 1 / 1 weight ratio) to obtain 4-chloro-7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine (3.21g, 11.94mmol, yield 93%). 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, CDCl3) δ 3.44 (d, J=12.5 Hz, 3H), 3.34-3.11 (m, 2H), 2.88-2.68 (m, 2H).
[0137] (2) Step B: Preparation of 1-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)azetidin-3-ol 4-Chloro-7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine (348 mg, 1.29 mmol), azetidin-3-ol hydrochloride (156 mg, 1.42 mmol), and triethylamine (393 mg, 3.88 mmol) prepared in step A were dissolved in 20 ml of dichloromethane and stirred at room temperature for 2 hours. After the reaction was completed, 1N aqueous hydrochloric acid was added to the reaction solution and extracted with dichloromethane. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (methanol / dichloromethane=1 / 10 weight ratio) to obtain 1-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)azetidin-3-ol (257 mg, 0.84 mmol, yield 65%). 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, CDCl3) δ 4.89 (s, 1H), 4.66 (s, 1H), 4.31 (s, 1H), 3.35 (s, 3H), 3.03 (d, J=7.6 Hz, 2H), 2.72-2.55 (m, 2H), 1.37-1.26 (m, 2H).
[0138] (3) Step C: Preparation of (S)-1-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)azetidin-3-ol 1-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)azetidin-3-ol (257 mg, 0.84 mmol) prepared in step B, (2S)-2-methylazetidine[(1R,4S)-7,7-dimethyl-2-oxo-norbornan-1-yl]methanesulfonate (306 mg, 1.01 mmol), and potassium carbonate (348 mg, 2.52 mmol) were dissolved in 30 ml of acetonitrile and stirred at 80° C. for 1 hour. After the reaction was completed, the reaction solution was concentrated under reduced pressure, a saturated sodium bicarbonate solution was added, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (ethyl acetate / hexane=1 / 1 weight ratio) to obtain (S)-1-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)azetidin-3-ol (182 mg, 0.61 mmol, yield 72%). 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, MeOH-d4) δ 4.73-4.59 (m, 1H), 4.51-4.33 (m, 3H), 4.00 (td, J=8.7, 4.9 Hz, 3H), 3.88 (dd, J=16.0, 8.7 Hz, 1H), 2.85 (d, J=4.3 Hz, 2H), 2.55-2.30 (m, 3H), 2.01-1.84 (m, 1H), 1.52 (dd, J=48.1, 6.3 Hz, 3H).
[0139] (4) Step D: Preparation of tert-butyl (S)-4-(2-((1-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)azetidin-3-yl)oxy)acetyl)piperazine-1-carboxylate (S)-1-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)azetidin-3-ol (182 mg, 0.61 mmol) prepared in step C was dissolved in 10 ml of dimethylformamide and cooled to 0° C. Sodium hydride (60%, 30 mg, 0.73 mmol) was added and stirred for 30 minutes. tert-Butyl 4-(2-bromoacetyl)piperazine-1-carboxylate (283 mg, 0.92 mmol) prepared in Preparation Example 7 was added and stirred at room temperature for 16 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure, a saturated aqueous ammonium chloride solution was added, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (ethyl acetate / hexane=2 / 1 weight ratio) to obtain tert-butyl (S)-4-(2-((1-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)azetidin-3-yl)oxy)acetyl)piperazine-1-carboxylate (171 mg, 0.32 mmol, yield 53%). 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, CDCl3) δ 4.58-4.47 (m, 1H), 4.39 (s, 1H), 4.20 (s, 2H), 4.14 (s, 3H), 4.04-3.90 (m, 1H), 3.76-3.56 (m, 2H), 3.48 (s, 8H), 2.80 (d, J=4.3 Hz, 2H), 2.57-2.42 (m, 2H), 2.42-2.29 (m, 1H), 2.01-1.86 (m, 1H), 1.50 (d, J=6.4 Hz, 12H).
[0140] (5) Step E: Preparation of (S)-2-((1-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)azetidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one tert-Butyl (S)-4-(2-((1-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)azetidin-3-yl)oxy)acetyl)piperazine-1-carboxylate (133 mg, 0.25 mmol) prepared in step D and 1 ml of trifluoroacetic acid were dissolved in 5 ml of dichloromethane and stirred for 18 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure, and a saturated aqueous ammonium chloride solution was added, followed by extraction with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (dichloromethane / 7N ammonia methanol=10 / 1 weight ratio) to obtain (S)-2-((1-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)azetidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one (68 mg, 0.16 mmol, yield 63%). 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, MeOH-d4) δ 4.52-4.25 (m, 4H), 4.21 (s, 2H), 4.07 (s, 2H), 4.00-3.75 (m, 2H), 3.44 (dt, J=58.6, 4.9 Hz, 4H), 2.85-2.67 (m, 6H), 2.49-2.24 (m, 3H), 1.96-1.79 (m, 1H), 1.42 (d, J=6.4 Hz, 3H).
[0141] Example 4: Preparation of (S)-2-((1-(8,8-difluoro-2-(2-(methylazetidin-1-yl)-5,6,7,8-tetrahydroquinazolin-4-yl)azetidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one As shown in the following reaction scheme 4, steps A to E were carried out in order to prepare the title compound of formula 1-4.
[0142] [Reaction Scheme 4] [ka]
[0143] (1) Step A: Preparation of 4-chloro-8,8-difluoro-2-(methylsulfonyl)-5,6,7,8-tetrahydroquinazoline 4-Chloro-8,8-difluoro-2-(methylsulfonyl)-5,6,7,8-tetrahydroquinazoline was prepared in the same manner as in Step A of Example 3, except that 4-chloro-7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidine was replaced with 4-chloro-8,8-difluoro-2-(methylthio)-5,6,7,8-tetrahydroquinazoline (89 mg, 0.35 mmol).
[0144] (2) Step B: Preparation of 1-(8,8-difluoro-2-(methylsulfonyl)-5,6,7,8-tetrahydroquinazolin-4-yl)azetidin-3-ol In step B of Example 3, 4-chloro-7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine was replaced with 4-chloro-8,8-difluoro-2-(methylsulfonyl)-5,6,7,8-tetrahydroquinazoline prepared in step A, except that azetidin-3-ol hydrochloride (41 mg, 0.38 mmol) was reacted with 1-(8,8-difluoro-2-(methylsulfonyl)-5,6,7,8-tetrahydroquinazolin-4-yl)azetidin-3-ol was prepared in the same manner as in step B of Example 3.
[0145] (3) Step C: Preparation of (S)-1-(8,8-difluoro-2-(2-methylazetidin-1-yl)-5,6,7,8-tetrahydroquinazolin-4-yl)azetidin-3-ol In step C of Example 3, instead of 1-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)azetidin-3-ol, 1-(8,8-difluoro-2-(methylsulfonyl)-5,6,7,8-tetrahydroquinazolin-4-yl)azetidin-3-ol prepared in step B was reacted with (2S)-2-methylazetidine [(1R,4S)-7,7-dimethyl-2-oxo-norbornan-1-yl] methanesulfonate (105 mg, 0.41 mmol), and the same procedure as in step C of Example 3 was carried out to prepare (S)-1-(8,8-difluoro-2-(2-methylazetidin-1-yl)-5,6,7,8-tetrahydroquinazolin-4-yl)azetidin-3-ol.
[0146] (4) Step D: Preparation of tert-butyl (S)-4-(2-((1-(8,8-difluoro-2-(2-methylazetidin-1-yl)-5,6,7,8-tetrahydroquinazolin-4-yl)azetidin-3-yl)oxy)acetyl)piperazine-1-carboxylate In step D of Example 3, instead of (S)-1-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)azetidin-3-ol, (S)-1-(8,8-difluoro-2-(2-methylazetidin-1-yl)-5,6,7,8-tetrahydroquinazolin-4-yl)azetidin-3-ol prepared in step C was used. The procedure was repeated as in Step D of Example 3, except that tert-butyl 4-(2-bromoacetyl)piperazine-1-carboxylate (105 mg, 0.34 mmol) was used to prepare tert-butyl (S)-4-(2-((1-(8,8-difluoro-2-(2-methylazetidin-1-yl)-5,6,7,8-tetrahydroquinazolin-4-yl)azetidin-3-yl)oxy)acetyl)piperazine-1-carboxylate.
[0147] (5) Step E: Preparation of (S)-2-((1-(8,8-difluoro-2-(2-methylazetidin-1-yl)-5,6,7,8-tetrahydroquinazolin-4-yl)azetidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one In step E of Example 3, instead of tert-butyl (S)-4-(2-((1-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)azetidin-3-yl)oxy)acetyl)piperazine-1-carboxylate, tert-butyl (S)-4-(2-((1-(8,8-difluoro-2-(2-methylazetidin-1-yl)-5,6,7 to give (S)-2-((1-(8,8-difluoro-2-(2-methylazetidin-1-yl)-5,6,7,8-tetrahydroquinazolin-4-yl)azetidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one (73 mg, 0.13 mmol, 39% yield),1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, MeOH-d4) δ 4.49-4.30 (m, 4H), 4.24 (s, 2H), 4.19-4.01 (m, 2H), 4.02-3.92 (m, 1H), 3.85 (q, J=8.3 Hz, 1H), 3.63-3.50 (m, 2H), 3.43 (t, J=4.9 Hz, 2H), 2.89-2.73 (m, 4H), 2.55 (s, 2H), 2.43-2.31 (m, 1H), 2.31-2.10 (m, 2H), 2.00-1.89 (m, 1H), 1.85 (q, J=6.1 Hz, 2H), 1.55-1.37 (m, 3H).
[0148] Example 5: Preparation of 2-(((2S,3R)-1-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-methylazetidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one As shown in the following reaction scheme 5, steps A to E were carried out in order to prepare the title compound of formula 1-5.
[0149] [Reaction Scheme 5] [ka]
[0150] (1) Step A: Preparation of 4-chloro-7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine 4-Chloro-7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine was produced in the same manner as in Step A of Example 3, except that 94 mg, 0.40 mmol of 4-chloro-7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidine was used in Step A of Example 3.
[0151] (2) Step B: Preparation of (2S)-1-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-methylazetidin-3-ol The same procedure as in Step B of Example 3 was carried out, except that (2S,3R)-2-methylazetidin-3-ol (7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl) methanesulfonate (142 mg, 0.44 mmol) was used instead of azetidin-3-ol hydrochloride, to prepare (2S)-1-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-methylazetidin-3-ol.
[0152] (3) Step C: Preparation of (2S)-1-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-methylazetidin-3-ol In step C of Example 3, instead of 1-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)azetidin-3-ol, (2S)-1-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-methylazetidin-3-ol prepared in step B was used as (2S)-2-methylazetidin-3-ol. The procedure was repeated as in step C of example 3, except that ethylazetidine [(1R,4S)-7,7-dimethyl-2-oxo-norbornan-1-yl]methanesulfonate (134 mg, 0.44 mmol) was used to prepare (2S)-1-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-methylazetidin-3-ol.
[0153] (4) Step D: Preparation of tert-butyl 4-(2-(((2S)-1-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-methylazetidin-3-yl)oxy)acetyl)piperazine-1-carboxylate In step D of Example 3, instead of (S)-1-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)azetidin-3-ol, (2S)-1-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-methylazetidin-3-ol prepared in step C was used. The procedure was repeated as in step D of example 3, except that tert-butyl 4-(2-bromoacetyl)piperazine-1-carboxylate (149 mg, 0.48 mmol) was used to prepare tert-butyl 4-(2-(((2S)-1-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-methylazetidin-3-yl)oxy)acetyl)piperazine-1-carboxylate.
[0154] (5) Step E: Preparation of 2-(((2S,3R)-1-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-methylazetidin-3-yl)oxy)-1-(piperidin-1-yl)ethan-1-one In step E of Example 3, instead of tert-butyl (S)-4-(2-((1-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)azetidin-3-yl)oxy)acetyl)piperazine-1-carboxylate, tert-butyl 4-(2-(((2S)-1-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[ d]pyrimidin-4-yl)-2-methylazetidin-3-yl)oxy)acetyl)piperazine-1-carboxylate to give 2-(((2S,3R)-1-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-methylazetidin-3-yl)oxy)-1-(piperidin-1-yl)ethan-1-one (59 mg, 0.13 mmol, 32% yield), 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, MeOH-d4) δ 4.52-4.35 (m, 3H), 4.35-4.19 (m, 2H), 4.13-3.96 (m, 3H), 3.89 (q, J=8.2 Hz, 1H), 3.54 (d, J=4.3 Hz, 2H), 3.44 (s, 2H), 2.95-2.86 (m, 1H), 2.86-2.70 (m, 5H), 2.54-2.30 (m, 3H), 2.01-1.86 (m, 1H), 1.59-1.50 (m, 3H), 1.47 (dd, J=14.8, 6.3Hz, 3H).
[0155] Example 6: Preparation of 2-(((S)-1-(2-((S)-2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)pyrrolidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one As shown in the following reaction scheme 6, steps A to D were carried out in order to prepare the title compound of formula 1-6. [Reaction Scheme 6] [ka]
[0156] (1) Step A: Preparation of 1-(2-chloro-6-(trifluoromethyl)pyrimidin-4-yl)pyrrolidin-3-ol The same procedure as in Step A of Example 1 was carried out, except that in Step A of Example 1, 2,4-dichloro-6-(trifluoromethyl)pyrimidine (45 mg, 0.17 mmol) was reacted with (S)-pyrrolidin-3-ol (14 mg, 0.17 mmol) instead of azetidin-3-ol hydrochloride, to produce 1-(2-chloro-6-(trifluoromethyl)pyrimidin-4-yl)pyrrolidin-3-ol.
[0157] (2) Step B: Preparation of 1-(2-((S)-2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)pyrrolidin-3-ol In step B of Example 1, 1-(2-chloro-6-(trifluoromethyl)pyrimidin-4-yl)pyrrolidin-3-ol prepared in step A was used instead of 1-(2-chloro-6-(trifluoromethyl)pyrimidin-4-yl)azetidin-3-ol. The same procedure as in step B of Example 1 was carried out except that 1-(2-chloro-6-(trifluoromethyl)pyrimidin-4-yl)pyrrolidin-3-ol was reacted with (S)-2-methylazetidine (7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)methanesulfonate (62 mg, 0.20 mmol) to prepare 1-(2-((S)-2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)pyrrolidin-3-ol.
[0158] (3) Step C: Preparation of tert-butyl 4-(2-((1-(2-((S)-2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)pyrrolidin-3-yl)oxy)acetyl)piperazine-1-carboxylate In step C of Example 1, instead of (S)-1-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)azetidin-3-ol, 1-(2-((S)-2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)pyrrolidin-3-ol prepared in step B was reacted with tert-butyl 4-(2-bromoacetyl)piperazine-1-carboxylate (61 mg, 0.19 mmol) prepared in Preparation Example 7, except that the same procedure was carried out as in step C of Example 1 to prepare tert-butyl 4-(2-((1-(2-((S)-2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)pyrrolidin-3-yl)oxy)acetyl)piperazine-1-carboxylate.
[0159] (4) Step D: Preparation of 2-(((S)-1-(2-((S)-2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)pyrrolidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one In step D of Example 1, instead of tert-butyl (S)-4-(2-((1-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)azetidin-3-yl)oxy)acetyl)piperazine-1-carboxylate, tert-butyl 4-(2-((1-(2-((S)-2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)azetidin-3-yl)oxy)acetyl)piperazine-1-carboxylate was used, The procedure was repeated as in step D of example 1, except that 2-(((S)-1-(2-((S)-2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)pyrrolidin-3-yl)oxy)acetyl)piperazine-1-carboxylate was used to prepare 2-(((S)-1-(2-((S)-2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)pyrrolidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one (28 mg, 0.07 mmol, 41% yield); 1 The synthesis was confirmed by 1 H NMR analysis. 1H NMR (500MHz, CDCl3) δ 5.96 (s, 1H), 4.52-4.36 (m, 1H), 4.28 (s, 1H), 4.18 (s, 2H), 4.10-3.86 (m, 2H), 3.67-3.35 (m, 7H), 2.84 (d, J=4.1 Hz, 4H), 2.46-2.29 (m, 1H), 2.30-1.85 (m, 3H), 1.72 (s, 1H), 1.56-1.41 (m, 3H).
[0160] Example 7: Preparation of 2-(((2S,3R)-1-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyrrolidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one As shown in the following reaction scheme 7, steps A to E were carried out in order to prepare the title compound of formula 1-7.
[0161] [Reaction Scheme 7] [ka]
[0162] (1) Step A: Preparation of 4-chloro-7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine 4-Chloro-7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine was produced in the same manner as in Step A of Example 3, except that 141 mg, 0.60 mmol of 4-chloro-7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidine was used in Step A of Example 3.
[0163] (2) Step B: Preparation of 1-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyrrolidin-3-ol The procedure was repeated as in Step B of Example 3, except that (S)-pyrrolidin-3-ol (53 mg, 0.61 mmol) was used instead of azetidin-3-ol hydrochloride, to prepare 1-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyrrolidin-3-ol.
[0164] (3) Step C: Preparation of 1-(7,7-difluoro-2-((S)-2-methylsulfonyl-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyrrolidin-3-ol In step C of Example 3, 1-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyrrolidin-3-ol prepared in step B was used in place of 1-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)azetidin-3-ol (2S)-2-methyl-1-pyrrolidin-3-ol). The procedure was repeated as in step C of example 3, except that ethylazetidine [(1R,4S)-7,7-dimethyl-2-oxo-norbornan-1-yl]methanesulfonate (203 mg, 0.67 mmol) was used to prepare 1-(7,7-difluoro-2-((S)-2-methylsulfonyl-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyrrolidin-3-ol.
[0165] (4) Step D: Preparation of tert-butyl 4-(2-((1-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyrrolidin-3-ol)oxy)acetyl)piperazine-1-carboxylate In step D of Example 3, instead of (S)-1-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)azetidin-3-ol, 1-(7,7-difluoro-2-((S)-2-methylsulfonyl-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyrrolidin-3-ol prepared in step C was used. The procedure was repeated as in step D of example 3, except that tert-butyl 4-(2-bromoacetyl)piperazine-1-carboxylate (204 mg, 0.66 mmol) was used to prepare tert-butyl 4-(2-((1-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyrrolidin-3-ol)oxy)acetyl)piperazine-1-carboxylate.
[0166] (5) Step E: Preparation of 2-(((S)-1-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyrrolidin-3-yl)oxy)-1-(piperidin-1-yl)ethan-1-one In step E of Example 3, instead of tert-butyl (S)-4-(2-((1-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)azetidin-3-yl)oxy)acetyl)piperazine-1-carboxylate, tert-butyl 4-(2-((1-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)azetidin-3-yl)oxy)acetyl)piperazine-1-carboxylate was used. cyclopenta[d]pyrimidin-4-yl)pyrrolidin-3-ol)oxy)acetyl)piperazine-1-carboxylate to give 2-(((S)-1-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyrrolidin-3-yl)oxy)-1-(piperidin-1-yl)ethan-1-one (93 mg, 0.17 mmol, 28% yield), 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, MeOH-d4) δ 4.41 (q, J=6.5 Hz, 1H), 4.25 (q, J=13.6 Hz, 3H), 4.07-3.56 (m, 6H), 3.48 (dt, J=36.5, 4.7 Hz, 4H), 3.09 (d, J=23.2 Hz, 2H), 2.86-2.68 (m, 4H), 2.53-2.29 (m, 3H), 2.17 (s, 1H), 2.04 (s, 1H), 1.97-1.89 (m, 1H), 1.48 (d, J=6.4 Hz, 3H).
[0167] Example 8: Preparation of 2-(((R)-1-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyrrolidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one In step B of Example 7, (R)-pyrrolidin-3-ol hydrochloride (75 mg, 0.61 mmol) was used instead of (S)-pyrrolidin-3-ol, in step C, 188 mg, 0.62 mmol of (2S)-2-methylazetidine [(1R,4S)-7,7-dimethyl-2-oxo-norbornan-1-yl] methanesulfonate was used, and in step D, 194 mg, 0.63 mmol of tert-butyl 4-(2-bromoacetyl)piperazine-1-carboxylate was used, except that the reaction was carried out in the same manner as in Example 7, the title compound of formula 1-8 (108 mg, 0.25 mmol, yield 41%), which is an isomer of the compound of formula 1-7, was prepared.
[0168] [Chemical formula 1-8] [ka]
[0169] 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, MeOH-d4) δ 4.40 (q, J=6.5 Hz, 1H), 4.24 (q, J=14.0 Hz, 3H), 4.07-3.59 (m, 6H), 3.58-3.38 (m, 4H), 3.08 (dd, J=33.9, 15.0 Hz, 2H), 2.86-2.68 (m, 4H), 2.53-2.29 (m, 3H), 2.17 (s, 1H), 2.03 (d, J=8.8 Hz, 1H), 1.97-1.85 (m, 1H), 1.48 (d, J=6.1 Hz, 3H).
[0170] Example 9 Preparation of 2-((R)-1-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyrrolidin-3-yl)-1-(piperazin-1-yl)ethan-1-one) As shown in the following reaction scheme 8, steps A to E were carried out in order to prepare the title compound of formula 1-9.
[0171] [Reaction Scheme 8] [ka]
[0172] (1) Step A: Preparation of ethyl (R)-2-(1-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyrrolidin-3-yl)acetate 4-Chloro-7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine (100mg, 0.37mmol) prepared in step A of Example 3, ethyl (R)-2-(pyrrolidin-3-yl)acetate hydrochloride (86mg, 0.44mmol), and triethylamine (113mg, 1.11mmol) were dissolved in 10ml of dichloromethane and stirred at room temperature for 16 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure, and 1N aqueous hydrochloric acid was added, followed by extraction with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (ethyl acetate / hexane=1 / 1 weight ratio) to obtain ethyl (R)-2-(1-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyrrolidin-3-yl)acetate (129 mg, 0.33 mmol, yield 89%). 1 The synthesis was confirmed by 1 H NMR analysis. 1H NMR (400MHz, CDCl3) δ 4.28-4.06 (m, 2H), 4.08-3.62 (m, 3H), 3.59-3.34 (m, 1H), 3.31 (d, J=11.3 Hz, 3H), 3.30-3.17 (m, 2H), 2.73 (s, 1H), 2.64-2.49 (s, 3H), 2.49-2.14 (m, 2H), 1.82-1.58 (m, 1H), 1.37-1.23 (m, 3H).
[0173] (2) Step B: Preparation of ethyl 2-((R)-1-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyrrolidin-3-yl)acetate The ethyl (R)-2-(1-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyrrolidin-3-yl)acetate (129 mg, 0.33 mmol) prepared in step A, (2S)-2-methylazetidine[(1R,4S)-7,7-dimethyl-2-oxo-norbornan-1-yl]methanesulfonate (120 mg, 0.39 mmol), and potassium carbonate (137 mg, 0.99 mmol) were dissolved in 10 ml of acetonitrile and stirred at 80° C. for 1 hour. After the reaction was completed, the reaction solution was concentrated under reduced pressure. A saturated aqueous sodium chloride solution was added to the reduced pressure concentrate, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (ethyl acetate / hexane=1 / 1 weight ratio) to obtain ethyl 2-((R)-1-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyrrolidin-3-yl)acetate (103 mg, 0.27 mmol, yield 81%). 1 The synthesis was confirmed by 1 H NMR analysis. 1H NMR (400MHz, CDCl3) δ 4.28-4.32 (m, 1H), 4.24-4.08 (m, 2H), 4.06-3.99 (m, 1H), 3.95 (q, J=8.2 Hz, 2H), 3.87-3.69 (m, 1H), 3.62 (q, 3.37-3.22 (m, 1H), 3.13-2.93 (m, 2H), 2.71-2.54 (m, 1H), 2.53-2.37 (m, 4H), 2.16 (dd, J=10.8, 4.7 Hz, 1H), 2.01-1.84 (m, 1H), 1.63 (dt, J=20.5, 8.7 Hz, 1H), 1.49 (d, J=6.1 Hz, 3H), 1.24 (dt, J=30.2, 7.0 Hz, 3H).
[0174] (3) Step C: Preparation of S-((R)-1-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyrrolidin-3-yl)acetic acid Ethyl 2-((R)-1-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyrrolidin-3-yl)acetate (103 mg, 0.27 mmol) prepared in step B and lithium hydride monohydrate (45 mg, 1.08 mmol) were dissolved in a mixture of tetrahydrofuran / water / methanol (4 / 1 / 1 weight ratio, 24 ml) and stirred at room temperature for 16 hours. After the reaction was completed, 1N hydrochloric acid solution was added to the reaction solution and extracted with ethyl acetate. The organic layer was washed with an aqueous sodium chloride solution, dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (dichloromethane / methanol = 20 / 1 weight ratio) to obtain S-((R)-1-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyrrolidin-3-yl)acetic acid (75 mg, 0.21 mmol, yield 78%). 1The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, MeOH-d4) δ 4.42 (td, J=13.3, 6.7 Hz, 1H), 4.12-3.92 (m, 2H), 3.92-3.55 (m, 3H), 3.34 (s, 1H), 3.19-2.99 (m, 2H), 2.59 (q, J=7.4 Hz, 1H), 2.53-2.41 (m, 4H), 2.41-2.29 (m, 1H), 2.17 (d, J=5.8 Hz, 1H), 2.03-1.84 (m, 1H), 1.66 (dd, J=19.1, 9.0 Hz, 1H), 1.55-1.40 (m, 3H).
[0175] (4) Step D: Preparation of tert-butyl 4-(2-((R)-1-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyrrolidin-3-yl)acetyl)piperazine-1-carboxylate S-((R)-1-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyrrolidin-3-yl)acetic acid (75 mg, 0.21 mmol) prepared in step C, N-[(dimethylamino)-1H-1,2,3-triazole-[4-5-b]pyridin-1-ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide (121 mg, 0.31 mmol), tert-butyl benzylazine-1-carboxylate (59 mg, 0.31 mmol), and N,N-diisopropylethylamine (82 mg, 0.63 mmol) were dissolved in 10 ml of dimethylformamide and stirred at room temperature for 18 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure, water was added, and the solution was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (dichloromethane / methanol = 20 / 1 weight ratio) to obtain tert-butyl 4-(2-((R)-1-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyrrolidin-3-yl)acetyl)piperazine-1-carboxylate (109 mg, 0.20 mmol, yield 98%). 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, CDCl3) δ 4.41 (dd, J=13.9, 6.3 Hz, 1H), 4.05 (td, J=8.7, 4.6 Hz, 1H), 3.96 (q, J=8.2 Hz, 2H), 3.78 (s, 1H), 3.62 (d, J=21.4 Hz, 3H), 3.53-3.34 (m, 6H), 3.34-3.23 (m, 1H), 3.12-2.98 (m, 2H), 2.76-2.63 (m, 1H), 2.54-2.26 (m, 6H), 2.16 (d, J=47.0 Hz, 1H), 2.01-1.84 (m, 1H), 1.71-1.55 (m, 1H), 1.55-1.30 (m, 12H).
[0176] (5) Step E: Preparation of 2-((R)-1-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyrrolidin-3-yl)-1-(piperazin-1-yl)ethan-1-one tert-Butyl 4-(2-((R)-1-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyrrolidin-3-yl)acetyl)piperazine-1-carboxylate (109 mg, 0.20 mmol) prepared in step D and 1 ml of trifluoroacetic acid were dissolved in 10 ml of dichloromethane and stirred for 18 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure, and saturated aqueous ammonium chloride solution was added and extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (dichloromethane / 7N ammonia methanol=10 / 1 weight ratio) to obtain 2-((R)-1-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyrrolidin-3-yl)-1-(piperazin-1-yl)ethan-1-one (80 mg, 0.19 mmol, yield 90%). 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, MeOH-d4) δ 4.39 (q, J=6.7 Hz, 1H), 3.99 (td, J=8.7, 4.7 Hz, 2H), 3.87 (t, J=8.1 Hz, 1H), 3.84-3.60 (m, 1H), 3.60-3.45 (m, 4H), 3.15-2.98 (m, 2H), 2.79 (dt, J=18.4, 5.0 Hz, 4H), 2.67-2.49 (m, 3H), 2.48-2.27 (m, 3H), 2.15 (s, 1H), 1.91 (dd, J=17.2, 7.5 Hz, 1H), 1.65 (s, 1H), 1.53-1.39 (m, 3H).
[0177] Example 10: Preparation of (S)-2-((1-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperidin-4-yl)oxy)-1-(piperazin-1-yl)ethan-1-one As shown in the following reaction scheme 9, steps A to E were carried out in order to prepare the title compound of formula 1-10.
[0178] [Reaction Scheme 9] [ka]
[0179] In step A of Example 9, 200 mg, 0.74 mmol of 4-chloro-7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine was used, ethyl 2-(piperidin-4-yloxy)acetate hydrochloride (251 mg, 1.12 mmol) was used instead of ethyl (R)-2-(pyrrolidin-3-yl)acetate hydrochloride, and 302 mg, 0.64 mmol of (2S)-2-methylazetidine[(1R,4S)-7,7-dimethyl-2-oxo-norbornan-1-yl]methanesulfonate was used in step B. Steps A to E were carried out in the same order as in Example 9 to prepare the title compound of formula 1-10 (110 mg, 0.24 mmol, yield 33%). 1 The synthesis was confirmed by 1 H NMR analysis. 1H NMR (400MHz, CDCl3) δ 4.40 (q, J=6.9 Hz, 1H), 4.18 (s, 2H), 3.91-4.07 (m, 4H), 3.67 (td, J=7.9, 4.0, 1H), 3.57 (t, J=4.8 Hz, 2H), 3.50 (t, J=5.0 Hz, 2H), 3.31-3.38 (m, 2H), 2.83-2.91 (m, 6H), 2.31-2.49 (m, 3H), 1.88-1.96 (m, 3H), 1.61 (m, 2H), 1.47 (d, J=5.9 Hz, 3H).
[0180] Example 11: Preparation of (S)-2-(4-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)piperazin-1-yl)-1-(piperazin-1-yl)ethan-1-one As shown in the following reaction scheme 10, steps A to E were carried out in order to prepare the title compound of formula 1-11.
[0181] [Reaction Scheme 10] [ka]
[0182] (1) Step A: Preparation of tert-butyl 4-(2-chloro-6-(trifluoro)pyrimidin-4-yl)piperazine-1-carboxylate 2,4-Dichloro-6-(trifluoro)pyrimidine (5 g, 23.04 mmol), tert-butyl piperazine-1-carboxylate (4.3 g, 23.04 mmol), and diisopropylethylamine (12 ml, 69.12 mmol) were dissolved in 200 ml of dichloromethane and stirred at room temperature for 2 hours. After the reaction was completed, 1N aqueous hydrochloric acid was added to the reaction solution, which was then extracted with dichloromethane. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the reduced pressure concentrate was purified by column chromatography to obtain tert-butyl 4-(2-chloro-6-(trifluoro)pyrimidin-4-yl)piperazine-1-carboxylate (7.28 g, 19.84 mmol, yield 86%). 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (400MHz, CDCl3) δ 6.71 (s, 1H), 3.78 (s, 4H), 3.56 (s, 4H), 1.49 (s, 9H).
[0183] (2) Step B: Preparation of tert-butyl (S)-4-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)piperazine-1-carboxylate tert-Butyl 4-(2-chloro-6-(trifluoro)pyrimidin-4-yl)piperazine-1-carboxylate (7.28 g, 19.84 mmol) prepared in step A, (2S)-2-methylazetidine [(1R,4S)-7,7-dimethyl-2-oxo-norbornan-1-yl] methanesulfonate (7.23 g, 23.81 mmol), and potassium carbonate (8.23 g, 59.52 mmol) were dissolved in 300 ml of acetonitrile and stirred at 80 ° C for 1 hour. After the reaction was completed, the reaction solution was cooled to room temperature, concentrated under reduced pressure, dissolved in ethyl acetate, and washed with saturated sodium chloride solution. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (ethyl acetate / hexane=1 / 1 weight ratio) to obtain tert-butyl (S)-4-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)piperazine-1-carboxylate (7.48 g, 18.63 mol, yield 93%). 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (400MHz, CDCl3) δ 6.15 (s, 1H), 4.45 (td, J=13.0, 6.5 Hz, 1H), 4.12-3.87 (m, 2H), 3.61 (s, 4H), 3.50 (d, J=4.6 Hz, 4H), 2.49-2.31 (m, 1H), 2.03-1.86 (m, 1H), 1.53-1.30 (m, 12H).
[0184] (3) Step C: Preparation of (S)-2-(2-methylazetidin-1-yl)-4-(piperazin-1-yl)-6-(trifluoromethyl)pyrimidine The tert-butyl (S)-4-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)piperazine-1-carboxylate (7.48 g, 18.63 mmol) prepared in step B and 14 ml of trifluoroacetic acid were dissolved in 10 ml of dichloromethane and stirred at room temperature for 18 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure, and saturated aqueous ammonium chloride solution was added and extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to obtain (S)-2-(2-methylazetidin-1-yl)-4-(piperazin-1-yl)-6-(trifluoromethyl)pyrimidine (5.6 g, 18.63 mmol, 100% yield), 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (400MHz, CDCl3) δ 6.18 (s, 1H), 4.50 (s, 1H), 4.21-3.94 (m, 2H), 3.89 (d, J=4.0 Hz, 4H), 3.29-3.16 (m, 4H), 2.55-2.36 (m, 1H), 2.02-1.88 (m, 1H), 1.51 (d, J=6.4 Hz, 3H).
[0185] (4) Step D: Preparation of tert-butyl (S)-4-(2-(4-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)piperazin-1-yl)acetyl)piperazine-1-carboxylate (S)-2-(2-methylazetidin-1-yl)-4-(piperazin-1-yl)-6-(trifluoromethyl)pyrimidine (5.6 g, 18.63 mmol) prepared in step C was dissolved in 100 ml of dimethylformamide, and potassium carbonate (6.86 g, 22.36 mmol) was added, and tert-butyl 4-(2-bromoacetyl)piperazine-1-carboxylate (7.72 g, 55.89 mmol) prepared in Preparation Example 7 was added and stirred at room temperature for 16 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure, dissolved in ethyl acetate, and washed with saturated sodium chloride solution. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (ethyl acetate / hexane=1 / 1 weight ratio) to obtain tert-butyl (S)-4-(2-(4-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)piperazin-1-yl)acetyl)piperazine-1-carboxylate (10.22 g, 19.37 mmol, yield 104%). 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, CDCl3) δ 6.15 (s, 1H), 4.44 (q, J=6.5 Hz, 1H), 4.03 (dd, J=13.7, 8.8 Hz, 1H), 3.95 (q, J=8.2 Hz, 1H), 3.61 (d, J=28.4 Hz, 8H), 3.44 (d, J=22.3 Hz, 4H), 3.25 (d, J=12.8 Hz, 2H), 2.56 (s, 4H), 2.39 (dd, J=23.7, 9.3 Hz, 1H), 1.93 (dd, J=17.5, 8.4 Hz, 1H), 1.53-1.42 (m, 12H).
[0186] (5) Step E: Preparation of ((S)-2-(4-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)piperazin-1-yl)-1-(piperazin-1-yl)ethan-1-one tert-Butyl (S)-4-(2-(4-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)piperazin-1-yl)acetyl)piperazine-1-carboxylate (10.22 g, 19.37 mmol) prepared in step D and 4 ml of trifluoroacetic acid were dissolved in 20 ml of dichloromethane and stirred for 18 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure, and ethyl acetate and a saturated aqueous ammonium chloride solution were added, followed by extraction with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (dichloromethane / 7N ammonia methanol=10 / 1 weight ratio) to obtain ((S)-2-(4-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)piperazin-1-yl)-1-(piperazin-1-yl)ethan-1-one (8.28 g, 19.37 mmol, 100% yield), 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (400MHz, MeOH-d4) δ 6.35 (s, 1H), 4.42 (d, J=7.3 Hz, 1H), 4.05-3.85 (m, 2H), 3.69 (s, 4H), 3.64-3.49 (m, 4H), 3.27 (s, 2H), 2.81 (dt, J=24.9, 5.0 Hz, 4H), 2.55 (t, J=5.0 Hz, 4H), 2.40 (s, 1H), 1.95 (s, 1H), 1.54-1.41 (m, 3H).
[0187] Example 12: Preparation of (S)-4-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)-1-(2-oxo-2-(piperazin-1-yl)ethyl)piperazin-2-one As shown in the following reaction scheme 11, the title compound of the chemical formula 1-12 was prepared by carrying out steps A to D in order.
[0188] [Reaction Scheme 11] [ka]
[0189] In step A of Example 1, 104 mg, 0.48 mmol of 2,4-dichloro-6-(trifluoromethyl)pyrimidine was used, piperazin-2-one (48 mg, 0.48 mmol) was used instead of azetidin-3-ol hydrochloride, 181 mg, 0.59 mmol of (2S)-2-methylazetidine [(1R,4S)-7,7-methyl-2-oxo-norbornan-1-yl] methanesulfonate was used in step B, and 166 mg, 0.54 mmol of tert-butyl 4-(2-bromoacetyl)piperazine-1-carboxylate was used in step C. Except for the above, steps A to D were carried out in the same order as in Example 1 to prepare the title compound of formula 1-13 (71 mg, 0.16 mmol, yield 34%). 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (400MHz, MeOH-d4) δ 6.38 (s, 1H), 4.60-4.41 (m, 1H), 4.34 (d, J=11.6 Hz, 4H), 3.95 (s, 4H), 3.61-3.43 (m, 6H), 2.92-2.75 (m, 4H), 2.47-2.37 (m, 1H), 2.02-1.84 (m, 1H), 1.50 (d, J=6.1 Hz, 3H).
[0190] Example 13: Preparation of (S)-2-4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-1-yl)-1-(piperazin-1-yl)ethan-1-one As shown in the following reaction scheme 12, the title compound of the chemical formula 1-13 was prepared by carrying out steps A to F in order.
[0191] [Reaction scheme 12] [ka]
[0192] In the above Reaction Scheme 12, Steps A and B were carried out in accordance with Steps A and B of Example 2, and Steps C to F in the above Reaction Scheme 12 were carried out in accordance with Steps B to E of Example 11.
[0193] Specifically, in Step A and Step B of Example 2, 20 mg, 0.07 mmol of 4-chloro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidine was used instead of 4,5-dichloro-2-(methylthio)-6-(trifluoromethyl)pyrimidine, and 15 mg, 0.11 mmol of tert-butyl piperazine-1-carboxylate was used instead of tert-butyl 4-(2-(azetidin-3-yloxy)acetyl)piperazine-1-carboxylate. Steps A and B of Reaction Scheme 12 were carried out in the same manner. Then, in succession of steps B to E of Example 11, 25 mg, 0.08 mmol of (2S)-2-methylazetidine [(1R,4S)-7,7-methyl-2-oxo-norbornan-1-yl] methanesulfonate were used in step B, and 18 mg, 0.12 mmol of tert-butyl 4-(2-bromoacetyl)piperazine-1-carboxylate were used in step D. Steps C to F of reaction formula 12 were carried out in the same manner to produce the title compound of chemical formula 1-13 (29 mg, 0.06 mmol, yield 95%). 1 The synthesis was confirmed by 1 H NMR analysis. 1H NMR (400MHz, MeOH-d4) δ 4.48-4.33 (m, 1H), 4.01 (td, J=8.7, 4.8 Hz, 1H), 3.89 (q, J=8.2 Hz, 1H), 3.78 (t, J=4.7 Hz, 4H), 3.58 (dt, J=23.8, 4.9 Hz, 4H), 3.26 (s, 2H), 2.96 (s, 2H), 2.82 (dt, J=26.5, 4.9 Hz, 4H), 2.57 (t, J=4.7 Hz, 4H), 2.53-2.32 (m, 3H), 1.94 (dd, J=19.1, 7.2 Hz, 1H), 1.55-1.40 (m, 3H).
[0194] Example 14: Preparation of (S)-2-4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-1-yl)-1-(piperazin-1-yl)morpholinoethan-1-one As shown in the following reaction scheme 13, the title compound of the chemical formula 1-14 was prepared by carrying out steps A to E in order.
[0195] [Reaction Scheme 13] [ka]
[0196] In the above reaction scheme 13, steps A to E were carried out in accordance with steps A to E of Example 13.
[0197] Specifically, in step A of Example 13, 10 mg, 0.04 mmol of 4-chloro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidine was used, and 8 mg, 0.06 mmol of tert-butyl piperazine-1-carboxylate was used. In step C, (2S)-2-methylazetidine[(1R,4S)-7,7-methyl-2-oxo-norbornan-1-yl]methanesulfone was used. The title compound of formula 1-14 (10 mg, 0.02 mmol, 50% yield) was produced by carrying out steps A to E in the same order as in Example 13, except that 12 mg, 0.04 mmol of tert-butyl 4-(2-bromoacetyl)piperazine-1-carboxylate was used, and 2-bromo-1-morpholinoethan-1-one (10 mg, 0.05 mmol) was used instead of tert-butyl 4-(2-bromoacetyl)piperazine-1-carboxylate in step D. 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (400MHz, MeOH-d4) δ 4.41 (q, J=6.8 Hz, 1H), 4.01 (td, J=8.8, 4.9 Hz, 1H), 3.89 (q, J=8.2 Hz, 1H), 3.78 (t, J=4.9 Hz, 4H), 3.73-3.61 (m, 6H), 3.57 (t, J=4.6 Hz, 2H), 3.27 (s, 2H), 2.96 (d, J=3.1 Hz, 2H), 2.64-2.53 (m, 4H), 2.53-2.31 (m, 3H), 2.02-1.85 (m, 1H), 1.47 (d, J=6.1 Hz, 3H).
[0198] Example 15: Preparation of (S)-1-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-(piperazin-1-yl)propane-1,3-dione As shown in the following reaction scheme 14, the title compound of the chemical formula 1-15 was prepared by carrying out steps A to D in order.
[0199] [Reaction Scheme 14] [ka]
[0200] (1) Step A: Preparation of tert-butyl 4-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazine-1-carboxylate 4-Chloro-7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine (385mg, 1.433mmol), tert-butyl piperazine-1-carboxylate (294mg, 1.576mmol), and triethylamine (0.3ml, 2.150mmol) were dissolved in 20ml of dichloromethane and stirred at room temperature for 18 hours. After the reaction was completed, the reaction solution was extracted with dichloromethane and water. The organic layer was dried over anhydrous magnesium sulfate and then filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography (ethyl acetate / hexane=1 / 1 weight ratio) to obtain tert-butyl 4-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazine-1-carboxylate (555.8 mg, yield 93%). 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (400MHz, CDCl3) δ 3.88 (t, J=5.3 Hz, 4H), 3.55 (t, J=5.3 Hz, 4H), 3.33 (s, 3H), 3.11-3.14 (m, 2H), 2.59 (dt, J=21.0, 7.5 Hz, 2H), 1.47 (s, 9H).
[0201] (2) Step B: Preparation of tert-butyl (S)-4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazine-1-carboxylate tert-Butyl 4-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazine-1-carboxylate (555 mg, 1.326 mmol) prepared in step A, (2S)-2-methylazetidine[(1R,4S)-7,7-dimethyl-2-oxo-norbornan-1-yl]methanesulfonate (443 mg, 1.459 mmol), and potassium carbonate (458 mg, 3.32 mmol) were dissolved in 50 ml of acetonitrile and stirred at 80° C. for 6 hours. After the reaction was completed, the reaction solution was extracted with ethyl acetate and water. The organic layer was dried over anhydrous magnesium sulfate and then filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography (0-50% ethyl acetate / hexane = 1 / 1 weight ratio) to obtain tert-butyl (S)-4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazine-1-carboxylate (395 mg, yield 72%). 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (400MHz, CDCl3) δ 4.42 (dd, J=14.2, 5.9 Hz, 1H), 4.05 (td, J=8.7, 4.6 Hz, 1H), 3.96 (q, J=8.2 Hz, 1H), 3.66 (t, J=5.3 Hz, 4H), 3.47 (t, J=5.3 Hz, 4H), 2.88-2.91 (m, 2H), 2.33-2.51 (m, 3H), 1.89-1.97 (m, 1H), 1.47-1.49 (m, 12H).
[0202] (3) Step C: Preparation of (S)-4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-4-(piperazin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine tert-Butyl (S)-4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazine-1-carboxylate (390 mg, 0.952 mmol) prepared in step B was dissolved in 12 ml of dichloromethane, and then 3 ml of trifluoroacetic acid was added and stirred at room temperature for 18 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure. The concentrated solution was dissolved in dichloromethane, neutralized with saturated sodium bicarbonate, and extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to obtain (S)-4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-4-(piperazin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine (308 mg), which was used in the next reaction without separation or purification.
[0203] (4) Step D: Preparation of (S)-3-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(piperazin-1-yl)propane-1,3-dione (S)-4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-4-(piperazin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine (106 mg, 0.343 mmol) prepared in step C, 3-(4-(tert-butoxycarbonyl)piperazin-1-yl)-3-oxopropanoic acid (103 mg, 0.377 mmol), and triethylamine (0.096 ml, 0.685 mmol) were dissolved in 10 ml of dichloromethane, and then propylphosphonic anhydride (50 wt%, 0.255 ml) was added. , 0.428mmol) was added and stirred at room temperature for 4 hours. After the reaction was completed, the reaction solution was extracted with dichloromethane and water. The organic layer was dried over anhydrous magnesium sulfate and then filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography to obtain tert-butyl (S)-3-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-oxopropanoyl)piperazine-1-carboxylate (122mg, yield 63%).
[0204] The prepared tert-butyl (S)-3-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-oxopropanoyl)piperazine-1-carboxylate and 1 ml of trifluoroacetic acid were dissolved in 4 ml of dichloromethane and stirred at room temperature for 3 hours. After the reaction was completed, the mixture was concentrated under reduced pressure. The concentrated liquid was neutralized with a saturated aqueous sodium bicarbonate solution and extracted with dichloromethane. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography to give (S)-(3-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(piperazin-1-yl)propane-1,3-dione (88 mg, 88% yield), 1 The synthesis was confirmed by 1 H NMR analysis. 1H NMR (500MHz, CDCl3) δ 4.38-4.43 (m, 1H), 4.02-4.06 (m, 1H), 3.95 (q, J=8.2 Hz, 1H), 3.74 (m, 2H), 3.68 (m, 6H), 3.60 (m, 4H), 3.55 (s, 2H), 2.85-2.90 (m, 6H), 2.55 (s, 1H), 2.41-2.49 (m, 2H), 2.34-2.39 (m, 1H), 1.90-1.97 (m, 1H), 1.48 (d, J=6.1 Hz, 3H).
[0205] Example 16: Preparation of (S)-4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-1-(2-oxo-2-(piperazin-1-yl)ethyl)piperazin-2-one
[0206] [Reaction Scheme 15] [ka]
[0207] The title compound of Formula 1-16 was prepared according to Reaction Scheme 15 by applying Steps B to E of Example 3.
[0208] (1) Step A The procedure was the same as in Step B of Example 3, except that in Step B of Example 3, 4-chloro-7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine (100 mg, 0.37 mmol) was used and piperazin-2-one (224 mg, 2.23 mmol) was used instead of azetidin-3-ol hydrochloride.
[0209] (2) Step B The procedure was the same as in step C of example 3, except that in step C of example 3, (2S)-2-methylazetidine [(1R,4S)-7,7-methyl-2-oxo-norbornan-1-yl] methanesulfonate was replaced with (S)-2-methylazetidine (7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl) methanesulfonate (209 mg, 0.45 mmol).
[0210] (3) Step C The reaction was carried out in the same manner as in Step D of Example 3, except that in Step D of Example 3, 125 mg, 0.41 mmol of tert-butyl 4-(2-bromoacetyl)piperazine-1-carboxylate was used.
[0211] (4) Step D The same procedure as in step E of example 3 was carried out except that the compound prepared in step C was used instead of tert-butyl (S)-4-(2-((1-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)azetidin-3-yl)oxy)acetyl)piperazine-1-carboxylate in step E of example 3, to prepare the title compound of formula 1-16 (25 mg, 0.06 mmol, yield 15%). 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (400MHz, CDCl3) δ 4.40-4.45 (m, 1H), 4.32-4.38 (m, 2H), 4.22 (s, 2H), 4.06 (m, 1H), 3.93-4.01 (m, 3H), 3.60 (t, J=5.0 Hz, 2H), 3.53 (t, J=5.3 Hz, 2H), 3.45 (t, J=4.8 Hz, 2H), 3.93-2.98 (m, 2H), 2.89 (td, J=9.4, 4.3 Hz, 4H), 2.34-2.51 (m, 3H), 1.89-1.97 (m, 1H), 1.48 (d, J=6.4 Hz, 3H).
[0212] Example 17: Preparation of (S)-2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)bepyridin-1-yl)-1-(piperazin-1-yl)ethan-1-one As shown in the following reaction scheme 16, the title compound of the chemical formula 1-17 was prepared by carrying out steps A to G in order.
[0213] [Reaction Scheme 16] [ka]
[0214] (1) Step A: Preparation of tert-butyl 4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3,6-dihydropyridine-1(2H)-carboxylate 4-Chloro-7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidine (577 mg, 2.438 mmol), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (1131 mg, 3.66 mmol), tetrakis(triphenylphosphine)palladium(O) (141 mg, 0.122 mmol), and 2M aqueous sodium carbonate solution (3.66 ml, 7.31 mmol) were dissolved in 30 ml of 1,4-dioxane and stirred at 80° C. for 18 hours. After the reaction was completed, the reaction solution was cooled to room temperature and extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and then filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography (ethyl acetate / hexane=4 / 1 weight ratio) to obtain tert-butyl 4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3,6-dihydropyridine-1(2H)-carboxylate (1.104 g, yield 99%). 1The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (400MHz, CDCl3) δ 6.52 (m, 1H), 4.17 (d, J=2.3 Hz, 2H), 3.61 (t, J=5.7 Hz, 2H), 3.05-3.10 (m, 2H), 2.68 (d, J=1.4 Hz, 2H), 2.53-2.64 (m, 5H), 1.48 (s, 9H).
[0215] (2) Step B: Preparation of tert-butyl 4-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3,6-dihydropyridine-1(2H)-carboxylate tert-Butyl 4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3,6-dihydropyridine-1(2H)-carboxylate (1.1 g, 2.87 mmol) prepared in step A and m-chlorobenzoic peroxyacid (70 wt%, 1.556 mg, 6.31 mmol) were dissolved in 100 ml of dichloromethane and stirred at room temperature for 18 hours. After the reaction was completed, water and sodium thiosulfate were added to the reaction solution and stirred. Extraction was performed by adding dichloromethane and saturated aqueous sodium bicarbonate solution. The organic layer was dried over anhydrous magnesium sulfate and then filtered. The filtrate was concentrated under reduced pressure to give tert-butyl 4-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3,6-dihydropyridine-1(2H)-carboxylate (552 mg, 46% yield), 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (400MHz, CDCl3) δ 6.74 (s, 1H), 4.23 (br, s, 2H), 3.64 (t, J=5.5 Hz, 2H), 3.41 (s, 3H), 3.25 (m, 2H), 2.65-2.76 (m, 4H), 1.48 (s, 9H).
[0216] (3) Step C: Preparation of tert-butyl 4-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperidine-1-carboxylate tert-Butyl 4-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3,6-dihydropyridine-1(2H)-carboxylate (456 mg, 1.098 mmol) prepared in step C was dissolved in 20 ml of methanol, and then palladium / charcoal (10 wt%, 50 mg) was added and stirred at room temperature for 18 hours. After the reaction was completed, the reaction solution was filtered through Celite and washed with methanol. The filtrate was concentrated under reduced pressure to obtain tert-butyl 4-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperidine-1-carboxylate (473 mg, 99% yield), 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (400MHz, CDCl3) δ 4.30 (m, 2H), 3.40 (s, 3H), 3.12-3.15 (m, 2H), 2.98-3.04 (m, 1H), 2.67-2.86 (m, 4H), 1.95 (m, 2H), 1.80 (m, 2H), 1.47 (s, 9H).
[0217] (4) Step D: Preparation of tert-butyl (S)-4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperidine-1-carboxylate tert-Butyl 4-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperidine-1-carboxylate (150 mg, 0.359 mmol) prepared in step C, (2S)-2-methylazetidine[(1R,4S)-7,7-dimethyl-2-oxo-norbornan-1-yl]methanesulfonate (120 mg, 0.395 mmol), potassium carbonate (124 mg, 0.898 mmol) were dissolved in 20 ml of acetonitrile and stirred at 80 ° C for 4 hours. After the reaction was completed, the reaction solution was cooled to room temperature and extracted with water and ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and then filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography to give tert-butyl (S)-4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperidine-1-carboxylate (140 mg, 95% yield), 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (400MHz, CDCl3) δ 4.48 (m, 1H), 3.98-4.20 (m, 5H), 2.81 (m, 4H), 2.69 (m, 1H), 2.44-2.57 (m, 3H), 2.01 (m, 1H), 1.71-1.82 (m, 4H), 1.50 (d, J=5.9 Hz, 3H), 1.47 (s, 9H).
[0218] (5) Step E: Preparation of (S)-7,7-difluoro-2-(2-methylazetidin-1-yl)-4-(piperidin-4-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine tert-Butyl (S)-4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperidine-1-carboxylate (140 mg, 0.343 mmol) prepared in step D was dissolved in 4 ml of dichloromethane, and then 0.5 ml of trifluoroacetic acid was added and stirred. After the reaction was completed, the reaction solution was concentrated under reduced pressure, and the concentrate was neutralized with saturated aqueous sodium bicarbonate solution and then extracted with dichloromethane. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to obtain (S)-7,7-difluoro-2-(2-methylazetidin-1-yl)-4-(piperidin-4-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine (86 mg, 82% yield), 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (400MHz, CDCl3) δ 4.48 (q, J=6.9 Hz, 1H), 3.96-4.12 (m, 2H), 3.20 (d, J=13.3 Hz, 2H), 2.80 (m, 2H), 2.66-2.76 (m, 3H), 2.37-2.57 (m, 3H), 1.93-2.01 (m, 1H), 1.76-1.86 (m, 2H), 1.70 (m, 2H), 1.52 (d, J=6.4 Hz, 3H).
[0219] (6) Step F: Preparation of tert-butyl (S)-4-(2-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperidin-1-yl)acetyl)piperazine-1-carboxylate (S)-7,7-difluoro-2-(2-methylazetidin-1-yl)-4-(piperidin-4-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine (34 mg, 0.110 mmol) prepared in step E and tert-butyl 4-(2-bromoacetyl)piperazine-1-carboxylate (45 mg, 0.331 mmol) were dissolved in N,N-dimethylformamide (5 ml) and stirred at room temperature for 8 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure and extracted with ethyl acetate and water. The organic layer was dried over anhydrous magnesium sulfate and then filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography to give tert-butyl (S)-4-(2-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperidin-1-yl)acetyl)piperazine-1-carboxylate (58 mg, 99% yield), 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (400MHz, CDCl3) δ 4.47 (q, J=6.9 Hz, 1H), 4.06-4.11 (m, 1H), 3.98 (m, 1H), 3.57-3.65 (m, 4H), 3.39-3.46 (m, 4H), 3.20 (s, 2H), 2.93-2.97 (m, 2H), 2.78-2.81 (m, 2H), 2.36-2.57 (m, 4H), 2.15-2.21 (m, 2H), 1.85-2.01 (m, 3H), 1.71 (m, 2H), 1.50 (d, J=6.4 Hz, 3H), 1.45 (s, 9H).
[0220] (7) Step G: Preparation of (S)-2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperidin-1-yl)-1-(piperazin-1-yl)ethan-1-one tert-Butyl (S)-4-(2-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperidin-1-yl)acetyl)piperazine-1-carboxylate (58 mg, 0.108 mmol) prepared in step F was dissolved in 4 ml of dichloromethane, and then 1 ml of trifluoroacetic acid was added and stirred. After the reaction was completed, the reaction solution was concentrated under reduced pressure, neutralized with saturated aqueous sodium bicarbonate solution, and extracted with dichloromethane. The organic layer was dried over anhydrous magnesium sulfate and then filtered, and the filtrate was concentrated under reduced pressure and purified by column chromatography to give (S)-2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperidin-1-yl)-1-(piperazin-1-yl)ethan-1-one (32 mg, yield 68%). 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (400MHz, CDCl3) δ 4.70 (br, 1H), 4.46 (q, J=6.7 Hz, 1H), 4.07 (td, J=8.9, 5.0 Hz, 1H), 3.97 (q, J=8.2 Hz, 1H), 3.59-3.72 (m, 4H), 3.20 (s, 2H), 2.95-2.98 (m, 4H), 2.78 (t, J=3.4 Hz, 2H), 2.35-2.57 (m, 6H), 2.19 (t, J=11.7 Hz, 2H), 1.87-2.00 (m, 3H), 1.71 (d, J=12.8 Hz, 2H), 1.49 (q, J=2.9 Hz, 3H).
[0221] Example 18: Preparation of 2-((1R,5S,6R)-3-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-azabicyclo[3.1.0]hexan-6-yl)-1-(piperazin-1-yl)ethan-1-one As shown in the following reaction scheme 17, steps A and B were carried out in order to prepare the title compound of formula 1-18.
[0222] [Reaction Scheme 17] [ka]
[0223] (1) Step A: Preparation of tert-butyl 4-(2-((1R,5S,6R)-2-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-azabicyclo[3.1.0]hexan-6-yl)acetyl)piperazine-1-carboxylate 2-((1R,5S,6R)-3-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-azabicyclo[3.1.0]hexan-6-yl) acetate (200 mg, 0.518 mmol, prepared according to Example 9 of KR10-2021-0129607A), tert-butyl piperazine-1-carboxylate (116 mg, 0.621 mmol), propyl phosphonic anhydride (50 wt%, 0.244 ml, 0.647 mmol), and triethylamine (0.144 ml, 1.035 mmol) were dissolved in 10 ml of dichloromethane and stirred at room temperature for 1 hour. After the reaction was completed, the reaction solution was extracted with water and dichloromethane. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography to obtain tert-butyl 4-(2-((1R,5S,6R)-2-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-azabicyclo[3.1.0]hexan-6-yl)acetyl)piperazine-1-carboxylate (93 mg, yield 34%). 1 The synthesis was confirmed by 1 H NMR analysis. 1H NMR (400MHz, CDCl3) δ 4.38 (q, J=6.9 Hz, 1H), 3.90-4.05 (m, 4H), 3.58-3.63 (m, 4H), 3.42 (s, 6H), 2.94-3.01 (m, 2H), 2.28-2.46 (m, 5H), 1.87-1.95 (m, 1H), 1.50 (s, 2H), 1.42-1.48 (m, 12H), 0.94 (td, J=6.9, 3.2 Hz, 1H).
[0224] (2) Step B: Preparation of 2-((1R,5S,6R)-2-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-azabicyclo[3.1.0]hexan-6-yl)-1-(piperazin-1-yl)ethan-1-one The tert-butyl 4-(2-((1R,5S,6R)-2-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-azabicyclo[3.1.0]hexan-6-yl)acetyl)piperazine-1-carboxylate (93 mmol, 0.175 mmol) prepared in step A was dissolved in 4 ml of dichloromethane, and then 0.5 ml of trifluoroacetic acid was added and stirred at room temperature. After the reaction was completed, the reaction solution was concentrated under reduced pressure, neutralized with a saturated aqueous sodium bicarbonate solution, and extracted with dichloromethane. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography to obtain 2-((1R,5S,6R)-2-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-azabicyclo[3.1.0]hexan-6-yl)-1-(piperazin-1-yl)ethan-1-one (67 mg, yield 88%). 1 The synthesis was confirmed by 1 H NMR analysis. 1H NMR (500MHz, CDCl3) δ 4.41 (q, J=6.7 Hz, 1H), 3.93-4.07 (m, 4H), 3.61-3.74 (m, 4H), 3.45-3.50 (m, 2H), 3.01 (t, J=3.8 Hz, 2H), 2.93 (d, J=4.3 Hz, 4H), 2.32-2.51 (m, 5H), 1.90-1.97 (m, 1H), 1.54 (s, 2H), 1.50 (d, J=6.1 Hz, 3H), 0.95 (td, J=6.7, 3.5 Hz, 1H).
[0225] Example 19: Preparation of 2-((1R,5S,6R)-3-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-azabicyclo[3.1.0]hexan-6-yl)-1-(4-methylpiperazin-1-yl)ethan-1-one In step A of Example 18 above, 50 mg, 0.13 mmol of 2-((1R,5S,6R)-3-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-azabicyclo[3.1.0]hexan-6-yl)acetate was used, and 1-methylpiperazine (19 mg, 0.19 mmol) was used instead of piperazine-1-carboxylate. The procedure was carried out in the same manner as in Step A of Example 18, except that 2-((1R,5S,6R)-3-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-azabicyclo[3.1.0]hexan-6-yl)-1-(4-methylpiperazin-1-yl)ethan-1-one (5.0 mg, 0.01 mmol, 8% yield) of formula 1-19 was obtained. 1 The synthesis was confirmed by 1 H NMR analysis.
[0226] [Chemical formula 1-19] [ka] 1 H NMR (400MHz, MeOH-d4) δ 4.40 (q, J=6.7 Hz, 1H), 4.12-3.96 (m, 3H), 3.87 (q, J=8.2 Hz, 1H), 3.61 (s, 4H), 3.58-3.47 (m, 2H), 3.06 (d, J=3.7 Hz, 2H), 2.52-2.34 (m, 9H), 2.31 (s, 3H), 1.93 (t, J=9.5 Hz, 1H), 1.62-1.49 (m, 2H), 1.49-1.40 (m, 3H), 0.94-0.79 (m, 1H).
[0227] Example 20: Preparation of 4-(2-((1R,5S,6R)-3-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-azabicyclo[3.1.0]hexan-6-yl)acetyl)piperazin-2-one In step A of Example 18 above, 50 mg, 0.13 mmol of 2-((1R,5S,6R)-3-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-azabicyclo[3.1.0]hexan-6-yl)acetate was used, and 19 mg, 0.19 mmol of 2-oxopiperazine was used instead of piperazine-1-carboxylate. The procedure was carried out in the same manner as in Step A of Example 18, except that 4-(2-((1R,5S,6R)-3-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-azabicyclo[3.1.0]hexan-6-yl)acetyl)piperazin-2-one (47 mg, 0.10 mmol, 81% yield) of formula 1-20 was obtained. 1 The synthesis was confirmed by 1 H NMR analysis.
[0228] [Chemical formula 1-20] [ka] 1 H NMR (400MHz, MeOH-d4) δ 4.39 (t, J=7.0 Hz, 1H), 4.14 (s, 2H), 4.10-3.93 (m, 3H), 3.87 (d, J=7.6 Hz, 1H), 3.74 (dt, J=27.5, 5.3 Hz, 2H), 3.64 (s, 2H), 3.43-3.32 (m, 1H), 3.07 (d, J=12.2 Hz, 2H), 2.55-2.21 (m, 5H), 1.93 (s, 1H), 1.57 (s, 2H), 1.48 (d, J=6.1 Hz, 3H), 1.37 (d, J=7.0 Hz, 1H), 0.90 (s, 1H).
[0229] Example 21: Preparation of 2-((1R,5S,6S)-3-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-azabicyclo[3.1.0]heptan-6-yl)-1-(piperazin-1-yl)ethan-1-one As shown in the following reaction scheme 18, steps A and B were carried out in order to prepare the title compound of formula 1-21.
[0230] [Reaction Scheme 18] [ka]
[0231] (1) Step A: Preparation of tert-butyl 4-(2-((1R,5S,6S)-3-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-azabicyclo[3.1.0]heptan-6-yl)acetyl)piperazine-1-carboxylate 2-((1R,5S,6S)-3-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-azabicyclo[3.1.1]heptan-6-yl)acetic acid (177 mg, 0.468 mmol, prepared and used according to Example 8 of KR10-2021-0129607A), tert-buffered Tylpiperazine-1-carboxylate (87 mg, 0.468 mmol), N-[(dimethylamino)-1H-1,2,3-triazole-[4-5-b]pyridin-1-ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide (213 mg, 0.561 mmol) were dissolved in 10 ml of dimethylformamide and stirred at room temperature for 2 hours. After the reaction was completed, the reaction solution was extracted with ethyl acetate and water. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography to obtain tert-butyl 4-(2-((1R,5S,6S)-3-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-azabicyclo[3.1.1]heptan-6-yl)acetyl)piperazine-1-carboxylate (272 mg, yield 99%). 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (400MHz, CDCl3) δ 4.40 (q, J=6.9 Hz, 1H), 3.92-4.10 (m, 5H), 3.58 (m, 2H), 3.39-3.46 (m, 6H), 3.14 (m, 2H), 2.68 (d, J=7.8 Hz, 2 H), 2.29-2.46 (m, 6H), 2.11 (m, 1H), 1.87-1.96 (m, 1H), 1.46-1.51 (m, 12H), 1.41 (m, 1H).
[0232] (2) Step B: Preparation of 2-((1R,5S,6S)-3-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-azabicyclo[3.1.1]heptan-6-yl)-1-(piperazin-1-yl)ethan-1-one tert-Butyl 4-(2-((1R,5S,6S)-3-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-azabicyclo[3.1.1]heptan-6-yl)acetyl)piperazine-1-carboxylate (270 mg, 0.464 mmol) prepared in step A was dissolved in 4 ml of dichloromethane, and then 1 ml of trifluoroacetic acid was added and stirred at room temperature. After the reaction was completed, the reaction solution was concentrated under reduced pressure, neutralized with dichloromethane and saturated aqueous sodium bicarbonate solution, and extracted. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography to obtain 2-((1R,5S,6S)-3-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-azabicyclo[3.1.1]heptan-6-yl)-1-(piperazin-1-yl)ethan-1-one (210 mg, yield 95%). 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, CDCl3) δ 4.40 (m, 1H), 3.92-4.07 (m, 6H), 3.73 (m, 2H), 3.63 (s, 2H), 3.15 (m, 2H), 2.94-3.02 (m, 4H), 2.67 (d, J=7.8 Hz, 2H), 2.29-2.46 (m, 6H), 2.10 (m, 1H), 1.88-1.96 (m, 1H), 1.48 (d, J=5.9 Hz, 3H), 1.42 (dd, J=9.1, 5.5 Hz, 1H).
[0233] Example 22: Preparation of 1-(4-acetylpiperazin-1-yl)-2-((1R,5S,6S)-3-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-azabicyclo[3.1.1]heptan-6-yl)ethan-1-one 2-((1R,5S,6S)-3-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-azabicyclo[3.1.1]heptan-6-yl)-1-(piperazin-1-yl)ethan-1-one (30 mg, 0.067 mmol) prepared in Example 21 and acetic anhydride (9.51 μl, 0.101 mmol) were dissolved in 4 ml of dichloromethane and cooled to 0° C. Triethylamine (18.73 μl, 0.134 mmol) was added and stirred at room temperature for 1 hour. After the reaction was completed, the reaction solution was extracted with dichloromethane and saturated aqueous sodium bicarbonate solution. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography to obtain the title compound of the following formula 1-22 (17 mg, yield 52%). 1 The synthesis was confirmed by 1 H NMR analysis.
[0234] [Chemical formula 1-22] [ka] 1 H NMR (500MHz, CDCl3) δ 4.42-4.47 (m, 1H), 3.97-4.10 (m, 6H), 3.66 (m, 4H), 3.49-3.55 (m, 4H), 3.18 (m, 2H), 2.73 (d, J=7.6 Hz, 2H), 2.34-2.48 (m, 6H), 2.16 (s, 3H), 1.92-1.99 (m, 1H), 1.51 (d, J=6.1 Hz, 3H), 1.46 (q, J=4.8 Hz, 1H).
[0235] Example 23: Preparation of 2-((1R,5S,6S)-3-(8,8-difluoro-2-((S)-2-methylazetidin-1-yl)-5,6,7,8-tetrahydroquinazolin-4-yl)-3-azabicyclo[3.1.1]heptan-6-yl)-1-(piperazin-1-yl)ethan-1-one In step A of Example 21, 2-((1R,5S,6S)-3-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-azabicyclo[3.1.1]heptan-6-yl)acetic acid was replaced with 2-((1R,5S,6S)-3-(8,8-difluoro-2-((S)-2-methylazetidin-1-yl) The same procedure as in Example 21 was repeated except that 33.6 mg, 0.180 mmol of tert-butyl piperazine-1-carboxylate was used, and the title compound of the following formula 1-23 was prepared (69 mg, 0.150 mmol, yield 91%). 1 The synthesis was confirmed by 1 H NMR analysis.
[0236] [Chemical formula 1-23] [ka] 1H NMR (500MHz, CDCl3) δ 4.39-4.44 (m, 1H), 3.88-4.09 (m, 6H), 3.65 (t, J=4.9 Hz, 2H), 3.54 (t, J=4.9 Hz, 2H), 3.19 (s, br, 1H), 2.92 (m, 4H), 2.77 (m, 2H), 2.68 (d, J=7.6 Hz, 2H), 2.30-2.38 (m, 4H), 2.19-2.30 (m, 2H), 2.15 (dd, J=13.1, 7.6 Hz, 1H), 1.91-1.97 (m, 1H), 1.83 (d, J=5.8 Hz, 2H), 1.50 (d, J=6.1 Hz, 3H), 1.44 (dd, J=9.0, 5.3 Hz, 1H).
[0237] Example 24: Preparation of 2-((1R,5S,6S)-3-(8,8-difluoro-2-((S)-2-methylazetidin-1-yl)-5,8-dihydro-6H-pyrazole[3,4-d]pyrimidin-4-yl)-3-azabicyclo[3.1.1]heptan-6-yl)-1-(piperazin-1-yl)ethan-1-one In step A of Example 21, 2-((1R,5S,6S)-3-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-azabicyclo[3.1.1]heptan-6-yl)acetic acid was replaced with 2-((1R,5S,6S)-3-(8,8-difluoro-2-((S)-2-methylazetidin-1-yl)-5 The same procedure as in Example 21 was repeated except that 1,8-dihydro-6H-pyrano[3,4-d]pyrimidin-4-yl)-3-azabicyclo[3.1.1]heptan-6-yl)acetic acid (160 mg, 0.384 mmol) and 75 mg, 0.403 mmol of tert-butyl piperazine-1-carboxylate were used to prepare the title compound of the following formula 1-24 (69 mg, 0.150 mmol, yield 91%). 1 The synthesis was confirmed by 1 H NMR analysis.
[0238] [Chemical formula 1-24] [ka] 1 H NMR (500MHz, CDCl3) δ 4.40-4.46 (m, 1H), 4.14 (t, J=5.3 Hz, 2H), 3.94-4.09 (m, 6H), 3.52-3.82 (m, 4H), 2.99-3.11 (m, 6H), 2.70 (d, 1.42-1.46 (m, 1H).
[0239] Example 25: Preparation of 7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-4-((1R,5S,6S)-6-((piperazin-1-ylsulfonyl)methyl)-3-azabicyclo[3.1.0]hexan-3-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine
[0240] [Reaction Scheme 19] [ka]
[0241] The methods of Step A, Step B, and Step D of Example 16 were applied in sequence according to Reaction Scheme 19 to prepare the title compound of Formula 1-25.
[0242] (1) Step A: Preparation of tert-butyl 4-((((1R,5S,6R)-3-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-azabicyclo[3.1.0]hexan-6-yl)methyl)sulfonyl)piperazine-1-carboxylate In Step A of Example 16, except that tert-butyl 4-((((1R,5S,6R)-3-azabicyclo[3.1.0]hexan-6-yl)methyl)sulfonyl)piperazine-1-carboxylate (89 mg, 0.258 mmol) prepared in Preparation Example 10 was used instead of piperazin-2-one, the same procedure as in Step A of Example 16 was carried out to prepare the title compound (135 mg, 0.234 mmol), and it was confirmed by mass spectrometry that it was synthesized (mass [M+H] = 522.1).
[0243] (2) Step B: Preparation of tert-butyl 4-((((1R,5S,6R)-3-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-azabicyclo[3.1.0]hexan-6-yl)methyl)sulfonyl)piperazine-1-carboxylate The method of step B of Example 16 was applied, except that tert-butyl 4-((((1R,5S,6R)-3-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-azabicyclo[3.1.0]hexan-6-yl)methyl)sulfonyl)piperazine-1-carboxylate (135 mg, 0.234 mmol) prepared in step A was reacted with (2S)-2-methylazetidine[(1R,4S)-7,7-dimethyl-2-oxo-norbornan-1-yl]methanesulfonate, to prepare the title compound (95 mg, 0.167 mmol), 1 The synthesis was confirmed by 1 H NMR analysis. 1H NMR (500MHz, CDCl3) δ 4.43 (q, J=6.7 Hz, 1H), 3.97-4.09 (m, 4H), 3.64-3.69 (m, 2H), 3.54 (s, 4H), 3.29 (s, 4H), 3.01 (d, J=3.7 Hz, 2H), 2.92-2.95 (m, 2H), 2.43-2.50 (m, 2H), 2.38 (s, 1H), 1.96 (d, J=9.5 Hz, 1H), 1.75 (s, 2H), 1.51 (d, J=6.4 Hz, 3H), 1.49 (s, 8H). 1.07 (dd, J=6.6, 3.6 Hz, 1H).
[0244] (3) Step C: Preparation of 7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-4-((1R,5S,6S)-6-((piperazin-1-ylsulfonyl)methyl)-3-azabicyclo[3.1.0]hexan-3-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine The title compound of formula 1-25 (61 mg, 0.130 mmol) was prepared by carrying out the same procedure as in step D of Example 16, except that tert-butyl 4-((((1R,5S,6R)-3-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-azabicyclo[3.1.0]hexan-6-yl)methyl)sulfonyl)piperazine-1-carboxylate (95 mg, 0.167 mmol) prepared in step B was used in step D of Example 16. 1 The synthesis was confirmed by 1 H NMR analysis. 1H NMR (500MHz, CDCl3) δ 4.42 (td, J=13.2, 6.5 Hz, 1H), 4.01-4.08 (m, 3H), 3.97 (q, J=8.2 Hz, 1H), 3.66 (t, J=12.2 Hz, 2H), 3.30 (t, J=4.7 Hz, 4H), 2.98-3.01 (m, 2H), 2.95-2.98 (m, 4H), 2.88-2.93 (m, 2H), 2.40-2.49 (m, 2H), 2.34-2.39 (m, 1H), 1.91-1.98 (m, 1H), 1.79 (s, 1H), 1.75 (s, 2H), 1.46-1.51 (m, 3H), 1.06-1.10 (m, 1H).
[0245] Example 26: Preparation of (S)-2-((1-(5-methyl-2-(2-methylazetidin-1-yl)-6-(trifluoro)pyrimidin-4-yl)azetidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one [Reaction Scheme 20] [ka]
[0246] The methods of Steps A to D of Example 2 were applied in accordance with Reaction Scheme 20 to prepare the title compound of Chemical Formula 1-26.
[0247] Specifically, in step A of Example 2, 4-chloro-5-methyl-2-(methylthio)-6-(trifluoro)pyrimidine (12.0 g, 49.45 mmol) was reacted with tert-butyl 4-(2-(azetidin-3-yloxy)acetyl)piperazine-1-carboxylate (14.8 g, 49.45 mmol) instead of 4,5-dichloro-2-(methylthio)-6-(trifluoromethyl)pyrimidine, and in step C, 18.0 g, 59.28 mmol of (2S)-2-methylazetidine[(1R,4S)-7,7-dimethyl-2-oxo-norbornan-1-yl]methanesulfonate was used, and the same procedure as in Example 2 was carried out to prepare the title compound of formula 1-26 (12.1 g, 28.31 mmol, yield 57%). 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, MeOH-d4) δ 4.84 (br, s, 3H), 4.42 (m, 1H). 4.35 (s, 2H), 4.14 (m, 2H), 3.95 (m, 1H), 3.87 (m, 1H), 3.55 (br, s, 2H), 3.44 (br, s, 2H), 2.81 (br, s, 4H), 2.37 (m, 1H). 2.09 (m, 1H), 1.47 (d, 3H).
[0248] Example 27: Preparation of ((S)-2-((1-(2-(2-methylazetidin-1-yl)-6-(trifluoro)pyrimidin-4-yl)piperidin-4-yl)oxy)-1-(piperazin-1-yl)ethan-1-one [Reaction Scheme 21] [ka]
[0249] The methods of Steps A to D of Example 2 were applied in accordance with Reaction Scheme 21 to prepare the title compound of Chemical Formula 1-27.
[0250] Specifically, in Step A of Example 2, 4-chloro-2-(methylthio)-6-(trifluoro)pyrimidine (229 mg, 1.00 mmol) was used instead of 4,5-dichloro-2-(methylthio)-6-(trifluoromethyl)pyrimidine, and tert-butyl 4-(2-(azetidin-3-yloxy)acetyl)piperazine-1-carboxylate prepared in Preparation Example 9 was used instead of tert-butyl 4-(2-(piperidine-4 The same procedure as in Example 2 was carried out except that 225 mg, 0.744 mmol of (2S)-2-methylazetidine [(1R,4S)-7,7-dimethyl-2-oxo-norbornan-1-yl] methanesulfonate was used in step C, to prepare the title compound of formula 1-27 (219 mg, 0.50 mmol, yield 50%). 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, MeOH-d4) δ 6.37 (s, 1H), 4.42 (q, J=6.5 Hz, 1H), 4.27 (s, 2H), 4.11-3.83 (m, 4H), 3.70 (s, 1H), 3.53 (d, J=23.8 Hz, 4 H), 3.40 (t, J=10.2 Hz, 2H), 2.81 (d, J=14.0 Hz, 4H), 2.49-2.32 (m, 1H), 2.03-1.84 (m, 3H), 1.60 (d, J=8.8 Hz, 2H), 1.48 (d, J=6.1 Hz, 3H).
[0251] Example 28: Preparation of ((S)-2-((1-(5-methyl-2-(2-methylazetidin-1-yl)-6-(trifluoro)pyrimidin-4-yl)piperidin-4-yl)oxy)-1-(piperazin-1-yl)ethan-1-one [Reaction Scheme 22] [ka]
[0252] The methods of Steps A to D of Example 2 were applied in accordance with Reaction Scheme 22 to prepare the title compound of Chemical Formula 1-28.
[0253] Specifically, in Step A of Example 2, 4-chloro-5-methyl-2-(methylthio)-6-(trifluoromethyl)pyrimidine (243 mg, 1.00 mmol) was used instead of 4,5-dichloro-2-(methylthio)-6-(trifluoromethyl)pyrimidine, and tert-butyl 4-(2-(azetidin-3-yloxy)acetyl)piperazine-1-carboxylate prepared in Preparation Example 9 was used instead of tert-butyl 4-(2-(piperidinyl)pyrimidine-1-carboxylate. The procedure was carried out in the same manner as in Example 2 except that (2S)-2-methylazetidine [(1R,4S)-7,7-dimethyl-2-oxo-norbornan-1-yl] methanesulfonate (264 mg, 0.87 mmol) was used in step C, and the title compound of formula 1-28 (213 mg, 0.47 mmol, yield 47%) was prepared. 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, MeOH-d4) δ 4.48-4.32 (m, 1H), 4.26 (s, 2H), 4.04-3.81 (m, 2H), 3.65 (s, 3H), 3.53 (d, J=18.9 Hz, 4H), 3.11 (t, J=9.6 Hz, 2H), 2.82 (d, J=16.2 Hz, 4H), 2.41 (d, J=13.7 Hz, 1H), 2.14 (s, 3H), 2.09-1.84 (m, 3H), 1.71 (q, J=8.8 Hz, 2H), 1.48 (d, J=6.1 Hz, 3H).
[0254] Manufacturing Example 11 The following steps A to K were carried out in order to produce 4-chloro-7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidine represented by the following chemical formula k.
[0255] [Chemical formula k] [ka]
[0256] (1) Step A: Preparation of 5-(tert-butyl) 1-ethyl 2,2-difluoropentanedioate Ethyl 2-bromo-2,2-difluoroacetate (20 g, 99 mmol), tert-butyl acrylate (11.1 ml, 76 mmol), copper (9.6 g, 152 mmol), N1,N1,N2,N2-tetramethylethane-1,2-diamine (5.7 ml, 37.9 mmol), and acetic acid (4.8 ml, 83 mmol) were dissolved in 100 ml of tetrahydrofuran and stirred at 50° C. for 4 hours. After the reaction was completed, a saturated aqueous solution of ammonium chloride was added to the reaction solution, and the solution was extracted with ethyl acetate. The organic layer was washed with an aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain 5-(tert-butyl) 1-ethyl 2,2-difluoropentanedioate. The obtained 5-(tert-butyl) 1-ethyl 2,2-difluoropentanedioate was 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (400 MHz, CDCl3) δ 4.31 (q, J=7.0 Hz, 2H), 2.32-2.47 (m, 4H), 1.43 (s, 9H), 1.34 (t, J=7.3 Hz, 3H).
[0257] (2) Step B: Preparation of 5-ethoxy-4,4-difluoro-5-oxopentanoic acid The 5-(tert-butyl) 1-ethyl 2,2-difluoropentanedioate obtained in step A was dissolved in trifluoroacetic acid (30 ml) and dichloromethane (70 ml) and stirred at room temperature for 8 hours. After the reaction was completed, the mixture was concentrated under reduced pressure. A saturated aqueous solution of sodium bicarbonate was added to the concentrated solution, and the solution was extracted with ethyl acetate. The organic layer was washed with an aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain 5-ethoxy-4,4-difluoro-5-oxopentanoic acid (15 g, 76 mmol, yield 100%). The obtained 5-ethoxy-4,4-difluoro-5-oxopentanoic acid was 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, CDCl3) δ 4.36 (q, J=7.2 Hz, 2H), 2.66 (t, J=7.6 Hz, 2H), 2.42-2.51 (m, 2H), 1.39 (t, J=7.2 Hz, 3H).
[0258] (3) Step C: Preparation of ethyl 2,2-difluoro-5-hydroxypentanoate 5-Ethoxy-4,4-difluoro-5-oxopentanoic acid (12.0 g, 61 mmol) obtained in step B and borane dimethyl sulfide tetrahydrofuran solution (2 M 36.6 ml, 73 mmol) were dissolved in 300 ml of tetrahydrofuran, and then stirred at 50° C. for 12 hours. After the reaction was completed, water (10 ml) was added to the reaction solution, and the solution was stirred at 60° C. for 1 hour. After the reaction was completed, water was added to the reaction solution, and the solution was extracted with ethyl acetate. The organic layer was washed with an aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain ethyl 2,2-difluoro-5-hydroxypentanoate (6.5 g, 35.7 mmol, yield 59%). The obtained ethyl 2,2-difluoro-5-hydroxypentanoate was 1 The synthesis was confirmed by 1 H NMR analysis. 1H NMR (500MHz, CDCl3) δ 4.35 (q, J=7.1 Hz, 2H), 3.74 (t, J=6.3 Hz, 2H), 2.16-2.26 (m, 2H), 1.72-1.81 (m, 2H), 1.38 (t, J=7.2 Hz, 3H).
[0259] (4) Step D: Preparation of ethyl 2,2-difluoro-5-((methanesulfonyl)oxy)pentanoate Ethyl 2,2-difluoro-5-hydroxypentanoate (9.4 g, 51.6 mmol), methanesulfonyl chloride (4.42 ml, 56.8 mmol), diisopropylethylamine (18.0 ml, 103 mmol), and 4-dimethylaminopyridine (315 mg, 2.58 mmol) obtained in step C were dissolved in dichloromethane (200 ml) and stirred at room temperature for 3 hours. After the reaction was completed, 1N hydrochloric acid solution was added to the reaction solution and extracted with ethyl acetate. The organic layer was washed with an aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography (ethyl acetate / hexane = 1 / 3 weight ratio) to obtain ethyl 2,2-difluoro-5-((methanesulfonyl)oxy)pentanoate (13.3 g, 51.1 mmol, yield 99%). The resulting ethyl 2,2-difluoro-5-((methanesulfonyl)oxy)pentanoate was 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, CDCl3) δ 4.37 (q, J=7.1 Hz, 2H), 4.31 (t, J=6.3 Hz, 2H), 3.06 (s, 3H), 2.20-2.29 (m, 2H), 1.99-2.05 (m, 2H), 1.38-1.40 (m, 3H).
[0260] (5) Step E: Preparation of ethyl 5-cyano-2,2-difluoropentanoate The ethyl 2,2-difluoro-5-((methanesulfonyl)oxy)pentanoate (13.3 g, 51.1 mmol) and potassium cyanate (10.0 g, 153.3 mmol) prepared in step D were dissolved in a mixed solution of 150 ml of tetrahydrofuran and 150 ml of dimethylformamide, and then stirred at 70° C. for 18 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure. A saturated aqueous solution of ammonium chloride was added to the concentrated solution, and the solution was extracted with ethyl acetate. The organic layer was washed with an aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography (ethyl acetate / hexane=1 / 1 weight ratio) to obtain ethyl 5-cyano-2,2-difluoropentanoate (7.1 g, 37.1 mmol, yield 73%). The obtained ethyl 5-cyano-2,2-difluoropentanoate was 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (400MHz, CDCl3) δ 4.27-4.35 (m, 2H), 2.45 (t, J=7.1 Hz, 2H), 2.15-2.29 (m, 2H), 1.91 (t, 7.1 Hz, 2H), 1.31-1.37 (m, 3H).
[0261] (6) Step F: Preparation of diethyl 2,2-difluorohexanedioate Ethyl 5-cyano-2,2-difluoropentanoate (7.1 g, 37.7 mmol) prepared in step E and acetyl chloride (30 ml) were dissolved in 60 ml of ethanol and refluxed for 48 hours. After the reaction was completed, the mixture was concentrated under reduced pressure. A saturated aqueous solution of sodium bicarbonate was added to the concentrate, and the concentrate was extracted with ethyl acetate. The organic layer was washed with an aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain diethyl 2,2-difluorohexanedioate (6.5 g, 27.3 mmol, yield 74%). The obtained diethyl 2,2-difluorohexanedioate was 1 The synthesis was confirmed by 1 H NMR analysis. 1H NMR (500MHz, CDCl3) δ 4.35 (q. J=7.1 Hz, 2H), 4.16 (q, J=7.1 Hz, 2H), 2.40 (t, J=7.3 Hz, 2H), 2.07-2.20 (m, 2H), 1.86 (m, 2H), 1.38 (t, J=7.2 Hz, 3H), 1.28 (t, J=7.2 Hz, 3H).
[0262] (7) Step G: Preparation of ethyl 3,3-difluoro-2-oxocyclopentane-1-carboxylate The diethyl 2,2-difluorohexanedioate (51.57g, 216mmol) prepared in step F was dissolved in tetrahydrofuran (1000ml), and potassium tert-butoxide (26.7g, 238mmol) was slowly added and stirred at room temperature for 4 hours. 240ml of 1N hydrochloric acid solution was slowly added to the solution after the reaction was completed at 0°C, and the mixture was stirred for about 10 minutes. The reactant was diluted with ethyl acetate, and the organic layer was washed with an aqueous sodium chloride solution. The aqueous solution was extracted with ethyl acetate, and the collected organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure and thoroughly dried under reduced pressure to obtain ethyl 3,3-difluoro-2-oxocyclopentane-1-carboxylate (41.6g, 216mmol, yield 99%), which was used in the subsequent reaction without further purification.
[0263] (8) Step H: Preparation of 7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-ol Ethyl 3,3-difluoro-2-oxocyclopentane-1-carboxylate (540 mg, 2.41 mmol), methylisothiourea hemisulfate (672 mg, 4.82 mmol), and sodium carbonate (767 mg, 7.24 mmol) prepared in step G were dissolved in 50 ml of water and stirred at room temperature for 12 hours. After the reaction was completed, excess water was added to the reaction solution, which was then extracted with ethyl acetate. The organic layer was washed with an aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography (ethyl acetate / hexane = 1 / 1 weight ratio) to obtain 7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-ol (250 mg, 1.15 mmol, yield 48%). The resulting 7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-ol was 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, DMSO-D6) δ 1.92-1.97 (m, 2H), 1.81 (s, 3H), 1.71-1.79 (m, 2H).
[0264] (9) Step I: Preparation of 4-chloro-7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidine 7,7-Difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-ol (5.2 g, 23.83 mmol), phosphoryl trichloride (22.21 ml, 238 mmol), and benzyltriethylammonium chloride (5.43 g, 23.93 mmol) prepared in step H were dissolved in 150 ml of dichloroethane and stirred at 80° C. for 3 hours. After the reaction was completed, the reaction solution was distilled under reduced pressure. A saturated sodium bicarbonate solution was added to the concentrated solution, and the solution was extracted with ethyl acetate. The organic layer was washed with an aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography (ethyl acetate / hexane = 1 / 10 weight ratio) to obtain 4-chloro-7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidine (5.00 g, 23.83 mmol, yield 89%). The obtained 4-chloro-7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidine was 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, CDCl3) δ 2.99-3.03 (m, 2H), 2.62-2.71 (m, 5H).
[0265] Manufacturing Example 12 4-Chloro-7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidine (26.84g, 113mmol) and 3-chloroperbenzoic acid (61.5g, 250mmol) prepared in Preparation Example 11 were dissolved in 500ml of dichloromethane and stirred at room temperature for 18 hours. Sodium thiosulfate (3.6g, 22.68mmol) was added to the reaction solution after the reaction was completed, and water and saturated sodium carbonate solution were added in sequence and stirred. The organic layer extracted with dichloromethane was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to obtain 4-chloro-7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine of the following formula l (30.5g, yield >99%), which was used in the subsequent reaction without further purification. The resulting 4-chloro-7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine was 1 The synthesis was confirmed by 1 H NMR analysis.
[0266] [Chemical formula l] [ka] 1 H NMR (400MHz, CDCl3) δ 2.80 (m, 2H), 2.65 (s, 3H), 2.49-2.60 (m, 2H).
[0267] Manufacturing Example 13 tert-Butyl piperazine-1-carboxylate (6.00g, 32.21mmol) and diisopropylethylamine (8.32g, 64.37mmol) were dissolved in 200ml of dichloromethane, and the temperature was lowered to -78℃. Bromoacetyl bromide (7.15g, 35.43mmol) was slowly added, and the temperature was gradually raised to room temperature and stirred for 1 hour. After the reaction was completed, the reaction solution was concentrated under reduced pressure. 1N aqueous hydrochloric acid was added, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography (ethyl acetate / hexane = 1 / 1 weight ratio) to obtain tert-butyl 4(2-bromoacetyl)piperazine-1-carboxylate (6.62g, 21.5mmol, yield 66%) of the following chemical formula m. The resulting tert-butyl 4(2-bromoacetyl)piperazine-1-carboxylate was 1 The synthesis was confirmed by 1 H NMR analysis.
[0268] [chemical formula m] [ka] 1 H NMR (400MHz, CDCl3) δ 3.87 (s, 2H), 3.77-3.55 (m, 2H), 3.51 (dd, J=16.2, 5.8 Hz, 4H), 3.47-3.32 (m, 2H), 1.49 (d, J=18.3 Hz, 9H).
[0269] Manufacturing Example 14 tert-Butyl 1,4-diazepane-1-carboxylate (3.00g, 14.97mmol) and diisopropylethylamine (3.86g, 29.94mmol) were dissolved in 100ml of dichloromethane, and the temperature was lowered to -78℃. Bromoacetyl bromide (3.32g, 16.47mmol) was slowly added, and the temperature was gradually raised to room temperature and stirred for 1 hour. After the reaction was completed, the reaction solution was concentrated under reduced pressure. 1N aqueous hydrochloric acid was added, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography (ethyl acetate / hexane = 1 / 1 weight ratio) to obtain tert-butyl 4-(2-bromoacetyl)-1,4-diazepane-1-carboxylate (2.21g, 6.88mmol, yield 45%) of the following chemical formula n. The resulting tert-butyl 4-(2-bromoacetyl)-1,4-diazepane-1-carboxylate was 1 The synthesis was confirmed by 1 H NMR analysis.
[0270] [chemical formula n] [ka] 1 H NMR (400MHz, CDCl3) δ 3.87 (d, J=8.8 Hz, 2H), 3.72-3.34 (m, 8H), 2.01-1.77 (m, 2H), 1.45 (d, J=8.8 Hz, 9H).
[0271] Manufacturing Example 15 Glycolic acid (5.00g, 65.74mmol), N-[(dimethylamino)-1H-1,2,3-triazole-[4-5-b]pyridin-1-ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide (37.47g, 98.54mmol), tert-butyl piperazine-1-carboxylate (12.24g, 65.71mmol), and triethylamine (13.29g, 131.33mmol) were dissolved in 200ml of dimethylformamide and stirred at room temperature for 18 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure. Water was added and extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography (ethyl acetate / hexane = 1 / 1 weight ratio) to obtain tert-butyl 4-(2-hydroxyacetyl)piperazine-1-carboxylate (4.81 g, 19.68 mmol, yield 29%) of the following chemical formula o. The obtained tert-butyl 4-(2-hydroxyacetyl)piperazine-1-carboxylate was 1 The synthesis was confirmed by 1 H NMR analysis.
[0272] [chemical formula o] [ka] 1 H NMR (400MHz, CDCl3) δ 4.19 (s, 2H), 3.66 (br, s, 2H), 3.59 (s, 1H), 3.48 (br, s, 4H), 2.27 (br s, 2H), 1.49 (s, 9H).
[0273] Manufacturing Example 16 The following steps A and B were carried out in order to prepare tert-butyl 4-(2-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)acetyl)piperazine-1-carboxylate represented by the following chemical formula p.
[0274] [chemical formula p] [ka]
[0275] (1) Step A: Preparation of tert-butyl 4-(2-(5-bromopyridin-2-yl)acetyl)piperazine-1-carboxylate 2-(5-bromopyridin-2-yl)acetic acid (1g, 4.63mmol), tert-butyl-piperazine-1-carboxylate (862mg, 4.63mmol), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (1.2g, 3.16mmol) were dissolved in 20ml of dimethylformamide, and then diisopropylethylamine (2.7ml, 15.47mmol) was added and stirred at room temperature for 18 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure. Water was added, and the organic layer extracted with ethyl acetate was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography (ethyl acetate / hexane=1 / 1 weight ratio) to obtain tert-butyl 4-(2-(5-bromopyridin-2-yl)acetyl)piperazine-1-carboxylate (884.8 mg, 2.303 mmol, 50% yield). The obtained tert-butyl 4-(2-(5-bromopyridin-2-yl)acetyl)piperazine-1-carboxylate was 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (400MHz, CDCl3) δ 8.57 (d, J=2.3 Hz, 1H), 7.76 (dd, J=8.2, 2.3 Hz, 1H), 7.25 (d, J=8.0 Hz, 1H), 3.87 (s, 2H), 3.57 (dd, J=10.7, 7.1 Hz, 4H), 3.35 (dt, J=13.1, 5.1 Hz, 4H), 1.44 (d, J=7.8 Hz, 9H).
[0276] (2) Step B: Preparation of tert-butyl 4-(2-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)acetyl)piperazine-1-carboxylate tert-Butyl 4-(2-(5-bromopyridin-2-yl)acetyl)piperazine-1-carboxylate (1.18g, 3.07mmol), 4,4,4',4'5,5,5',5'-octamethyl-2,2-bi(1,3,2-dioxaborolane) (1.17g, 4.61mmol), and potassium acetate (904mg, 9.21mmol) were dissolved in 30ml of 1,4-dioxane, and then [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium dichloromethane complex (251mg, 0.307mmol) was added and stirred at 100°C for 18 hours. After the reaction was completed, the reaction solution was cooled to room temperature and extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to give tert-butyl 4-(2-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)acetyl)piperazine-1-carboxylate (1.74 g, 4.03 mmol, crude). The obtained tert-butyl 4-(2-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)acetyl)piperazine-1-carboxylate was 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (400MHz, CDCl3) δ 8.33 (s, 1H), 8.01 (dd, J=7.5, 1.6 Hz, 1H), 7.33 (d, J=7.8 Hz, 1H). 3.94 (s, 2H), 3.53-3.59 (m, 4H), 3.34 (t, J=5.0 Hz, 2H), 3.24 (t, J=5.3 Hz, 2H), 1.43 (s, 9H), 1.34 (s, 12H).
[0277] Manufacturing Example 17 The following steps A and B were carried out in order to prepare tert-butyl 4-(2-((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate of the following chemical formula q.
[0278] [Chemical formula q] [ka]
[0279] (1) Step A: Preparation of tert-butyl 4-(2-((5-bromopyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate tert-Butyl 4(2-hydroxyacetyl)piperazine-1-carboxylate (2.3g, 9.35mmol) and sodium hydride (60%, 374mg, 9.35mmol) were dissolved in 30ml of dimethylformamide and stirred at 0°C for 30 minutes, after which 5-bromo-2-chloropyridine (1.5g, 7.79mmol) was added and stirred at 50°C for 2 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure. 1N hydrochloric acid solution was added, and the organic layer extracted with ethyl acetate was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography (ethyl acetate / hexane = 1 / 1 weight ratio) to obtain tert-butyl 4(2-((5-bromopyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate (1.58g, 3.95mmol, yield 51%). The resulting tert-butyl 4(2-((5-bromopyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate was 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (400MHz, CDCl3) δ 8.15 (s, 1H), 7.70 (d, 1H), 6.83 (d, 1H), 5.00 (s, 2H), 3.62 (br, s, 2H), 3.50 (br s, 4H), 3.45 (br s, 2H), 1.49 (s, 9H).
[0280] (2) Step B: Preparation of tert-butyl 4-(2-((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate tert-Butyl 4(2-((5-bromopyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate (6 g, 14.99 mmol) prepared in step A, bis(pinacolato)diboron (4.19 g, 16.49 mmol), and potassium acetate (3.68 g, 37.5 mmol) were dissolved in 20 ml of 1,4-dioxane, and degassed for 5 minutes. 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloride dichloromethane complex (612 mg, 0.749 mmol) was added and stirred at 80°C for 18 hours. After the reaction was completed, ethyl acetate was added to the reaction solution, which was washed with water and saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain tert-butyl 4-(2-((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate (6.71 g, 23.96 mmol, crude). The obtained tert-butyl 4-(2-((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate was confirmed to be synthesized by mass spectrometry (MS) measurement. MS 448.3, 470.2(Na + )
[0281] Manufacturing Example 18 The following steps A and B were carried out in order to prepare tert-butyl 4-(2-((3-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate represented by the following chemical formula r.
[0282] [Chemical formula r] [ka]
[0283] (1) Step A: Preparation of tert-butyl 4-(2-((5-bromo-3-chloropyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate tert-Butyl 4(2-hydroxyacetyl)piperazine-1-carboxylate (2.5g, 10.1mmol) and sodium hydride (60%, 402mg, 10.1mmol) were dissolved in 30ml of dimethylformamide and stirred at 0℃ for 30 minutes, then 5-bromo-2,3-dichloropyridine (1.5g, 7.79mmol) was added and stirred at 50℃ for 2 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure. 1N hydrochloric acid solution was added, and the organic layer extracted with ethyl acetate was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography (ethyl acetate / hexane = 1 / 1 weight ratio) to obtain tert-butyl 4-(2-((5-bromo-3-chloropyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate (2.1g, 4.83mmol, yield 58%). The resulting tert-butyl 4-(2-((5-bromo-3-chloropyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate was 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (400MHz, CDCl3) δ 8.05 (s, 1H), 7.80 (d, J=5.5 Hz, 1H), 5.08 (d, J=11.6 Hz, 2H), 3.60 (s, 2H), 3.47 (d, J=30.5 Hz, 6H), 1.48 (s, 9H).
[0284] (2) Step B: Preparation of tert-butyl 4-(2-((3-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate tert-Butyl 4-(2-((5-bromo-3-chloropyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate (700 mg, 1.61 mmol) prepared in step A, bis(pinacolato)diboron (450 mg, 1.77 mmol), and potassium acetate (395 mg, 4.03 mmol) were dissolved in 20 ml of 1,4-dioxane, and degassed for 5 minutes. 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloride dichloromethane complex (66 mg, 0.08 mmol) was added and stirred at 80°C for 18 hours. After the reaction was completed, ethyl acetate was added to the reaction solution, which was washed with water and saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain tert-butyl 4-(2-((3-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate. It was confirmed by mass spectrometry (MS) measurement that the obtained tert-butyl 4-(2-((3-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate was synthesized.
[0285] Example 29: Preparation of ((S)-2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenyl)acetic acid As shown in the following reaction scheme 23, steps A to D were carried out in order to prepare the title compound of formula 1-29.
[0286] [Reaction Scheme 23] [ka]
[0287] (1) Step A: Preparation of methyl 2-(4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenyl)acetate 4-Chloro-7,7-difluoro-2-(methylthio)-6,7-dihydro-cyclopenta[d]pyrimidine (200mg, 0.845mmol) of formula (a) prepared in Preparation Example 11, methyl 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetate (350mg, 1.268mmol), tetrakis(triphenylphosphine)palladium(O) (49mg, 0.04mmol), and sodium carbonate solution (2M, 27ml, 2.54mmol) were dissolved in 20ml of 1,4-dioxane, and degassed for 5 minutes. The mixture was then stirred at 80°C for 2 hours. After the reaction was completed, the reaction solution was washed with water, then ethyl acetate was added, washed with water and saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure and then purified by column chromatography (ethyl acetate / hexane = 1 / 3 weight ratio) to obtain methyl 2-(4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenyl)acetate (200 mg, 0.57 mmol, yield 98%). The obtained methyl 2-(4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenyl)acetate was 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, CDCl3) δ 7.93 (d, 2H), 7.44 (d, 2H), 3.71 (s, 3H), 3.70 (s, 2H), 3.21 (m, 2H), 2.64 (s, 3H), 2.62 (m, 2H).
[0288] (2) Step B: Preparation of methyl 2-(4-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenyl)acetate Methyl 2-(4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenyl)acetate (200 mg, 0.57 mmol) prepared in step A and 3-chloroperbenzoic acid (70%, 352 mg, 1.43 mmol) were dissolved in 20 ml of dichloromethane and stirred at room temperature for 10 hours. After the reaction was completed, a saturated sodium thiosulfate solution and a saturated sodium bicarbonate solution were added to the reaction solution in this order, and the solution was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (ethyl acetate / hexane = 1 / 1 weight ratio) to obtain methyl 2-(4-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenyl)acetate (150 mg, 0.39 mmol, yield 68%). The obtained methyl 2-(4-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenyl)acetate was 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, CDCl3) δ 8.03 (d, 2H), 7.49 (d, 2H), 3.73 (s, 3H), 3.72 (s, 2H), 3.45 (s, 3H), 3.38 (m, 2H), 2.74 (m, 2H).
[0289] (3) Step C: Preparation of methyl (S)-2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenyl)acetate The methyl 2-(4-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenyl)acetate (130 mg, 0.34 mmol) prepared in step B, (2S)-2-methylazetidine[(1R,4S)-7,7-dimethyl-2-oxo-norbornan-1-yl]methanesulfonate (239 mg, 0.51 mmol), and potassium carbonate (141 mg, 1.02 mmol) were dissolved in 20 ml of acetonitrile and stirred at 80° C. for 2 hours. After the reaction was completed, water was added to the reaction solution and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (ethyl acetate / hexane = 1 / 1 weight ratio) to obtain methyl (S)-2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenyl)acetate (110 mg, 0.30 mmol, yield 88%). The obtained methyl (S)-2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenyl)acetate was 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, CDCl3) δ 7.87 (d, 2H), 7.39 (d, 2H), 4.59 (m, 1H), 4.15 (m, 1H), 4.08 (m, 1H), 3.70 (s, 3H), 3.68 (s, 2H), 3.08 (m, 2H), 2.53 (m, 2H), 2.47 (m, 1H), 2.01 (m, 1H), 1.59 (d, 3H).
[0290] (4) Step D: Preparation of (S)-2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenyl)acetic acid Methyl (S)-2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenyl)acetate (110 mg, 0.30 mmol) prepared in step C and 1 ml of 1N aqueous sodium hydroxide solution were dissolved in 3 ml of tetrahydrofuran and stirred at room temperature for 10 hours. After the reaction was completed, 1N hydrochloric acid solution was added to the reaction solution and extracted with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (methanol / dichloromethane = 1 / 9 weight ratio) to obtain (S)-2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenyl)acetic acid (38 mg, 0.11 mmol, yield 38%). The obtained (S)-2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenyl)acetic acid was 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, CDCl3) δ 7.87 (d, 2H), 7.40 (d, 2H), 4.59 (m, 1H), 4.16 (m, 1H), 4.06 (m, 1H), 3.70 (s, 3H), 3.07 (s, 2H), 2.55 (m, 2H), 2.47 (m, 1H), 2.01 (m, 1H), 1.58 (d, 3H).
[0291] Example 30: Preparation of (S)-2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenyl)-1-(piperazin-1-yl)ethan-1-one As shown in the following Reaction Scheme 24, the title compound of Chemical Formula 1-30 was prepared by carrying out Steps A and B in order.
[0292] [Reaction Scheme 24] [ka]
[0293] (1) Step A: Preparation of tert-butyl (S)-4-(2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenyl)acetyl)piperazine-1-carboxylate (S)-2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenyl)acetic acid (38 mg, 0.11 mmol) of formula 1-29 prepared in Example 29, 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane-2,4,6-trioxide (40.4 mg, 0.13 mmol), tert-butylpiperazine-1-carboxylate (24 mg, 0.13 mmol), and triethylamine (0.04 ml, 0.32 mmol) were dissolved in 5 ml of dichloromethane and stirred at room temperature for 2 hours. After the reaction was completed, 1N hydrochloric acid solution was added and extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure and then purified by column chromatography (dichloromethane / methanol = 9 / 1 weight ratio) to obtain tert-butyl (S)-4-(2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenyl)acetyl)piperazine-1-carboxylate (55 mg, 0.10 mmol, yield 99%). The obtained tert-butyl (S)-4-(2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenyl)acetyl)piperazine-1-carboxylate was, 1 The synthesis was confirmed by 1 H NMR analysis. 1H NMR (500MHz, CDCl3) δ 7.88 (d, 2H), 7.34 (d, 2H), 4.57 (m, 1H), 4.10 (m, 1H), 3.78 (s, 2H), 3.60 (s, 2H), 3.40 (m, 4H), 3.20 (m, 2H), 3.07 (m, 2H), 2.52 (m, 2H), 2.49 (m, 1H), 2.00 (m, 1H), 1.57 (d, 23H), 1.43 (s, 9H).
[0294] (2) Step B: Preparation of (S)-2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenyl)-1-(piperazin-1-yl)ethan-1-one tert-Butyl (S)-4-(2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenyl)acetyl)piperazine-1-carboxylate (55 mg, 0.10 mmol) prepared in step A and 1 ml of trifluoroacetic acid were dissolved in 4 ml of dichloromethane and stirred at room temperature for 8 hours. After the reaction was completed, the mixture was concentrated under reduced pressure. A saturated aqueous solution of ammonium hydroxide was added to the concentrate and extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (dichloromethane / methanol = 9 / 1 weight ratio) to obtain (S)-2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenyl)-1-(piperazin-1-yl)ethan-1-one (32 mg, 0.075 mmol, yield 75%). The obtained (S)-2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenyl)-1-(piperazin-1-yl)ethan-1-one was, 1 The synthesis was confirmed by 1 H NMR analysis. 1H NMR (500MHz, CDCl3) δ 7.87 (d, 2H), 7.34 (d, 2H), 4.59 (m, 1H), 4.15 (m, 1H), 4.06 (m, 1H), 3.76 (s, 2H), 3.61 (m, 2H), 3.43 (m, 2H), 3.08 (m, 2H), 2.83 (m, 2H), 2.72 (m, 2H), 3.60 (m, 2H), 3.50 (m, 1H), 2.00 (m, 1H), 1.57 (d, 3H).
[0295] Example 31: Preparation of ((S)-2-(5-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)pyridin-2-yl)-1-(piperazin-1-yl)ethan-1-one As shown in the following reaction scheme 25, steps A to C were carried out in order to prepare the title compound of formula 1-31.
[0296] [Reaction Scheme 25] [ka]
[0297] (1) Step A: Preparation of tert-butyl 4-(2-(5-(2-chloro-6-(trifluoromethyl)pyrimidin-4-yl)pyridin-2-yl)acetyl)piperazine-1-carboxylate 2,4-Dichloro-6-(trifluoromethyl)pyrimidine (98 mg, 0.450 mmol), tert-butyl 4-(2-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)acetyl)piperazine-1-carboxylate (388 mg, 0.900 mmol) of formula p prepared in Preparation Example 16, sodium carbonate solution (2 M, 0.675 ml, 1.349 mmol), and tetrakis(triphenylphosphine)palladium (52 mg, 0.045 mmol) were dissolved in 1,4-dioxane 10 ml, and the mixture was stirred at 80° C. for 18 hours. After the reaction was completed, water was added and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure and then purified by column chromatography to obtain tert-butyl 4-(2-(5-(2-chloro-6-(trifluoromethyl)pyrimidin-4-yl)pyridin-2-yl)acetyl)piperazine-1-carboxylate (140 mg, yield 64%). The obtained tert-butyl 4-(2-(5-(2-chloro-6-(trifluoromethyl)pyrimidin-4-yl)pyridin-2-yl)acetyl)piperazine-1-carboxylate was 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (400MHz, CDCl3) δ 9.23 (d, J=1.8 Hz, 1H), 8.42 (dd, J=8.2, 2.3 Hz, 1H), 7.95 (s, 1H), 4.03 (s, 2H), 3.61 (t, J=5.0 Hz, 4H), 3.35-3.40 (m, 4H), 1.45 (s, 9H).
[0298] (2) Step B: Preparation of tert-butyl (S)-4-(2-(5-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)pyridin-2-yl)acetyl)piperazine-1-carboxylate tert-Butyl 4-(2-(5-(2-chloro-6-(trifluoromethyl)pyrimidin-4-yl)pyridin-2-yl)acetyl)piperazine-1-carboxylate (140 mg, 0.29 mmol) prepared in step A, (2S)-2-methylazetidine [(1R,4S)-7,7-dimethyl-2-oxo-norbornan-1-yl] methanesulfonate (105 mg, 0.35 mmol), and potassium carbonate (120 mg, 0.87 mmol) were dissolved in 20 ml of acetonitrile and stirred at 80° C. for 3 hours. After the reaction was completed, water was added and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (ethyl acetate / hexane=1 / 1 weight ratio) to obtain tert-butyl (S)-4-(2-(5-(2-methylazetidin-1-yl)-5-(trifluoromethyl)pyrimidin-4-yl)pyridin-2-yl)acetyl)piperazine-1-carboxylate (135 mg, yield 90%). The obtained tert-butyl (S)-4-(2-(5-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)pyridin-2-yl)acetyl)piperazine-1-carboxylate was 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (400MHz, CDCl3) δ 9.17 (d, J=2.3 Hz, 1H), 8.27 (dd, J=8.2, 2.3 Hz, 1H), 7.53 (dd, J=7.5, 1.6 Hz, 1H), 7.16 (s, 1H), 4.61 (dd, J=14.4, 6.2 Hz, 1H), 4.06-4.20 (m, 2H), 3.99 (s, 2H), 3.60 (t, J=5.3 Hz, 4H), 3.37 (dd, J=13.3, 5.5 Hz, 4H), 2.47-2.55 (m, 1H), 2.00-2.08 (m, 1H), 1.58 (d, J=6.4 Hz, 3H), 1.44 (s, 9H).
[0299] (3) Step C: Preparation of (S)-2-(5-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)pyridin-2-yl)-1-(piperazin-1-yl)ethan-1-one tert-Butyl (S)-4-(2-(5-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)pyridin-2-yl)acetyl)piperazine-1-carboxylate (135 mg, 0.259 mmol) prepared in step B and 1 ml of trifluoroacetic acid were dissolved in 4 ml of dichloromethane and stirred at room temperature for 4 hours. After the reaction was completed, the mixture was concentrated under reduced pressure. The concentrated solution was neutralized with saturated aqueous sodium bicarbonate solution and extracted with dichloromethane. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (methanol / dichloromethane=1 / 9 weight ratio) to obtain (S)-2-(5-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)pyridin-2-yl)-1-(piperazin-1-yl)ethan-1-one (78 mg, yield 72%). The obtained (S)-2-(5-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)pyridin-2-yl)-1-(piperazin-1-yl)ethan-1-one was, 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (400MHz, CDCl3) δ 9.16 (d, J=1.8 Hz, 1H), 8.27 (dd, J=8.2, 2.3 Hz, 1H), 7.46 (d, J=8.2 Hz, 1H), 7.16 (s, 1H), 4.60 (dd, J=14.0, 6.2 Hz, 1H), 4.06-4.19 (m, 2H), 3.98 (s, 2H), 3.59 (td, J=9.6, 4.7 Hz, 4H), 2.79 (dt, J=22.0, 5.0 Hz, 4H), 2.46-2.55 (m, 1H), 1.99-2.08 (m, 1H), 1.58 (d, J=6.4 Hz, 3H).
[0300] Example 32: Preparation of (S)-2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)-1-(piperazin-1-yl)ethan-1-one) As shown in the following reaction scheme 26, steps A to E were carried out in order to prepare the title compound of formula 1-32.
[0301] [Reaction Scheme 26] [ka]
[0302] (1) Step A: Preparation of 4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenol 4-Chloro-7,7-difluoro-2-(methylthio)-6,7-dihydro-cyclopenta[d]pyrimidine (200mg, 0.845mmol) of formula k prepared in Preparation Example 11, (4-hydroxyphenyl)boronic acid (175mg, 1.268mmol), tetrakis(triphenylphosphine)palladium(O) (49mg, 0.042mmol), and sodium carbonate solution (2M, 1.27ml, 2.54mmol) were dissolved in 20ml of 1,4-dioxane and stirred at 80°C for 2 hours. After the reaction was completed, water was added to the reaction solution and extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure and then purified by column chromatography (ethyl acetate / hexane = 1 / 3 weight ratio) to obtain 4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenol (130 mg, 0.44 mmol, yield 52%). The obtained 4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenol was 1 The synthesis was confirmed by 1 H NMR analysis. 1H NMR (500MHz, CDCl3) δ 7.69 (d, 2H), 6.70 (d, 2H), 3.24 (m, m, 2H), 2.69 (s, 3H), 2.65 (m, 2H).
[0303] (2) Step B: Preparation of tert-butyl 4-(2-(4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)acetyl)piperazine-1-carboxylate 4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenol (130 mg, 0.44 mmol) prepared in step A, tert-butyl 4-(2-bromoacetyl)piperazine-1-carboxylate of formula c (203 mg, 0.66 mmol) prepared in preparation example 3, and potassium carbonate (183 mg, 1.33 mmol) were dissolved in 10 ml of dimethylformamide and stirred at room temperature for 2 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure. The solution was dissolved in ethyl acetate and washed with saturated sodium chloride solution. The organic layer was then dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (ethyl acetate / hexane=1 / 1 weight ratio) to obtain tert-butyl 4-(2-(4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)acetyl)piperazine-1-carboxylate (160 mg, 0.31 mmol, yield 70%). The obtained tert-butyl 4-(2-(4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)acetyl)piperazine-1-carboxylate was 1 The synthesis was confirmed by 1 H NMR analysis. 1H NMR (400MHz, CDCl3) δ 7.97 (dd, J=6.9, 2.3 Hz, 2H), 7.07 (dd, J=6.9, 1.8 Hz, 2H), 4.78 (s, 2H), 3.57 (q, J=5.6 Hz, 4H), 3.39-3.44 (m, 4H), 3.18-3.22 (m, 2H), 2.66 (s, 3H), 2.63 (m, 2H), 1.46 (s, 9H).
[0304] (3) Step C: Preparation of tert-butyl 4-(2-(4-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)acetyl)piperazine-1-carboxylate tert-Butyl 4-(2-(4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)acetyl)piperazine-1-carboxylate (160 mg, 0.31 mmol) prepared in step B and 3-chloroperbenzoic acid (70%, 189 mg, 0.77 mmol) were dissolved in 20 ml of dichloromethane and stirred at room temperature for 10 hours. After the reaction was completed, a saturated sodium thiosulfate solution and a saturated sodium bicarbonate solution were added to the reaction solution in this order, and the solution was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (methanol / dichloromethane = 1 / 9 weight ratio) to obtain tert-butyl 4-(2-(4-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)acetyl)piperazine-1-carboxylate (141 mg, 0.26 mmol, yield 84%). The obtained tert-butyl 4-(2-(4-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)acetyl)piperazine-1-carboxylate was confirmed to be synthesized by mass spectrometry (MS) measurement. MS 552.6, 574.6 (Na+ )
[0305] (4) Step D: Preparation of tert-butyl (S)-4-(2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)acetyl)piperazine-1-carboxylate tert-Butyl 4-(2-(4-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)acetyl)piperazine-1-carboxylate (141 mg, 0.26 mmol) prepared in step C, (2S)-2-methylazetidine[(1R,4S)-7,7-dimethyl-2-oxo-norbornan-1-yl]methanesulfonate (173 mg, 0.37 mmol), and potassium carbonate (127 mg, 0.92 mmol) were dissolved in 20 ml of acetonitrile and stirred at 80° C. for 2 hours. After the reaction was completed, an excess of water was added to the reaction solution and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (ethyl acetate / hexane = 1 / 1 weight ratio) to obtain tert-butyl (S)-4-(2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)acetyl)piperazine-1-carboxylate (95 mg, 0.18 mmol, yield 58%). The obtained tert-butyl (S)-4-(2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)acetyl)piperazine-1-carboxylate was, 1 The synthesis was confirmed by 1 H NMR analysis. 1H NMR (500MHz, CDCl3) δ 7.90 (d, 2H), 7.02 (d, 2H), 4.75 (s, 2H), 4.55 (m, 1H), 4.13 (m, 1H), 4.05 (m, 1H), 3.57 (m, 2H), 3.40 (m, 4H), 3.05 (m, 2H), 2.50 (m, 3H), 2.00 (m, 1H), 1.56 (d, 3H), 1.43 (s, 9H).
[0306] (5) Step E: Preparation of (S)-4-(2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)-1-(piperazin-1-yl)ethan-1-one tert-Butyl (S)-4-(2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)acetyl)piperazine-1-carboxylate (95 mg, 0.18 mmol) prepared in step D and 1 ml of trifluoroacetic acid were dissolved in 3 ml of dichloromethane and stirred at room temperature for 10 hours. After the reaction was completed, a saturated sodium bicarbonate solution was added to the reaction solution, and the solution was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (7N ammonia methanol solution / dichloromethane=1 / 9 weight ratio) to obtain (S)-4-(2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)-1-(piperazin-1-yl)ethan-1-one (55 mg, 0.12 mmol, yield 69%). The obtained (S)-4-(2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)-1-(piperazin-1-yl)ethan-1-one was, 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, CDCl3) δ 7.88 (d, 2H), 7.01 (d, 2H), 4.71 (s, 2H), 4.54 (m, 1H), 4.13 (m, 1H), 4.03 (m, 1H), 3.56 (m, 2H), 3.51 (m, 2H), 3.05 (m, 2H), 2.81 (m, 4H), 2.52 (m, 2H), 2.48 (m, 1H), 1.97 (m, 1H), 1.55 (d, 3H).
[0307] Example 33: Preparation of (S)-2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-fluorophenoxy)-1-(piperazin-1-yl)ethan-1-one) As shown in the following reaction scheme 27, steps A to E were carried out in order to prepare the title compound of formula 1-33.
[0308] [Reaction Scheme 27] [ka]
[0309] (1) Step A: Preparation of 4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-fluorophenol 4-Chloro-7,7-difluoro-2-(methylthio)-6,7-dihydro-cyclopenta[d]pyrimidine (200mg, 0.845mmol) of formula k prepared in Preparation Example 11, (3-fluoro-4-hydroxyphenyl)boronic acid (198mg, 1.27mmol), tetrakis(triphenylphosphine)palladium(O) (49mg, 0.042mmol), and sodium carbonate solution (2M, 1.27ml, 2.54mmol) were dissolved in 20ml of 1,4-dioxane and stirred at 80°C for 2 hours. After the reaction was completed, water was added to the reaction solution and extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure and then purified by column chromatography (ethyl acetate / hexane = 1 / 3 weight ratio) to obtain 4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-fluorophenol (260 mg, 0.83 mmol, yield 98%). The obtained 4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-fluorophenol was 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, CDCl3) δ 7.8 (d, 1H), 7.72 (2H, 1H), 7.13 (t, 1H), 3.24 (m, 2H), 2.67 (s, 3H), 2.66 (m, 2H).
[0310] (2) Step B: Preparation of tert-butyl 4-(2-(4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-fluorophenoxy)acetyl)piperazine-1-carboxylate 4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-fluorophenol (260 mg, 0.83 mmol) prepared in step A, tert-butyl 4-(2-bromoacetyl)piperazine-1-carboxylate of formula c (307 mg, 1.00 mmol) prepared in Preparation Example 3, and potassium carbonate (345 mg, 345 mmol) were dissolved in 10 ml of dimethylformamide and stirred at room temperature for 2 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure. The solution was dissolved in ethyl acetate and washed with saturated sodium chloride solution. The organic layer was then dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (ethyl acetate / hexane = 1 / 1 weight ratio) to obtain tert-butyl 4-(2-(4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-fluorophenoxy)acetyl)piperazine-1-carboxylate (447 mg, 0.83 mmol, yield 100%). The obtained tert-butyl 4-(2-(4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-fluorophenoxy)acetyl)piperazine-1-carboxylate was confirmed to be synthesized by mass spectrometry (MS) measurement. MS 538.6, 560.6 (Na + )
[0311] (3) Step C: Preparation of tert-butyl 4-(2-(4-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-fluorophenoxy)acetyl)piperazine-1-carboxylate tert-Butyl 4-(2-(4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-fluorophenoxy)acetyl)piperazine-1-carboxylate (447 mg, 0.83 mmol) prepared in step B and 3-chloroperbenzoic acid (70%, 512 mg, 2.08 mmol) were dissolved in 20 ml of dichloromethane and stirred at room temperature for 10 hours. After the reaction was completed, a saturated sodium thiosulfate solution and a saturated sodium bicarbonate solution were added to the reaction solution in this order, and the solution was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (methanol / dichloromethane = 1 / 9 weight ratio) to obtain tert-butyl 4-(2-(4-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-fluorophenoxy)acetyl)piperazine-1-carboxylate (420 mg, 0.74 mmol, yield 89%). The obtained tert-butyl 4-(2-(4-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-fluorophenoxy)acetyl)piperazine-1-carboxylate was confirmed to be synthesized by mass spectrometry (MS) measurement. MS 570.6, 592.6 (Na + )
[0312] (4) Step D: Preparation of tert-butyl (S)-4-(2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-fluorophenoxy)acetyl)piperazine-1-carboxylate tert-Butyl 4-(2-(4-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-fluorophenoxy)acetyl)piperazine-1-carboxylate (420 mg, 0.74 mmol) prepared in step C, (2S)-2-methylazetidine[(1R,4S)-7,7-dimethyl-2-oxo-norbornan-1-yl]methanesulfonate (481 mg, 1.02 mmol), and potassium carbonate (127 mg, 0.92 mmol) were dissolved in 20 ml of acetonitrile and stirred at 80° C. for 2 hours. After the reaction was completed, an excess of water was added to the reaction solution and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (ethyl acetate / hexane = 1 / 1 weight ratio) to obtain tert-butyl (S)-4-(2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-fluorophenoxy)acetyl)piperazine-1-carboxylate (320 mg, 0.57 mmol, yield 77%). The obtained tert-butyl (S)-4-(2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-fluorophenoxy)acetyl)piperazine-1-carboxylate was, 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, CDCl3) δ 7.79 (d, 1H), 7.66 (d, 1H). 7.13 (t, 1H), 4.83 (s, 2H), 4.58 (m, 1H), 4.16 (m, 1H), 4.08 (m, 1H), 3.59 (m, 4H), 3.50 (m, 2H), 3.40 (m, 2H), 2.59-2.40 (m, 3H), 2.03 (m, 1H), 1.58 (d, 3H), 1.45 (s, 9H).
[0313] (5) Step E: Preparation of (S)-4-(2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-fluorophenoxy)-1-(piperazin-1-yl)ethan-1-one tert-Butyl (S)-4-(2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-fluorophenoxy)acetyl)piperazine-1-carboxylate (320 mg, 0.57 mmol) prepared in step D and 1 ml of trifluoroacetic acid were dissolved in 3 ml of dichloromethane and stirred at room temperature for 10 hours. After the reaction was completed, a saturated sodium bicarbonate solution was added to the reaction solution, which was then extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (7N ammonia methanol solution / dichloromethane=1 / 9 weight ratio) to obtain (S)-4-(2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-fluorophenoxy)-1-(piperazin-1-yl)ethan-1-one (150 mg, 0.33 mmol, yield 58%). The obtained (S)-4-(2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-fluorophenoxy)-1-(piperazin-1-yl)ethan-1-one was, 1 The synthesis was confirmed by 1 H NMR analysis. 1H NMR (500MHz, CDCl3) δ 7.73 (dd, 1H), 7.62 (d, 1H), 7.08 (t, 1H), 4.80 (s, 2H), 4.53 (m, 1H), 4.12 (m, 1H), 4.04 (m, 1H), 3.55 (m, 4H), 3.04 (m, 2H), 2.85 (m, 4H), 2.51 (m, 2H), 2.48 (m, 1H), 1.99 (m, 1H), 1.54 (d, 3H).
[0314] Example 34: Preparation of (S)-2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2,6-difluorophenoxy)-1-(piperazin-1-yl)ethan-1-one) As shown in the following reaction scheme 28, steps A to E were carried out in order to prepare the title compound of formula 1-34.
[0315] [Reaction Scheme 28] [ka]
[0316] (1) Step A: Preparation of 4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2,6-difluorophenol 4-Chloro-7,7-difluoro-2-(methylthio)-6,7-dihydro-cyclopenta[d]pyrimidine (200mg, 0.845mmol) of formula k prepared in Preparation Example 11, (3,5-difluoro-4-hydroxyphenyl)boronic acid (176mg, 1.01mmol), tetrakis(triphenylphosphine)palladium(O) (49mg, 0.042mmol), and sodium carbonate solution (2M, 1.27ml, 2.54mmol) were dissolved in 20ml of 1,4-dioxane and stirred at 80°C for 2 hours. After the reaction was completed, water was added to the reaction solution and extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure and then purified by column chromatography (ethyl acetate / hexane = 1 / 3 weight ratio) to obtain 4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2,6-fluorophenol (214 mg, 0.647 mmol, yield 76%). The obtained 4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2,6-difluorophenol was 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, CDCl3) δ 7.66 (dd, J=16.3, 7.8 Hz, 2H), 3.73 (s, 1H), 3.32-3.18 (m, 2H), 2.07 (s, 1H), 1.58 (s, 3H), 1.28 (t, J=7.0 Hz, 1H).
[0317] (2) Step B: Preparation of tert-butyl 4-(2-(4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2,6-difluorophenoxy)acetyl)piperazine-1-carboxylate 4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2,6-difluorophenol (214 mg, 0.647 mmol) prepared in step A, tert-butyl 4-(2-bromoacetyl)piperazine-1-carboxylate of formula c (238 mg, 0.77 mmol) prepared in Preparation Example 3, and potassium carbonate (282 mg, 2.04 mmol) were dissolved in 10 ml of dimethylformamide and stirred at room temperature for 2 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure. The solution was dissolved in ethyl acetate and washed with saturated sodium chloride solution. The organic layer was then dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (ethyl acetate / hexane=1 / 1 weight ratio) to obtain tert-butyl 4-(2-(4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2,6-difluorophenoxy)acetyl)piperazine-1-carboxylate (310 mg, 0.556 mmol, yield 85%). The obtained tert-butyl 4-(2-(4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2,6-difluorophenoxy)acetyl)piperazine-1-carboxylate was 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (400MHz, CDCl3) δ 7.63 (d, J=9.2 Hz, 2H), 5.01-4.91 (m, 3H), 3.63 (d, J=4.0 Hz, 2H), 3.52 (d, J=35.4 Hz, 10H), 3.24 (t, J=6.6 Hz, 2H), 1.50 (d, J=3.1 Hz, 9H).
[0318] (3) Step C: Preparation of tert-butyl 4-(2-(4-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2,6-difluorophenoxy)acetyl)piperazine-1-carboxylate tert-Butyl 4-(2-(4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2,6-difluorophenoxy)acetyl)piperazine-1-carboxylate (310 mg, 0.556 mmol) prepared in step B and 3-chloroperbenzoic acid (70%, 288 mg, 1.67 mmol) were dissolved in 20 ml of dichloromethane and stirred at room temperature for 10 hours. After the reaction was completed, a saturated sodium thiosulfate solution and a saturated sodium bicarbonate solution were added to the reaction solution in this order, and the solution was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (methanol / dichloromethane=1 / 9 weight ratio) to obtain tert-butyl 4-(2-(4-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2,6-difluorophenoxy)acetyl)piperazine-1-carboxylate (244 mg, 0.414 mmol, yield 74%). The obtained tert-butyl 4-(2-(4-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2,6-difluorophenoxy)acetyl)piperazine-1-carboxylate was 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, CDCl3) δ 7.81-7.67 (m, 2H), 5.04 (s, 2H), 3.63 (s, 2H), 3.54 (d, J=8.5 Hz, 4H), 3.49 (s, 3H), 3.42 (t, J=6.6 Hz, 2H), 2.90-2.71 (m, 2H), 1.51 (s, 9H).
[0319] (4) Step D: Preparation of tert-butyl (S)-4-(2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2,6-difluorophenoxy)acetyl)piperazine-1-carboxylate tert-Butyl 4-(2-(4-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2,6-difluorophenoxy)acetyl)piperazine-1-carboxylate (244 mg, 0.41 mmol) prepared in step C, (2S)-2-methylazetidine[(1R,2S)-7,7-dimethyl-2-oxo-norbornan-1-yl]methanesulfonate (150 mg, 0.49 mmol), and potassium carbonate (171 mg, 1.24 mmol) were dissolved in 20 ml of acetonitrile and stirred at 80° C. for 2 hours. After the reaction was completed, an excess of water was added to the reaction solution and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (ethyl acetate / hexane = 1 / 1 weight ratio) to obtain tert-butyl (S)-4-(2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2,6-difluorophenoxy)acetyl)piperazine-1-carboxylate (228 mg, 0.39 mmol, yield 94%). The obtained tert-butyl (S)-4-(2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2,6-difluorophenoxy)acetyl)piperazine-1-carboxylate was 1 The synthesis was confirmed by 1 H NMR analysis. 1H NMR (500MHz, CDCl3) δ 7.62-7.48 (m, 2H), 4.91 (s, 2H), 4.58 (q, J=6.7 Hz, 1H), 4.25-4.01 (m, 2H), 3.69-3.39 (m, 8H), 3.09 (d. J=3.7 Hz, 2H), 2.67-2.42 (m, 3H), 1.62-1.55 (m, 3H), 1.47 (d, J=12.8 Hz, 10H), 1.26 (t, J=7.2 Hz, 1H).
[0320] (5) Step E: Preparation of (S)-4-(2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2,6-difluorophenoxy)-1-(piperazin-1-yl)ethan-1-one tert-Butyl (S)-4-(2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2,6-difluorophenoxy)acetyl)piperazine-1-carboxylate (0.18 mmol) prepared in step D and 1 ml of trifluoroacetic acid were dissolved in 3 ml of dichloromethane and stirred at room temperature for 10 hours. After the reaction was completed, a saturated sodium bicarbonate solution was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (7N ammonia methanol solution / dichloromethane=1 / 9 weight ratio) to obtain (S)-4-(2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2,6-difluorophenoxy)-1-(piperazin-1-yl)ethan-1-one (139 mg, 0.2828 mmol, yield 73%). The obtained (S)-4-(2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2,6-difluorophenoxy)-1-(piperazin-1-yl)ethan-1-one was, 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, MeOD) δ 7.55 (dd, J=15.3, 5.5 Hz, 2H), 5.00 (s, 2H), 4.60-4.45 (m, 1H), 4.17-3.93 (m, 2H), 3.64-3.44 (m, 4H), 3.15-2.99 (m, 2H), 2.95-2.75 (m, 4H), 2.64-2.40 (m, 3H), 2.11-1.89 (m, 1H), 1.61-1.47 (m, 3H).
[0321] Example 35: Preparation of (S)-2-(2-chloro-4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)-1-(piperazin-1-yl)ethan-1-one) As shown in the following reaction scheme 29, steps A to E were carried out in order to prepare the title compound of formula 1-35.
[0322] [Reaction Scheme 29] [ka]
[0323] (1) Step A: Preparation of 2-chloro-4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenol 4-Chloro-7,7-difluoro-2-(methylthio)-6,7-dihydro-cyclopenta[d]pyrimidine (200mg, 0.845mmol) of formula k prepared in Preparation Example 11, (3-chloro-4-hydroxyphenyl)boronic acid (174mg, 1.01mmol), tetrakis(triphenylphosphine)palladium(O) (49mg, 0.042mmol), and sodium carbonate solution (2M, 1.27ml, 2.54mmol) were dissolved in 20ml of 1,4-dioxane and stirred at 80°C for 2 hours. After the reaction was completed, water was added to the reaction solution and extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure and then purified by column chromatography (ethyl acetate / hexane = 1 / 3 weight ratio) to obtain 2-chloro-4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenol (224 mg, 0.68 mmol, yield 80%). The obtained 2-chloro-4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenol was 1 The synthesis was confirmed by 1 H NMR analysis. 1H NMR (500MHz, CDCl3) δ 8.07 (d, J=1.7 Hz, 1H), 7.84 (dd, J=8.5, 2.1 Hz, 1H), 7.22-7.02 (m, 1H), 3.22 (t, J=6.6 Hz, 2H), 2.75-2.55 (m, 5H).
[0324] (2) Step B: Preparation of tert-butyl 4-(2-(2-chloro-4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)acetyl)piperazine-1-carboxylate 4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2,6-difluorophenol (224 mg, 0.681 mmol) prepared in step A, tert-butyl 4-(2-bromoacetyl)piperazine-1-carboxylate of formula c (251 mg, 0.81 mmol) prepared in Preparation Example 3, and potassium carbonate (282 mg, 2.04 mmol) were dissolved in 10 ml of dimethylformamide and stirred at room temperature for 2 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure. The solution was dissolved in ethyl acetate and washed with saturated sodium chloride solution. The organic layer was then dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (ethyl acetate / hexane=1 / 1 weight ratio) to obtain tert-butyl 4-(2-(2-chloro-4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)acetyl)piperazine-1-carboxylate (333 mg, 0.59 mmol, yield 88%). The obtained tert-butyl 4-(2-(2-chloro-4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)acetyl)piperazine-1-carboxylate was 1 The synthesis was confirmed by 1 H NMR analysis. 1H NMR (400MHz, CDCl3) δ 8.22 (s, 1H), 8.01 (d, J=7.9 Hz, 1H), 7.21 (d, J=8.8 Hz, 1H), 4.93 (s, 2H), 3.72-3.55 (m, 4H), 3.57-3.46 (m, 5H), 3.46-3.34 (m, 4H), 2.88-2.70 (m, 2H), 1.49 (s, 9H).
[0325] (3) Step C: Preparation of tert-butyl 4-(2-(2-chloro-4-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)acetyl)piperazine-1-carboxylate tert-Butyl 4-(2-(2-chloro-4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)acetyl)piperazine-1-carboxylate (333 mg, 0.559 mmol) prepared in step B and 3-chloroperbenzoic acid (70%, 310 mg, 1.779 mmol) were dissolved in 20 ml of dichloromethane and stirred at room temperature for 10 hours. After the reaction was completed, a saturated sodium thiosulfate solution and a saturated sodium bicarbonate solution were added to the reaction solution in this order, and the solution was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (methanol / dichloromethane=1 / 9 weight ratio) to obtain tert-butyl 4-(2-(2-chloro-4-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)acetyl)piperazine-1-carboxylate (329 mg, 0.566 mmol, yield 93%). The obtained tert-butyl 4-(2-(2-chloro-4-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)acetyl)piperazine-1-carboxylate was, 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, CDCl3) δ 8.22 (s, 1H), 8.01 (d, J=7.9 Hz, 1H), 7.21 (d, J=8.8 Hz, 1H), 4.93 (s, 2H), 3.72-3.55 (m, 4H), 3.57-3.46 (m, 5H), 3.46-3.34 (m, 4H), 2.88-2.70 (m, 2H), 1.49 (s, 9H).
[0326] (4) Step D: Preparation of tert-butyl 4-(2-(2-chloro-4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)acetyl)piperazine-1-carboxylate tert-Butyl 4-(2-(2-chloro-4-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)acetyl)piperazine-1-carboxylate (329 mg, 0.56 mmol) prepared in step C, (2S)-2-methylazetidine[(1R,4S)-7,7-dimethyl-2-oxo-norbornan-1-yl]methanesulfonate (204 mg, 0.67 mmol), and potassium carbonate (232 mg, 1.68 mmol) were dissolved in 20 ml of acetonitrile and stirred at 80° C. for 2 hours. After the reaction was completed, an excess of water was added to the reaction solution and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (ethyl acetate / hexane = 1 / 1 weight ratio) to obtain tert-butyl 4-(2-(2-chloro-4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)acetyl)piperazine-1-carboxylate (299 mg, 0.51 mmol, yield 92%). The obtained tert-butyl 4-(2-(2-chloro-4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)acetyl)piperazine-1-carboxylate was 1 The synthesis was confirmed by 1 H NMR analysis. 1H NMR (500MHz, CDCl3) δ 8.03 (d, J=1.8 Hz, 1H), 7.81 (d, J=8.5 Hz, 1H), 7.11 (d, J=8.5 Hz, 1H), 4.86 (s, 2H), 4.59 (dt, J=20.0, 6.3 Hz, 1H), 4.26-4.01 (m, 3H), 3.72-3.51 (m, 4H), 3.44 (d, J=35.1 Hz, 4H), 3.20-2.99 (m, 2H), 2.66-2.39 (m, 3H), 2.12-1.94 (m, 1H), 1.61-1.57 (m, 3H), 1.52-1.38 (m, 9H).
[0327] (5) Step E: Preparation of (S)-2-(2-chloro-4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)-1-(piperazin-1-yl)ethan-1-one tert-Butyl 4-(2-(2-chloro-4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)acetyl)piperazine-1-carboxylate (299 mg, 0.51 mmol) prepared in step D and 1 ml of trifluoroacetic acid were dissolved in 3 ml of dichloromethane and stirred at room temperature for 10 hours. After the reaction was completed, a saturated sodium bicarbonate solution was added to the reaction solution, which was then extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (7N ammonia methanol solution / dichloromethane=1 / 9 weight ratio) to obtain (S)-2-(2-chloro-4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)-1-(piperazin-1-yl)ethan-1-one (179 mg, 0.37 mmol, yield 72%). The obtained (S)-2-(2-chloro-4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)-1-(piperazin-1-yl)ethan-1-one was, 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, MeOD) δ 7.97 (d, J=1.8 Hz, 1H), 7.85-7.66 (m, 1H), 7.08-6.91 (m, 1H), 5.12-4.87 (m, 2H), 4.49 (dt, J=19.8, 6.3 Hz, 1H), 4.17-3.88 (m, 2H), 3.71-3.40 (m, 4H), 3.14-2.93 (m, 2H), 2.93-2.60 (m, 4H), 2.65-2.35 (m, 3H), 2.10-1.89 (m, 1H), 1.72-1.18 (m, 3H).
[0328] Example 36: Preparation of (S)-2-(2-(chloro-4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)-1-(1,4-diazepan-1-yl)ethan-1-one) As shown in the following reaction scheme 30, steps A to E were carried out in order to prepare the title compound of formula 1-36.
[0329] [Reaction Scheme 30] [ka]
[0330] (1) Step A: Preparation of 2-chloro-4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenol 2-Chloro-4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenol was prepared in the same manner as in Example 35(1).
[0331] (2) Step B: Preparation of tert-butyl 4-(2-(2-chloro-4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)acetyl)-1,4-diazepane-1-carboxylate 2-Chloro-4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenol (205 mg, 0.62 mmol) prepared in step A, tert-butyl 4-(2-bromoacetyl)-1,4-diazepane-1-carboxylate (240 mg, 0.74 mmol) of formula d prepared in preparation example 4, and potassium carbonate (258 mg, 1.87 mmol) were dissolved in 10 ml of dimethylformamide and stirred at room temperature for 2 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure. The solution was dissolved in ethyl acetate and washed with saturated sodium chloride solution. The organic layer was then dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (ethyl acetate / hexane=1 / 1 weight ratio) to obtain tert-butyl 4-(2-(2-chloro-4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)acetyl)-1,4-diazepane-1-carboxylate (303 mg, 0.53 mmol, yield 85%). The obtained tert-butyl 4-(2-(2-chloro-4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)acetyl)-1,4-diazepane-1-carboxylate was 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (400MHz, CDCl3) δ 8.11 (s, 1H), 7.88 (d, J=8.5 Hz, 1H), 7.14 (d, J=8.8 Hz, 1H), 4.90 (d, J=7.9 Hz, 2H), 3.78-3.11 (m, 12H), 2.76-2.57 (m, 5H), 2.03-1.81 (m, 2H), 1.60 (d, J=11.0 Hz, 6H), 1.48 (s, 6H), 1.46 (s, 4H).
[0332] (3) Step C: Preparation of tert-butyl 4-(2-(2-chloro-4-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)acetyl)-1,4-azepane-1-carboxylate tert-Butyl 4-(2-(2-chloro-4-(7,7-difluoro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)acetyl)-1,4-diazepane-1-carboxylate (303 mg, 0.532 mmol) prepared in step B and 3-chloroperbenzoic acid (70%, 189 mg, 0.77 mmol) were dissolved in 20 ml of dichloromethane and stirred at room temperature for 10 hours. After the reaction was completed, a saturated sodium thiosulfate solution and a saturated sodium bicarbonate solution were added to the reaction solution in this order, and the solution was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (methanol / dichloromethane=1 / 9 weight ratio) to obtain tert-butyl 4-(2-(2-chloro-4-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)acetyl)-1,4-diazepane-1-carboxylate (281 mg, 0.467 mmol, yield 87%). The obtained tert-butyl 4-(2-(2-chloro-4-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)acetyl)-1,4-diazepane-1-carboxylate was, 1 The synthesis was confirmed by 1 H NMR analysis. 1H NMR (500MHz, CDCl3) δ 8.22 (d, J=22.3 Hz, 1H), 8.06-7.93 (m, 1H), 7.17 (d, J=8.8 Hz, 1H), 4.93 (d, J=6.7 Hz, 2H), 3.79-3.29 (m, 12H), 2.88-2.69 (m, 2H), 2.05-1.81 (m, 2H), 1.47 (d, J=10.1 Hz, 9H).
[0333] (4) Step D: Preparation of (S)-tert-butyl 4-(2-(2-chloro-4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)acetyl)-1,4-diazepane-1-carboxylate tert-Butyl 4-(2-(2-chloro-4-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)acetyl)-1,4-diazepane-1-carboxylate (281 mg, 0.24 mmol) prepared in step C, (2S)-2-methylazetidine[(1R,4S)-7,7-dimethyl-2-oxo-norbornan-1-yl]heptane-methanesulfonate (170 mg, 0.56 mmol), and potassium carbonate (193 mg, 1.40 mmol) were dissolved in 20 ml of acetonitrile and stirred at 80° C. for 2 hours. After the reaction was completed, an excess of water was added to the reaction solution and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (ethyl acetate / hexane = 1 / 1 weight ratio) to obtain (S)-tert-butyl 4-(2-(2-chloro-4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)acetyl)-1,4-diazepane-1-carboxylate (255 mg, 0.43 mmol, yield 92%). The obtained (S)-tert-butyl 4-(2-(2-chloro-4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)acetyl)-1,4-diazepane-1-carboxylate was 1 The synthesis was confirmed by 1 H NMR analysis. 1H NMR (500MHz, CDCl3) δ 8.04 (s, 1H), 7.82 (d, J=7.9 Hz, 1H), 7.13 (s, 1H), 4.61 (s, 1H), 4.26-4.04 (m, 4H), 3.72 (s, 3H), 3.66-3.42 (m, 1H), 3.44-3.27 (m, 2H), 3.12 (s, 3H), 2.67-2.48 (m, 2H), 2.02 (d, J=49.4 Hz, 4H), 1.61 (d, J=6.4 Hz, 5H), 1.47 (d, J=9.5 Hz, 12H).
[0334] (5) Step E: Preparation of (S)-2-(2-chloro-4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)-1-(1,4-diazepan-1-yl)ethan-1-one (S)-tert-butyl 4-(2-(2-chloro-4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)acetyl)-1,4-diazepane-1-carboxylate (255 mg, 0.43 mmol) prepared in step D and 1 ml of trifluoroacetic acid were dissolved in 3 ml of dichloromethane and stirred at room temperature for 10 hours. After the reaction was completed, a saturated sodium bicarbonate solution was added to the reaction solution, which was then extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (7N ammonia methanol solution / dichloromethane = 1 / 9 weight ratio) to obtain (S)-2-(2-chloro-4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)-1-(piperazin-1-yl)ethan-1-one (190 mg, 0.368 mmol, yield 90%). The obtained (S)-2-(2-chloro-4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)-1-(1,4-diazepan-1-yl)ethan-1-one was, 1 The synthesis was confirmed by 1 H NMR analysis. 1H NMR (500MHz, MeOD) δ 8.07 (s, 1H), 7.88 (d, J=8.8 Hz, 1H), 7.16 (t, J=8.2 Hz, 1H), 5.02 (d, J=9.5 Hz, 2H), 4.57 (q, J=6.6 Hz, 1H), 4.19-3.98 (m, 2H), 3.75-3.57 (m, 4H), 3.14 (t, J=6.4 Hz, 2H), 3.03 (t, J=5.3 Hz, 1H), 2.97-2.79 (m, 3H), 2.66-2.43 (m, 3H), 2.05 (d, J=9.5 Hz, 1H), 1.94 (d, J=11.3 Hz, 1H), 1.80 (t, J=5.8 Hz, 1H), 1.57 (d, J=6.4 Hz, 3H).
[0335] Example 37: Preparation of (S)-2-((5-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyridin-2-yl)oxy)-1-(piperazin-1-yl)ethan-1-one) As shown in the following reaction scheme 31, steps A to C were carried out in order to prepare the title compound of formula 1-37.
[0336] [Reaction Scheme 31] [ka]
[0337] (1) Step A: Preparation of tert-butyl 4-(2-((5-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate 4-Chloro-7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine (317 mg, 1.18 mmol), tert-butyl 4-(2-((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate (792 mg, 1.77 mmol) prepared in Preparation Example 17, and potassium carbonate (489 mg, 3.54 mmol) were dissolved in 20 ml of 1,2-dimethoxyethane / water (4 / 1 weight ratio) and degassed for 5 minutes. 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloride dichloromethane complex (48 mg, 0.059 mmol) was added and stirred at 60°C for 1 hour. After the reaction was completed, the reaction solution was diluted with ethyl acetate and washed with water and saturated aqueous sodium chloride solution, and the organic layer was then dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the reduced pressure concentrate was purified by column chromatography (dichloromethane / methanol = 19 / 1 weight ratio) to obtain tert-butyl 4-(2-((5-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate (367 mg, 0.66 mmol, yield 56%). The obtained tert-butyl 4-(2-((5-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate was, 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (400MHz, DMSO-d6) δ 8.87 (d, J=2.1 Hz, 1H), 8.48 (dd, J=8.7, 2.3 Hz, 1H), 7.16 (d, J=8.8 Hz, 1H), 5.23 (s, 2H), 3.54 (s, 3H), 3.45 (d, J=24.1 Hz, 8H), 3.29-3.23 (m, 2H), 2.87-2.67 (m, 2H), 1.41 (d, J=12.8 Hz, 9H).
[0338] (2) Step B: Preparation of tert-butyl (S)-4-(2-((5-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate tert-Butyl 4-(2-((5-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate (367 mg, 0.66 mmol) prepared in step A, (2S)-2-methylazetidine[(1R,4S)-7,7-dimethyl-2-oxo-norbornan-1-yl]methanesulfonate (241 mg, 0.79 mmol), and potassium carbonate (274 mg, 1.98 mmol) were dissolved in 20 ml of acetonitrile and stirred at 80° C. for 1 hour. After the reaction was completed, the reaction solution was concentrated under reduced pressure. Ethyl acetate was added to the reduced pressure concentrate and washed with a saturated aqueous sodium chloride solution. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (ethyl acetate / hexane=1 / 1 weight ratio) to obtain tert-butyl (S)-4-(2-((5-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate (332 mg, 0.60 mmol, yield 91%). The obtained tert-butyl (S)-4-(2-((5-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate was, 1 The synthesis was confirmed by 1 H NMR analysis. 1H NMR (500MHz, CDCl3) δ 8.88 (d, J=2.1 Hz, 1H), 8.25 (dd, J=8.7, 2.3 Hz, 1H), 7.00 (d, J=8.5 Hz, 1H), 5.10 (s, 2H), 4.71-4.47 (m, 1H), 4.10 (dd, J=21.8, 2.1 Hz, 3H), 3.62 (s, 2H), 3.48 (d, J=30.5 Hz, 6H), 3.09 (d, J=6.7 Hz, 2H), 2.57 (s, 2H), 2.04-1.99 (m, 1H), 1.58 (d, J=6.1 Hz, 3H), 1.48 (s, 9H).
[0339] (3) Step C: Preparation of (S)-2-((5-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyridin-2-yl)oxy)-1-(piperazin-1-yl)ethan-1-one tert-Butyl (S)-4-(2-((5-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate (332 mg, 0.60 mmol) prepared in step B and 2 ml of trifluoroacetic acid were dissolved in 20 ml of dichloromethane and stirred at room temperature for 18 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure. A saturated aqueous ammonium solution was added to the reduced pressure concentrate and extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (7N ammonia methanol solution / dichloromethane=1 / 10 weight ratio) to obtain (S)-2-((5-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyridin-2-yl)oxy)-1-(piperazin-1-yl)ethan-1-one (230 mg, 0.51 mmol, yield 84%). The obtained (S)-2-((5-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyridin-2-yl)oxy)-1-(piperazin-1-yl)ethan-1-one was, 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, MeOD) δ 8.72 (s, 1H), 8.35 (d, J=8.5 Hz, 1H), 7.02 (d, J=8.8 Hz, 1H), 5.17 (s, 2H), 4.57 (q, J=7.0 Hz, 1H), 4.19-3.98 (m, 2H), 3.55 (d. J=4.9 Hz, 4H), 3.13 (d, J=4.6 Hz, 2H), 2.96-2.75 (m, 4H), 2.66-2.44 (m, 3H), 2.05 (d, J=9.8 Hz, 1H), 1.57 (d, J=6.1 Hz, 3H).
[0340] Example 38: Preparation of (S)-2-((3-chloro-5-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyridin-2-yl)oxy)-1-(piperazin-1-yl)ethan-1-one) As shown in the following reaction scheme 32, steps A to C were carried out in order to prepare the title compound of formula 1-38.
[0341] [Reaction Scheme 32] [ka]
[0342] (1) Step A: Preparation of tert-butyl 4-(2-((3-chloro-5-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate 4-Chloro-7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine (260 mg, 0.97 mmol), tert-butyl 4-(2-((3-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate (776 mg, 1.61 mmol) prepared in Preparation Example 18, and potassium carbonate (416 mg, 3.00 mmol) were dissolved in 20 ml of 1,2-dimethoxyethane / water (4 / 1 weight ratio) and degassed for 5 minutes. 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloride dichloromethane complex (41 mg, 0.05 mmol) was added and stirred at 60°C for 1 hour. After the reaction was completed, the reaction solution was diluted with ethyl acetate and washed with water and saturated aqueous sodium chloride solution, and the organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the reduced pressure concentrate was purified by column chromatography (dichloromethane / methanol = 19 / 1 weight ratio) to obtain tert-butyl 4-(2-((3-chloro-5-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate (560 mg, 0.95 mmol, yield 98%). The synthesis of the obtained tert-butyl 4-(2-((3-chloro-5-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate was confirmed by mass spectrometry (MS) measurement. MS 588.0, 610.0 (Na + )
[0343] (2) Step B: Preparation of tert-butyl (S)-4-(2-((3-chloro-5-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate tert-Butyl 4-(2-((3-chloro-5-(7,7-difluoro-2-(methylsulfonyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate (560 mg, 0.95 mmol) prepared in step A, (2S)-2-methylazetidine[(1R,4S)-7,7-dimethyl-2-oxo-norbornan-1-yl]methanesulfonate (490 mg, 1.62 mmol), and potassium carbonate (525 mg, 3.80 mmol) were dissolved in 20 ml of acetonitrile and stirred at 80° C. for 1 hour. After the reaction was completed, the reaction solution was concentrated under reduced pressure. Ethyl acetate was added to the concentrated solution under reduced pressure and washed with a saturated aqueous sodium chloride solution. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (ethyl acetate / hexane=1 / 1 weight ratio) to obtain tert-butyl (S)-4-(2-((3-chloro-5-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate (299 mg, 0.51 mmol, yield 54%). The obtained tert-butyl (S)-4-(2-((3-chloro-5-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate was 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, CDCl3) δ 8.55 (s, 1H), 8.32 (s, 1H), 5.17 (s, 2H), 4.59 (td, J=13.4, 6.7 Hz, 1H), 4.18-4.00 (m, 2H), 3.70-3.37 (m, 8H), 3.09 (d, J=3.1 Hz, 2H), 2.68-2.40 (m, 3H), 1.53-1.41 (m, 9H).
[0344] (3) Step C: Preparation of (S)-2-((3-chloro-5-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyridin-2-yl)oxy)-1-(piperazin-1-yl)ethan-1-one tert-Butyl (S)-4-(2-((3-chloro-5-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate (299 mg, 0.52 mmol) prepared in step B and 2 ml of trifluoroacetic acid were dissolved in 20 ml of dichloromethane and stirred at room temperature for 18 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure. A saturated aqueous ammonium solution was added to the reduced pressure concentrate and extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (7N ammonia methanol solution / dichloromethane=1 / 10 weight ratio) to obtain (S)-2-((3-chloro-5-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyridin-2-yl)oxy)-1-(piperazin-1-yl)ethan-1-one (214 mg, 0.44 mmol, yield 86%). The obtained (S)-2-((3-chloro-5-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyridin-2-yl)oxy)-1-(piperazin-1-yl)ethan-1-one was, 1 The synthesis was confirmed by 1 H NMR analysis. 1H NMR (500MHz, MeOD) δ 8.62 (s, 1H), 8.41 (d, J=1.8 Hz, 1H), 5.30-5.19 (m, 2H), 4.58 (q, J=6.7 Hz, 1H), 4.21 -3.98 (m, 2H), 3.56 (d, J=4.3 Hz, 4H), 3.14 (d, J=3.1 Hz, 2H), 2.97-2.74 (m, 4H), 2.68-2.44 (m, 3H), 2.20-1.98 (m, 1H), 1.57 (d, J=6.1 Hz, 3H).
[0345] Example 39: Preparation of (S)-2-((5-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)pyridin-2-yl)oxy)-1-(piperazin-1-yl)ethan-1-one As shown in the following reaction scheme 33, steps A to C were carried out in order to prepare the title compound of formula 1-39.
[0346] [Reaction Scheme 33] [ka]
[0347] (1) Step A: Preparation of tert-butyl 4-(2-((5-(2-chloro-6-(trifluoromethyl)pyrimidin-4-yl)pyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate 2,4-Dichloro-6-(trifluoromethyl)pyrimidine (456 mg, 2.10 mmol), tert-butyl 4-(2-((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate (1128 mg, 2.52 mmol) prepared in Preparation Example 17, and sodium carbonate (2 M, 3.15 ml, 6.30 mmol) were dissolved in 20 ml of 1,4-dioxane, and the mixture was degassed for 5 minutes. 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloride (44 mg, 0.063 mmol) was added and stirred at 60°C for 1 hour. After the reaction was completed, the reaction solution was diluted with ethyl acetate and washed with water and saturated aqueous sodium chloride solution, and the organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to obtain tert-butyl 4-(2-((5-(2-chloro-6-(trifluoromethyl)pyrimidin-4-yl)pyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate (976 mg, 1.945 mmol, crude), which was used in the subsequent reaction without further purification.
[0348] (2) Step B: Preparation of tert-butyl (S)-4-(2-((5-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)pyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate tert-Butyl 4-(2-((5-(2-chloro-6-(trifluoromethyl)pyrimidin-4-yl)pyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate (976 mg, 1.945 mmol) prepared in step A, (2S)-2-methylazetidine [(1R,4S)-7,7-dimethyl-2-oxo-norbornan-1-yl] methanesulfonate (708 mg, 2.334 mmol), and potassium carbonate (274 mg, 1.98 mmol) were dissolved in 20 ml of acetonitrile and stirred at 80° C. for 1 hour. After the reaction was completed, the reaction solution was concentrated under reduced pressure. Ethyl acetate was added to the concentrated solution under reduced pressure and washed with a saturated aqueous sodium chloride solution. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (ethyl acetate / hexane=1 / 1 weight ratio) to obtain tert-butyl (S)-4-(2-((5-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)pyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate (558 mg, 1.041 mmol, yield 53%). The obtained tert-butyl (S)-4-(2-((5-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)pyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate was 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, CDCl3) δ 8.84 (s, 1H), 8.31 (d, J=8.8 Hz, 1H), 7.13 (s, 1H), 7.01 (d, J=8.5 Hz, 1H), 5.12 (s, 2H), 4.62 (q, J=6.6 Hz, 1H), 4.10-4.19 (m, 2H), 3.47-3.64 (m, 8H), 2.52 (m, 1H), 2.06 (m, 1H), 1.60 (d, J=7.6 Hz, 3H), 1.49 (s, 9H).
[0349] (3) Step C: Preparation of (S)-2-((5-2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)pyridin-2-yl)oxy)-1-(piperazin-1-yl)ethan-1-one tert-Butyl (S)-4-(2-((5-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)pyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate (558 mg, 1.040 mmol) prepared in step B and 2 ml of trifluoroacetic acid were dissolved in 20 ml of dichloromethane and stirred at room temperature for 18 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure. A saturated aqueous sodium bicarbonate solution was added to the reduced pressure concentrate and extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (7N ammonia methanol solution / dichloromethane=1 / 10 weight ratio) to obtain (S)-2-((5-2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)pyridin-2-yl)oxy)-1-(piperazin-1-yl)ethan-1-one (230 mg, 0.528 mmol, yield 50%). The obtained (S)-2-((5-2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)pyridin-2-yl)oxy)-1-(piperazin-1-yl)ethan-1-one was, 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (500MHz, CDCl3) δ 8.84 (s, 1H), 8.30 (d, J=8.5 Hz, 1H), 7.13 (s, 1H), 7.02 (d, J=8.5 Hz, 1H), 5.12 (s, 2H), 4.62 (q, J=6.6 Hz, 1H), 4.08-4.21 (m, 2H), 3.65 (s, 2H), 3.53 (s, 2H), 2.93 (d, J=24.7 Hz, 4H), 2.53 (dd, J=8.5, 5.5 Hz, 1H), 2.03-2.08 (m, 1H), 1.61 (d, J=5.8 Hz, 3H).
[0350] Example 40: Preparation of (S)-2-((5-(5-methyl-2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)pyridin-2-yl)oxy)-1-(piperazin-1-yl)ethan-1-one As shown in the following reaction scheme 34, steps A to C were carried out in order to prepare the title compound of formula 1-40.
[0351] [Reaction Scheme 34] [ka]
[0352] (1) Step A: Preparation of tert-butyl 4-(2-((5-(2-chloro-5-methyl-6-(trifluoromethyl)pyrimidin-4-yl)pyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate 2,4-Dichloro-5-methyl-6-(trifluoromethyl)pyrimidine (253 mg, 1.095 mmol), tert-butyl 4-(2-((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate (588 mg, 1.314 mmol) prepared in Preparation Example 17, and sodium carbonate (2 M, 1.64 ml, 3.29 mmol) were dissolved in 20 ml of 1,4-dioxane, and the mixture was degassed for 5 minutes. Bis(triphenylphosphine)palladium(II) (23 mg, 0.033 mmol) was added and stirred at 60° C. for 1 hour. After the reaction was completed, the reaction solution was diluted with ethyl acetate and washed with water and saturated aqueous sodium chloride solution, and the organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (dichloromethane / methanol=2 / 1 weight ratio) to obtain tert-butyl 4-(2-((5-(2-chloro-5-methyl-6-(trifluoromethyl)pyrimidin-4-yl)pyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate (275 mg, 0.533 mmol, yield 48%). The obtained tert-butyl 4-(2-((5-(2-chloro-5-methyl-6-(trifluoromethyl)pyrimidin-4-yl)pyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate was 1 The synthesis was confirmed by 1 H NMR analysis. 1 H NMR (400MHz, CDCl3) δ 8.39 (d, J=1.8 HZ, 1H), 7.91 (dd, J=8.7, 2.3 Hz, 1H), 7.03 (d, J=8.7 Hz, 1H), 5.09 (s, 2H), 3.44-3.60 (m, 8H), 2.50 (d, J=1.8 Hz, 3H), 1.46 (s, 9H).
[0353] (2) Step B: Preparation of tert-butyl (S)-4-(2-((5-(5-methyl-2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)pyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate tert-Butyl 4-(2-((5-(2-chloro-5-methyl-6-(trifluoromethyl)pyrimidin-4-yl)pyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate (0.533 mmol) prepared in step A, (2S)-2-methylazetidine [(1R,4S)-7,7-dimethyl-2-oxo-norbornan-1-yl] methanesulfonate (0.64 mmol), and potassium carbonate (221 mg, 1.60 mmol) were dissolved in 20 ml of acetonitrile and stirred at 80° C. for 1 hour. After the reaction was completed, the reaction solution was concentrated under reduced pressure. Ethyl acetate was added to the reduced pressure concentrate and washed with a saturated aqueous sodium chloride solution. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (ethyl acetate / hexane=1 / 1 weight ratio) to obtain tert-butyl (S)-4-(2-((5-(5-methyl-2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)pyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate (232 mg, 0.42 mmol, yield 79%). The obtained tert-butyl (S)-4-(2-((5-(5-methyl-2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)pyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate was 1 The synthesis was confirmed by 1 H NMR analysis. 1H NMR (400MHz, CDCl3) δ 8.32 (d, J=2.7 Hz, 1H), 7.82 (dd, J=8.5, 2.5 Hz, 1H), 6.95-6.98 (m, 1H), 5.07 (s, 2H), 4.51 (m, 1H), 3.98-4.12 (m, 2H), 3.56 (m, 8H), 2.50-2.34 (1H), 2.02 (m, 2H), 1.47 (s, 9H).
[0354] (3) Step C: Preparation of (S)-2-((5-(5-methyl-2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)pyridin-2-yl)oxy)-1-(piperazin-1-yl)ethan-1-one tert-Butyl (S)-4-(2-((5-(5-methyl-2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)pyridin-2-yl)oxy)acetyl)piperazine-1-carboxylate (0.60 mmol) prepared in step B and 2 ml of trifluoroacetic acid were dissolved in 20 ml of dichloromethane and stirred at room temperature for 18 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure. A saturated aqueous ammonium solution was added to the reduced pressure concentrate and extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the concentrated solution was purified by column chromatography (7N ammonia methanol solution / dichloromethane=1 / 10 weight ratio) to obtain (S)-2-((5-(5-methyl-2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)pyridin-2-yl)oxy)-1-(piperazin-1-yl)ethan-1-one (95.4 mg, 0.212 mmol, yield 50%). The obtained (S)-2-((5-(5-methyl-2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)pyridin-2-yl)oxy)-1-(piperazin-1-yl)ethan-1-one was, 1 The synthesis was confirmed by 1 H NMR analysis. 1H NMR (400MHz, CDCl3) δ 8.32 (d, J=2.3 Hz, 1H), 7.81 (dd, J=8.7, 2.3 Hz, 1H), 6.97 (d, J=8.2 Hz, 1H), 5.07 (s, 2H), 4.50 (q, J=6.9 Hz, 1H), 3.96-4.10 (m, 2H), 3.55 (m, 4H), 2.89 (m, 4H), 2.39-2.48 (m, 1H), 2.25 (d, J=1.8 Hz, 3H), 1.96-2.06 (m, 1H), 1.52 (d, J=6.4 Hz, 3H).
[0355] Experimental example: Ketohexokinase inhibitor in vitro activity measurement Ketohexokinase (KHK) was expressed in E. coli and purified using His tag. The activity of purified KHK was measured using the Transcreener ADP2 TR-FRET Red Assay kit from BellBrook Labs. The KHK protein was reacted with a solution containing ATP and fructose at the appropriate concentration for 15 minutes, and the amount of ADP produced was measured using TR-FRET. To measure the activity of ketohexokinase (KHK) inhibitors, ketohexokinase (KHK) was first reacted with an inhibitor at the appropriate concentration for 30 minutes, and then reacted with a solution containing a substrate for ketohexokinase (KHK) for 15 minutes. After the reaction for TR-FRET was allowed to proceed for 1 hour, fluorescence was measured using a PerkinElmer Envision instrument. The Envision instrument settings were determined according to the TR-FRET optimization procedure published by BellBrook Labs.
[0356] The results for each concentration of ketohexokinase (KHK) inhibitors are determined from the ratio of 665 nm wavelength to 615 nm wavelength. The 665 / 615 ratio for each inhibitor concentration was converted to ADP concentration based on the ADP standard curve, and the inhibitory activity Ki value was calculated using the Morrison equation in statistical software (Prizm). Meanwhile, the Ki value indicates the binding affinity between the inhibitor and the enzyme, and a lower value indicates better inhibitory activity.
[0357] [Table 1]
[0358] In the above Table 1, A≧1 μM, B=1 to 0.1 μM, C=0.1 to 0.01 μM, and D≦0.01 μM. From the results in the above Table 1, it can be confirmed that the compounds of Examples 1 to 40 according to the present invention have excellent inhibitory activity against ketohexokinase.
Claims
1. A compound of the following formula 1, a pharma- ceutically acceptable salt, or an isomer thereof: [Chemical formula 1] 【Chemistry 1】 (In the above Chemical Formula 1, A is unsubstituted or C 1 ~C 3 C substituted with an alkyl or carbonyl group 3 ~C 8 or a heterocycloalkyl group of the formula: 【Chemistry 2】 and X and Y are each independently N or C-R a and R a is hydrogen or a halogen radical, Z is a direct bond, C 1 ~C 3 an alkylene group, —O—, or —C(O)—; R 1 and R 2 are each independently hydrogen, a halogen group, or a C 1 ~C 3 or an alkyl group of R 1 and R 2 are linked to each other and are unsubstituted or substituted with 1 to 3 halogen groups. 3 ~C 6 or an aliphatic ring group of the formula: 3 ~C 6 forming a heterocycloalkyl group of the formula R 3 is -(CR 4 R 5 ) n -B-R 6 and R 4 and R 5 are each independently hydrogen or C 1 ~C 3 is an alkyl group of the formula n is an integer from 0 to 3, B is a direct bond, -C(O)-, or -S(O) 2 - and R 6 is a hydroxy group or is unsubstituted or 1 ~C 3 an alkyl group, a carbonyl group, or 1 ~C 3 C containing N substituted with an alkylcarbonyl group 3 ~C 7 is a heterocycloalkyl group represented by the formula:
2. In the above Chemical Formula 1, The compound according to claim 1 , or a pharma- ceutically acceptable salt or isomer thereof, wherein when A is a heterocycloalkyl group, A is a substituent represented by the following formula 1a or 1b: [Chemical formula 1a] 【Chemistry 3】 (In the above chemical formula 1a, X and Y are, independently of each other, CH or N; R a and R b are, independently of each other, C 1 ~C 3 is an alkylene group of the formula: R c is C 1 ~C 3 is an alkyl or carbonyl group of the formula m is 0 or 1; [Chemical formula 1b] 【Chemistry 4】 In the above Chemical Formula 1b, R d is a direct bond or CH 2 It is.)
3. A 【Chemistry 5】 If In the above Chemical Formula 1, X and Y are each independently N or C-R a and R a is hydrogen or a halogen radical, Z is C 1 ~C 3 or -O-, R 1 and R 2 are linked to each other and are unsubstituted or substituted with 1 to 3 halogen groups. 3 ~C 6 and forming an aliphatic ring group of R 3 is -(CR 4 R 5 ) n -B-R 6 and R 4 and R 5 is hydrogen, n is an integer from 0 to 3, B is -C(O)-, R 6 is a hydroxy group or is unsubstituted or 1 ~C 3 C containing N substituted with an alkyl group 4 ~C 6 or a pharma- ceutically acceptable salt, or isomer thereof.
4. A 【Chemistry 6】 If In the above Chemical Formula 1, X is N Y is CR a where R a is hydrogen, Z is C 1 ~C 3 or -O-, R 1 is C substituted with 1 to 3 halogen groups 1 ~C 3 is an alkyl group of the formula R 2 is hydrogen or C 1 ~C 3 is an alkyl group of the formula R 3 is -(CR 4 R 5 ) n -B-R 6 and R 4 and R 5 is hydrogen, n is an integer from 0 to 3, B is -C(O)-, R 6 is unsubstituted or C 1 ~C 3 C containing N substituted with an alkyl group 4 ~C 6 or a pharma- ceutically acceptable salt, or isomer thereof.
5. 2. The compound of claim 1, or a pharma- ceutically acceptable salt or isomer thereof, wherein said halogen group is F or Cl.
6. The compound of claim 1, or a pharma- ceutically acceptable salt or isomer thereof, wherein the compound of formula 1 is one or more selected from the group consisting of: (S)-2-((1-(2-(2-methylazetidin-2-yl)-6-(trifluoromethyl)pyrimidin-4-yl)azetidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; (S)-2-((1-(5-chloro-2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)azetidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; (S)-2-((1-(7,7-difluoro-2-(2-(methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)azetidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; (S)-2-((1-(8,8-difluoro-2-(2-methylazetidin-1-yl)-5,6,7,8-tetrahydroquinazolin-4-yl)azetidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; 2-(((2S,3R)-1-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-methylazetidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; 2-(((S)-1-(2-((S)-2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)pyrrolidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; 2-(((S)-1-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyrrolidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; 2-(((R)-1-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyrrolidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; 2-((R)-1-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyrrolidin-3-yl)-1-(piperazin-1-yl)ethan-1-one; (S)-2-((1-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperidin-4-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; (S)-2-(4-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)piperazin-1-yl)-1-(piperazin-1-yl)ethan-1-one; (S)-2-(4-(5-chloro-2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)piperazin-1-yl)-1-(piperazin-1-yl)ethan-1-one; (S)-2-(4-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)-1-(2-oxo-2-(piperazin-1-yl)ethyl)piperazin-2-one; (S)-2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-1-(piperazin-1-yl)ethan-1-one; (S)-2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-1-morpholinoethan-1-one; (S)-1-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(piperazin-1-yl)propane-1,3-dione; (S)-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-1-(2-oxo-2-(piperazin-1-yl)ethyl)piperazin-2-one; (S)-2(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]-pyrimidin-4-yl)piperidin-1-yl)-1-(piperazin-1-yl)ethan-1-one; 2-((1R,5S,6R)-3-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-azabicyclo[3.1.0]hexan-6-yl)-1-(piperazin-1-yl)ethan-1-one; 2-((1R,5S,6R)-3-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-azabicyclo[3.1.0]hexan-6-yl)-1-(4-methylpiperazin-1-yl)ethan-1-one; 4-(2-((1R,5S,6R)-3-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-azabicyclo[3.1.0]hexan-6-yl)acetyl)piperazin-2-one; 2-((1R,5S,6S)-3-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-azabicyclo[3.1.0]hexan-6-yl)-1-(piperazin-1-yl)ethan-1-one; 1-(4-acetylpiperazin-1-yl)-2-((1R,5S,6S)-3-(7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopentane[d]pyrimidin-4-yl)-3-azabicyclo[3.1.1]heptan-6-yl)ethan-1-one; 2-((1R,5S,6S)-3-(8,8-difluoro-2-((S)-2-methylazetidin-1-yl)-5,6,7,8-tetrahydroquinazolin-4-yl)-3-azabicyclo[3.1.1]heptan-6-yl)-1-(piperazin-1-yl)ethan-1-one; 2-((1R,5S,6S)-3-(8,8-difluoro-2-((S)-2-methylazetidin-1-yl)-5,8-dihydro-6H-pyrazole[3,4-d]pyrimidin-4-yl)-3-azabicyclo[3.1.1]heptan-6-yl)-1-(piperazin-1-yl)ethan-1-one; 7,7-difluoro-2-((S)-2-methylazetidin-1-yl)-4-((1R,5S,6S)-6-((piperazin-1-ylsulfonyl)methyl)-3-azabicyclo[3.1.0]hexan-3-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine; (S)-2-((1-(5-methyl-2-(2-methylazetidin-1-yl)-6-(trifluoro)pyrimidin-4-yl)azetidin-3-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; (S)-2-((1-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)piperidin-4-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; (S)-2-((1-(5-methyl-2-(2-methylazetidin-1-yl)-6-(trifluoro)pyrimidin-4-yl)piperidin-4-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; (S)-2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]-pyrimidin-4-yl)phenyl)acetic acid; (S)-2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]-pyrimidin-4-yl)phenyl)-1-(piperazin-1-yl)ethan-1-one; (S)-2-(5-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)pyridin-2-yl)-1-(piperazin-1-yl)ethan-1-one; (S)-2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)-1-(piperazin-1-yl)ethan-1-one; (S)-2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-fluorophenoxy)-1-(piperazin-1-yl)ethan-1-one; (S)-2-(4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2,6-difluorophenoxy)-1-(piperazin-1-yl)ethan-1-one; (S)-2-(2-chloro-4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)-1-(piperazin-1-yl)ethan-1-one; (S)-2-(2-chloro-4-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)phenoxy)-1-(1,4-diazepan-1-yl)ethan-1-one; (S)-2-((5-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyridin-2-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; (S)-2-((3-chloro-5-(7,7-difluoro-2-(2-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyridin-2-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; (S)-2-((5-(2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)pyridin-2-yl)oxy)-1-(piperazin-1-yl)ethan-1-one; (S)-2-((5-(5-methyl-2-(2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)pyridin-2-yl)oxy)-1-(piperazin-1-yl)ethan-1-one.
7. 2. The compound of claim 1, or a pharma- ceutically acceptable salt or isomer thereof, which is a ketohexokinase (KHK) inhibitor.
8. 10. The compound of claim 1, or a pharma- ceutically acceptable salt or isomer thereof, for use in the prophylaxis or treatment of a metabolic disease.
9. A pharmaceutical composition for a ketohexokinase (KHK) inhibitor, comprising the compound according to claim 1 or a pharma- ceutically acceptable salt or isomer thereof as an active ingredient.
10. A pharmaceutical composition for preventing or treating a metabolic disease, comprising the compound according to claim 1 or a pharma- ceutically acceptable salt or isomer thereof as an active ingredient.
11. The pharmaceutical composition for preventing or treating a metabolic disease according to claim 10, wherein the metabolic disease is diabetes, diabetic complications, obesity, non-alcoholic steatohepatitis, or steatohepatitis.
12. The pharmaceutical composition for preventing or treating a metabolic disease according to claim 10, wherein the metabolic disease is non-alcoholic steatohepatitis.
13. A method for producing a pharmaceutical composition for preventing or treating diabetes, diabetic complications, obesity, non-alcoholic steatohepatitis, and steatohepatitis, comprising the step of mixing, as an active ingredient, the compound according to claim 1, or a pharma- ceutically acceptable salt or isomer thereof, with a pharma- ceutically acceptable carrier.
14. 13. A method of treating metabolic disorders, including non-alcoholic steatohepatitis, in a mammal, comprising the step of administering a compound of claim 1, a pharma- ceutically acceptable salt thereof, or an isomer thereof.
Citation Information
Patent Citations
Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
JP2019500383A
3-azabicyclo[3,1,1]heptane derivative and pharmaceutical composition comprising same
WO2020067735A1
Hexone glucokinase inhibitor and use thereof
WO2020156445A1
Compound having KHK inhibitory effect
WO2021129737A1
Pyrimidine-based compound having inhibitory effect of ketohexokinase (KHK)
WO2021129817A1
